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Human papillomaviruses (HPVs) cause cervical cancer and are also closely linked to other 
malignancies in the anogenital and oropharyngeal regions. It is widely assumed that 
HPV-positive cancer cells are ‘oncogene addicted’ in that they depend on the continuous 
expression of the two viral oncogenes, E6 and E7, to maintain their malignant phenotype and 
to avoid tumor-suppressive senescence induction. However, recently it was shown that 
hypoxic HPV-positive cancer cells efficiently shut down E6/E7 expression and enter a growth 
arrest without inducing senescence. This process is reversible upon reoxygenation and can 
be counteracted by high glucose concentrations. These surprising findings shed new light on 
the crosstalk between the viral oncogenes and the host cell, particularly under hypoxia, a 
condition frequently found in cervical cancer that is associated with poor patient prognosis. 
The present work aimed to delineate the regulatory mechanisms underlying hypoxic E6/E7 
repression. It was revealed that E6/E7 mRNA and protein expression is impaired in hypoxic 
HPV-positive cancer cells by a combination of transcriptional repression and reduction of 
mRNA and protein half-lives. Moreover, hypoxic repression of E6/E7 was shown to be not 
only glucose-sensitive, but also dependent on intracellular calcium. There was no indication 
for a role of HIF transcription factors, considered master orchestrators of the cellular 
response to hypoxia, or for involvement of transcription factors from the glucose-responsive 
Mlx network. However, the PI3K/AKT signaling pathway was identified as being crucial for 
the hypoxic repression of E6/E7. AKT is activated by hypoxia which can be counteracted by 
high glucose concentrations. Blocking of hypoxia-induced AKT activation by chemical 
inhibitors, including clinically applied drugs that target AKT or its upstream activators PI3K 
and mTORC2, counteracts repression of E6/E7 under hypoxia. Knockdown and 
overexpression experiments showed that the AKT1 and AKT2 isoforms act redundantly in 
hypoxic repression of E6/E7. Reactivation of E6/E7 expression under hypoxia upon inhibition 
of the PI3K/AKT pathway does not induce proliferation and can sensitize HPV-positive cells 
to therapeutic effects of chemotherapy in a cell line-dependent manner. Finally, comparison 
of the proteome composition of HPV-positive cancer cells under normoxia and hypoxia as 
well as proteome analyses of hypoxic cells treated with an AKT inhibitor or high glucose 
concentrations were performed. They identified several novel candidate proteins possibly 
linked to hypoxic repression of E6/E7 providing an experimental basis for future 
investigations. Collectively, these findings provide new insights into the regulation of the viral 
oncogenes in hypoxic HPV-positive tumor cells and have implications for the development of 






Humane Papillomviren (HPVs) verursachen das Zervixkarzinom und sind eng assoziiert mit 
anderen Krebserkrankungen im Anogenitalbereich und im Oropharynx. Der maligne 
Phänotyp HPV-positiver Tumorzellen gilt als abhängig („oncogene addicted“) von der 
kontinuierlichen Expression der zwei viralen Onkogene, E6 und E7, die die Induktion von 
tumorsuppressiver Seneszenz verhindern. Kürzlich wurde jedoch gezeigt, dass hypoxische 
HPV-positive Tumorzellen die E6/E7-Expression effizient abschalten können und einen 
Wachstumsarrest eingehen ohne dabei Seneszenz zu induzieren. Dieser Vorgang ist 
umkehrbar durch Reoxygenierung und wird durch hohe Glukosekonzentrationen verhindert. 
Diese überraschenden Befunde führten zu neuen Einblicken in die Wechselwirkungen 
zwischen den viralen Onkogenen und der Wirtszelle, insbesondere unter Hypoxie, ein 
Zustand, der häufig in Subregionen von Zervixkarzinomen vorliegt und der mit einer 
schlechten Prognose assoziiert ist. Ziel dieser Arbeit war es regulatorische Mechanismen, 
die der hypoxischen E6/E7-Repression zugrunde liegen, zu entschlüsseln. Es wurde 
beobachtet, dass die Repression von E6/E7-mRNA und -Proteinen unter Hypoxie durch eine 
Kombination aus transkriptioneller Repression und Verkürzung der mRNA- und 
Protein-Halbwertszeiten erfolgt. Überdies wurde gezeigt, dass die hypoxische 
E6/E7-Repression nicht nur glukosesensitiv, sondern auch calciumabhängig ist. Die 
Ergebnisse ergaben keinen Hinweis auf eine Rolle für HIF-Transkriptionsfaktoren, die als 
Schlüsselfaktoren der zellulären Antwort auf Hypoxie gelten, oder für Transkriptionsfaktoren 
aus dem glukoseresponsiven Mlx-Netzwerk. Vielmehr wurde entdeckt, dass der 
PI3K/AKT-Signalweg entscheidend für die hypoxische Repression von E6/E7 ist. AKT wird 
durch Hypoxie aktiviert, was durch hohe Glukosekonzentrationen verhindert wird. Eine 
Inhibition der Hypoxie-induzierten AKT-Aktivierung durch (auch klinisch eingesetzte) 
Hemmstoffe, die gegen AKT oder vorgeschaltete Aktivatoren (PI3K und mTORC2) gerichtet 
sind, wirkt der hypoxischen Repression von E6/E7 entgegen. Sowohl ein gezieltes 
Ausschalten als auch eine ektopische Expression von AKT1 und AKT2 ergaben, dass diese 
AKT-Isoformen in der hypoxischen E6/E7-Repression funktionell redundant wirken. Die 
durch PI3K/AKT-Hemmung vermittelte Reaktivierung von E6/E7 unter Hypoxie induziert 
keine Proliferation und kann HPV-positive Zellen zellinienabhängig für Chemotherapeutika 
sensibilisieren. Schließlich wurden auch Proteomanalysen von HPV-positiven Zellen unter 
Hypoxie und Normoxie, sowie unter Hypoxie mit gleichzeitiger Behandlung mit einem 
AKT-Inhibitor oder hohen Glukosekonzentrationen durchgeführt. Als Grundlage für 
zukünftige Studien wurden dabei neue Kandidatenproteine identifiziert, die möglicherweise 
zur hypoxischen E6/E7-Repression beitragen. Zusammengefasst führen diese Resultate zu 
neuen Erkenntnissen über die Regulation der HPV-Onkogenexpression in hypoxischen 
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       Chapter 1 









Cancer is a significant global health burden accounting for an estimated 8.2 million deaths in 
2012 worldwide that is expected to increase in the years to come, largely due to rising 
expectancy of life and changes in lifestyle behavior [1].  
The development of cancer is a multistep process. During this process, cells accumulate 
several mutations and acquire an increasingly aberrant behavior [2]. Hence, the cause for 
malignant transformation from healthy cells into tumor cells is complex and encompasses 
many aspects of cellular biology. In a seminal paper Hanahan and Weinberg initially defined 
six common biological characteristics of tumor cells as the ‘hallmarks of cancer’. These 
consist of sustained proliferative signaling, evasion from growth suppressors, tissue invasion 
and metastasis, limitless replicative potential, sustained angiogenesis and the resistance 
towards apoptosis. In an updated version, the authors later included deregulation of 
metabolism and immune evasion as additional emerging hallmarks and genomic instability 
and tumor-promoting inflammation as characteristics for tumor progression [3]. 
Due to the often time-consuming multistep nature of tumorigenesis, old age represents a 
strong cancer risk factor. However, additional factors exist that can significantly increase the 
risk for developing cancer. These include most prominently tobacco use, but also ultraviolet 
or ionizing radiation, alcohol, obesity, physical inactivity, chemical and biological toxins and 
infections [4, 5]. For the year 2012 it was estimated that approximately 15 % of all new 
cancer cases were attributable to infections with viruses, bacteria or parasites [6]. Human 
papillomaviruses (HPVs) are amongst the strongest contributors to infection-associated 
carcinogenesis with 4.5 % of all cancers worldwide being attributable to HPV [7].  
1.2 Human papillomaviruses (HPVs) and cancer 
HPVs are a diverse group of cutaneous and mucosal non-enveloped DNA viruses that 
belong to the family of papillomaviridae. More than 170 types of HPVs are classified today 
[8]. They are grouped into low-risk and high-risk types. While low-risk types are mainly 
characterized by their ability to cause benign lesions, skin and genital warts, high-risk HPVs 
represent major risk factors for the development of anogenital cancers such as cancer of the 
penis, vagina, vulva, anus and cervix, but also of oropharyngeal cancers at the tonsils, 
oropharynx and base of tongue [9].  
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1.2.1 Cervical cancer 
Harald zur Hausen and colleagues first established a close connection between HPV and 
cervical cancer in 1983 [10]. The importance of his work was later recognized with the Nobel 
Prize in Physiology or Medicine in 2008.  
Today, cervical cancer is well characterized for being in virtually all cases caused by sexually 
transmitted mucosa-infecting high-risk HPVs. Currently, twelve types are classified as 
carcinogenic: HPV-16, 18, 31, 33, 35, 45, 52, 58, 39, 51, 56 and 59. Several other types are 
classified as ‘probably’ or ‘possibly carcinogenic’ [11]. HPV16 is the most frequent type 
detected in cervical cancer cases, followed by HPV18 which together have a prevalence of 
approximately 70 % [12].  
With more than 500,000 new cases and 250,000 deaths per year, cervical cancer is the 
fourth most common cancer in women worldwide. Although incidence rates are declining in 
many high-income industrialized countries, incidence and mortality remain especially high 
and are predicted to further increase in low-income developing countries where screening 
programs are scarce [1, 13, 14]. Consequently, development and implementation of effective 
treatment and prevention strategies are of great importance. 
1.2.2 Prevention and therapy of cervical cancer  
Currently recommended standard treatment for invasive cervical cancer consists of surgery 
often combined with radiotherapy or cisplatin-based chemoradiation. The development of 
aggressive cervical carcinomas can in many cases be prevented by screening that detects 
the presence of precancerous lesions. Available screening methods in industrialized 
countries are cytological evaluation of cells from cervical samples, HPV testing (detection of 
DNA or RNA) or cytology-HPV co-testing [15].  
However, the most effective protection against any disease can be achieved by already 
preventing its initial establishment. In the case of cervical cancer, this can be accomplished 
by prophylactic vaccination. At present, three prophylactic vaccines have been licensed. The 
bivalent Cervarix (GlaxoSmithKline) contains antigens of HPV16 and 18, which are 
responsible for 70 % of all cervical cancer cases. The quadrivalent Gardasil (Merck) protects 
against HPV6, 11, 16 and 18 and thus, also protects against two low-risk HPV types causing 
roughly 90 % of genital warts. The most recently developed vaccine, the nonavalent 
Gardasil9 (Merck), comprises the four HPV types of the quadrivalent vaccine and protects 
against five additional carcinogenic types (31, 33, 45, 52, 58), thereby covering up to 90 % of 
HPV infections linked to cervical cancer. All vaccines show good safety profiles and high 
efficiency, especially in their main target group; young females prior to their first sexual 
encounter [16]. They are all based on virus-like particles (VLPs) of the HPV major coat 
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protein L1 and lead to a strong seroconversion with antibody titers much higher than 
obtained by natural infection [17].  
However, despite the promising impact of HPV vaccination, there remain practical limitations. 
First, vaccination rates are disappointingly low, particularly in less developed countries where 
cervical cancer incidence is highest and where the recommended three-dose vaccination, 
now already discussed to be reduced to a two-dose vaccination, poses a considerable 
financial and logistic issue [18, 19]. Second, vaccination is directed against specific HPV 
types and is consequently not able to prevent 100 % of HPV-induced cervical cancer. In this 
regard, effort is currently put in the development of vaccines based on the minor capsid 
protein L2 that are expected to elicit an immune response comprising of broadly cross-type 
neutralizing antibodies [19]. Third, current vaccinations are only prophylactic and cannot 
prevent progression of the disease in already infected individuals. Since broad vaccination 
programs were implemented earliest in 2006 [16] and the time period between initial infection 
and progression to cancer often lasts decades [20], cervical cancer will remain a major 
health care problem for many years to come. Thus, development of novel therapeutic 
strategies for the management of HPV-associated cancers remains a significant challenge. 
1.2.3 The biology of HPV infection and mechanisms of HPV-associated carcinogenesis 
HPVs have a small circular double-stranded DNA genome of less than 8,000 base pairs (bp) 
that is divided into six early (E1, E2, E4, E5, E6, E7) and two late (L1 and L2) open reading 
frames (ORFs), termed ‘late’ and ‘early’ according to their expression during the viral life 
cycle. Additionally, there is a transcriptional regulatory region designated long control region 
(LCR) or upstream regulatory region (URR). Expression of different gene products is 
controlled by the early and late promoter (p97 and p670, respectively, for HPV16, see Fig. 1) 
and by mRNA splicing [21]. 
The late genes code for structural proteins, essential for virus assembly, with L1 representing 
the major and L2 representing a smaller capsid protein. E1 and E2 are proteins involved in 
viral replication and gene expression. The functions of E4-E7 are more diverse [15]. The E4 
protein plays a role in genome amplification and may be involved in virus release and 
transmission [22]. E5 also contributes to genome amplification [23] and moreover, is 
suggested to exert transforming activities early in the transformation process [24]. E6 and E7 
are the two viral oncoproteins that are essential for malignant transformation to cancer (see 
chapter 1.2.4). 
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The peak of cervical cancer diagnosis lies at an age of 45 to 60 years, whereas HPV 
infection typically occurs in adolescent or young women demonstrating the decades are often 
required to develop invasive cervical cancer [25]. Initial infection is often rapidly cleared. 
However, HPV can modulate the immune response of their host cells facilitating immune 
evasion [26]. Long-term persistence of the virus can lead to the development of 
precancerous lesions that can regress over time or further progress to more critical 
precancer forms that can eventually result in invasive cancer. Several classifications have 
been established to stage cervical lesions according to their risk of developing into invasive 
carcinoma such as the histological staging from mild to severe dysplasia classified as 
cervical intraepithelial neoplasia (CIN) 1-3. Notably, only a small minority of HPV infected 
women develop cervical carcinomas during their life-time indicating that HPV infection is 
required but not sufficient to induce cancer of the cervix [25]. 
During HPV infection, the virus enters cells of the epithelial basal layer, usually via 
microwounds. As the basal cells divide and cells begin to migrate to the mid and upper 
epithelial layers, they start a differentiation program. The differentiation-associated changes 
of the host cell support the differential expression of viral gene products at various stages. 
Expression of E6 and E7 is tightly regulated and mainly involved in genome amplification in 
mid-epithelial layers, whereas strong expression of L1, L2 and E4 can be detected primarily 
in the mid to upper epithelial layers. Assembly and release of virus particles eventually 
occurs in layers close to the epithelial surface [15, 27] (Fig. 2).  
Fig. 1. Genome structure of HPV16. The eight ORFs of HPV16, encoded on one DNA strand, are depicted: L1, 
L2 (yellow), E1, E2, E4, E5 (green) and E6, E7 (red). Early (p97) and late (p670) promoters are indicated by 
arrows. LCR = long control region, also designated upstream regulatory region (URR), PAE = early 
polyadenylation site, PAL = late polyadenylation site. Modified from [21].  
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HPV-associated neoplasias and ultimately cancerous lesions occur when this productive viral 
life-cycle is impaired, which is characterized by increased cell proliferation up into the mid 
epithelial layers. This is mainly driven by enhanced activity of E6 and E7 that promote cell 
cycle progression and inhibit differentiation. Elevated levels of E6 and E7 go along with more 
and more restricted expression of late viral genes, thereby no longer allowing virion 
production [15, 28] (Fig. 2). Continuously elevated expression of E6/E7 generates 
chromosomal instability that facilitates integration of HPV DNA into the host cell genome. 
Thus, many invasive cervical carcinomas do no longer contain viral episomes and are 
instead characterized by integrated viral DNA with disruption of the E1/E2 ORF, but with an 
intact E6/E7 ORF [29, 30].  
 
The majority of cervical cancers develop at the transformation zone or the endocervix 
(cervical canal) and rarely at the ectocervix. The ectocervix, the vaginal portion of the cervix, 
consists of stratified squamous epithelium and is maintained by epithelial stem cells. HPV 
infection of these conventional epithelial stem cells is suggested to result primarily in a 
productive viral life cycle. Persistent lesions are thought to be caused by infection of cervical 
reserve cells that maintain the transformation zone between ecto- and endocervix or of 
reserve cells of the endocervix itself, which consists of a simple columnar epithelium that 
Fig. 2. HPV life cycle and cancer development. During the productive viral life cycle (left) viral gene expression 
is regulated during epithelial differentiation and virus is released from the epithelial surface. In cancerous tissue 
(right) late gene expression is retarded and E6 and E7 expression is elevated no longer allowing virion 
production. Protein expression of L1, L2, E4 (green) and of E6, E7 (red) is indicated. Figure modified from [15].      
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occasionally undergoes metaplasia [15, 28]. Noteworthy, a second cell type has recently 
been proposed as cell of origin for persistent HPV infections; a stem-like cell at the 
squamocolumnar (SC) junction, where columnar epithelium of the endocervix meets 
squamous epithelium [31].  
1.2.4 E6 and E7 – the viral oncoproteins 
The transforming abilities of high-risk HPVs are attributed to two rather small proteins: E6 
and E7 with a length of approximately 150 and 100 amino acids, respectively. In contrast to 
other HPV encoded proteins, expression of E6 and E7 is always retained in cervical cancer 
cells. HPV-associated cancer cells are even considered to be ‘oncogene addicted’ meaning 
that they depend on sustained expression of E6/E7 to maintain their malignant phenotype 
[32]. This is demonstrated by findings revealing that silencing of E6/E7 rapidly induces 
senescence, an irreversible growth arrest [33-35]. 
E6 and E7 are transcribed as polycistronic transcripts from a common early promoter under 
the control of the transcriptional control region URR (Fig. 1) that encompasses a 5’ terminal 
region, a central enhancer element and a promoter proximal region (PPR) at the 3’ part of 
the URR [36, 37]. In principle, the viral E2 protein can act as transcriptional repressor for 
E6/E7. However, E2-mediated repression of E6/E7 is commonly abolished in HPV-positive 
tumor cells, largely by disruption of the E2 ORF upon integration of viral DNA into host cell 
chromosomes or by methylation of E2 binding sites in the URR [38]. Functional binding sites 
for several host transcription factors in the URR that regulate expression of E6/E7 have been 
characterized. This includes most prominently AP1 and SP1, which are important cellular 
activators of E6 and E7 expression [39, 40].  
The molecular mechanisms employed by E6 and E7 to contribute to cellular transformation 
are diverse and include modulation of various cellular proteins. 
One major critical target of E6 is the tumor suppressor p53, which is bound by E6 and 
subsequently degraded [41]. More precisely, E6 forms a trimeric complex with p53 and E6-
associated protein (E6-AP), which results in the ubiquitination and subsequent proteasomal 
degradation of p53 with E6-AP functioning as ubiquitin ligase [42, 43].  
A key target for E7 is the pRb family, which encompasses important regulators of the cell 
cycle. In non-dividing cells, pRb is unphosphorylated and binds to and inactivates E2F 
transcription factors. Upon mitogenic signals, pRB is phosphorylated and E2Fs are released, 
which then activate transcription of a variety of genes driving cell cycle progression [44]. E7 
can bind pRb, disrupt its interaction with E2F and even induce its degradation [45-47]. As a 




Protective cellular mechanisms against uncontrolled cell growth include the induction of 
apoptosis or senescence via p53. Indeed, stabilization of p53 can be observed in cells 
expressing E7, but no E6 [48]. However, in HPV-positive cancer cells E6 and E7 are 
expressed together and thus, E6 mediated degradation of p53 prevents apoptosis (Fig. 3) or 
senescence otherwise induced by uncontrolled pRb-driven proliferation. In line with this 
model, it has been shown that transforming abilities of E6 and E7 are strongest when both 
are expressed [49] indicating how E6 and E7 cooperate in cellular transformation.  
 
Apart from their best characterized targets, p53 and pRB, E6 and E7 interact with many 
additional cellular factors. The E6 protein, for instance, contains a PDZ (post synaptic density 
protein, drosophila disc large tumor suppressor, zonula occludens-1 protein) ligand motif and 
can bind to numerous PDZ domain containing cellular proteins leading to their degradation. 
Since many of the PDZ domain containing targets of E6 are tumor suppressors and play 
roles in regulation of cell polarity (e.g. DLG, MAG1-3, Scribble), this poses an important 
tumorigenic feature of E6 [50].  
Moreover, E6 can induce telomerase activity [51] by upregulating transcription of human 
telomerase reverse transcriptase (hTERT), a component of telomerase [52]. The absence of 
telomerase activity in healthy cells leads to telomere erosion during mitosis eventually 
resulting in cellular senescence. Hence, via activation of telomerase E6 can prevent 
replicative senescence. Increased expression of hTERT was suggested to be achieved via 
the c-Myc oncoprotein, which was reported to be stabilized by E6 [53, 54] and whose mRNA 
and protein expression is downregulated upon silencing of E6 in HPV18-positive HeLa cells 
Fig. 3. Cooperation of E6 and E7 in cellular transformation. E7 induces inactivation of pRb and subsequent 
deregulation of proliferation, which leads to p53-dependent apoptosis. Concomitant expression of E6 counteracts 
this by the formation of a trimeric E6/E6-AP/p53 complex followed by degradation of p53. Blockade of apoptosis 
results in the outgrowth of deregulated cells. Figure from [32]. 
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[55, 56]. However, there are also reports suggesting a c-Myc independent mechanism of E6-
induced telomerase activity [57].  
While E7 mainly drives cell cycle progression via inactivation of pRb, E7 can also directly 
bind to E2F1 and increase expression of pro-proliferative genes [58] or promote cell growth 
by modulating activity of histone-modifying enzymes such as class I histone deacetylases 
(HDACs) [59]. 
Expression of E6 and E7 is a requirement for HPV-associated tumorigenesis, but additional 
oncogenic events are necessary for the formation of invasive cancer indicated by the long 
latency between HPV infection and cancer development (see chapter 1.2.3). For instance, 
full transformation of keratinocytes immortalized by expression of E6 and E7 only occurs 
after many passages in cell culture [60]. Likely, E6 and E7 generate a predisposition for the 
accumulation of mutagenic events by facilitating genomic instability. Hence, chromosomal 
aberrations are frequently found in E6/E7-immortalized keratinocytes and HPV-positive 
tumor cells [61, 62]. 
Many of the described transforming characteristics of E6 and E7 are exclusively found in 
high-risk but not in low-risk types further emphasizing the oncogenic potential of high-risk 
HPV types. E6 of low-risk types, for instance, lacks the PDZ ligand motif and only weakly 
interacts with p53, if at all, without mediating its degradation. Likewise, only high-risk E7 has 
the potential to induce degradation of pRb [63]. 
The dependency of HPV-positive tumor cells on continuous expression of E6 and E7 makes 
the viral oncoproteins interesting highly tumor-specific therapeutic targets. Particularly the 
targeting of E6 should be a promising strategy since its inhibition leads to apoptosis in HPV-
positive cancer cells (Fig. 3). Thus, numerous studies were performed using siRNAs, small 
molecule inhibitors, small peptides, peptide aptamers, intrabodies or immunotherapeutic 
approaches directed against E6 and E7. However, despite the promising potential of these 
strategies, no E6 or E7 targeted therapy has reached the clinic yet [32]. 
1.3 Tumor hypoxia 
The level of tissue oxygenation is an important biological and clinical aspect with a strong 
impact on the cellular phenotype [64-66]. Typically, solid tumors are heterogeneously 
oxygenized and frequently characterized by the presence of areas with oxygen (O2) 
concentrations significantly below the physiological level (‘hypoxia’). Tissue hypoxia is 
usually defined as O2 concentrations below 1.5-2 %. This in vivo situation forms a 
tremendous contrast to many in vitro studies, which are usually performed under standard 
cell culture conditions at 20-21 % O2, hereafter defined as ‘normoxia’. Even O2 concentrations 
of normal healthy tissue (‘physoxia’, for most tissues in the range between 3.5-7 % O2) are 
only poorly represented under standard experimental conditions [64, 65].  
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Inadequate supply of tumor cells with O2 can be caused by large distances from blood 
vessels (> 70 µm) that do not allow sufficient diffusion of O2. This diffusion-limited hypoxia is 
described as chronic hypoxia. A state of chronic hypoxia can also be the result of anemia or 
low O2 levels in the blood (hypoxemia). Intermittent, or also termed acute hypoxia, is often a 
consequence of perfusion-limited O2 delivery, for example due to structural and functional 
defects of tumor microvessels [66].  
Hypoxic tumors are usually associated with poor patient prognosis and high resistance 
towards therapy. Hypoxia contributes to malignant tumor progression since hypoxic tumor 
cells undergo extensive adaptations to survive under low oxygen conditions. These include 
alterations in gene expression mainly regulated by hypoxia-inducible factors (HIFs, see 
chapter 1.4.2), genetic changes and clonal selection of especially resistant cells [64, 66]. An 
important aspect of hypoxia-mediated therapy resistance is the radioprotective effect of 
hypoxia. Ionizing radiation produces free radicals, for instance in DNA, that can react with O2 
to generate fixed peroxy radicals. This DNA damage leads to the desired therapeutic effect. 
However, if O2 is missing during radiation, the generated radicals can be reduced to their 
original composition. Apart from radiotherapy, hypoxic tumor cells are also more resistant 
towards many chemotherapeutic or other anticancer drugs. This is partly caused by 
insufficient drug delivery to the hypoxic cells due to inadequate tumor vascularization. 
Moreover, chemotherapeutics often target highly proliferative cells and hypoxic tumor cells 
commonly show lower proliferation rates than non-hypoxic tumor cells. Additionally, the 
aforementioned selection for extremely malignant cells that often downregulate conventional 
apoptosis pathways, contributes to hypoxic therapy resistance [67].  
Moreover, hypoxia contributes to immune evasion of tumor cells by enhancing 
immunosuppressive pathways and by inhibiting the activity of immunocompetent cells. Thus, 
hypoxia also poses a major obstacle for immunotherapeutic approaches [68]. 
Consequently, in recent years research efforts have been put in anticancer drugs that are 
effective under hypoxic conditions such as hypoxia-activated prodrugs (HAPs) that get 
activated under hypoxia or small molecule inhibitors directed against essential hypoxia-
induced molecular targets [69, 70].  
1.3.1 Hypoxia and HPVs 
The median O2 concentration of cervical cancer lies at 1.2 %. Hence, hypoxia is frequently 
detected in cervical cancer patients and importantly, has a negative impact on patient 
prognosis [65, 66]. Nevertheless, functional investigations of HPV-positive cancer cells under 
hypoxia are rare, as is true for many tumor diseases. Intriguingly however, work of the 
Hoppe-Seyler lab recently revealed that the viral oncogenes E6 and E7 are strongly, but 
reversibly, downregulated at protein and mRNA level in hypoxic cervical cancer cells. E6 and 
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E7 level slightly decreased at 3 % O2 when compared to normoxic cells, but significantly 
dropped when cells were cultured at 1 % O2 [71] (Fig. 4). Notably, this downregulation was 
counteracted by unphysiologically high glucose concentrations [71].  
 
Silencing of E6 and E7 expression in HPV-positive cancer cells under normoxia has well 
established consequences. First, cells undergo an irreversible growth arrest by entering 
senescence and second, they restore p53 level otherwise degraded via E6 and E6-AP (see 
also chapter 1.2.4). Surprisingly these conceptions are not valid under hypoxic conditions 
where cells only undergo a reversible growth arrest that can be overcome by reoxygenation 
and where p53 levels remain low despite efficient downregulation of E6 and E7. 
Mechanistically, it was shown that hypoxic HPV-positive cancer cells evade efficient 
induction of senescence by downregulation of mechanistic target of rapamycin (mTOR) 
signaling that plays a crucial role in senescence induction under various conditions [72]. In 
line with this, reactivation of mTOR signaling under hypoxia by silencing of protein regulated 
in development and DNA damage response 1 (REDD1) or tuberous sclerosis complex 2 
(TSC2), both negative regulators of mTOR complex 1 (mTORC1), counteracted the evasion 
of hypoxic cervical cancer cells from chemotherapy-induced senescence [71]. 
Hence, hypoxia causes significant alterations in HPV-positive tumor cells that provide 
resistance towards conventional therapies. Moreover, the inhibition of viral oncogene 
Fig. 4. E6 and E7 expression is downregulated in hypoxic cervical cancer cells. HPV16- and HPV18-
positive cervical cancer cell lines were cultured at the indicated O2 concentrations. Left panel: Immunoblot 
analyses show expression of HIF-1α (hypoxia-linked marker), HPV16/18 E6 and E7, Rb, phosphorylated Rb (P-
Rb), p53 and p21. β-actin = loading control. Right panel: qRT-PCR analyses of relative E6/E7 mRNA expression 
(all three transcript classes). Standard deviations are depicted. Asterisks indicate statistically significant 
differences to normoxia (21 % O2), ***p < 0.001. Figure from [71]. 
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expression may render hypoxic HPV-positive tumor cells less vulnerable to E6/E7-targeted 
therapeutic approaches and may contribute to immune evasion mechanisms due to reduced 
presentation of viral antigens on the cell surface in combination with the overall 
immunosuppressive effects of hypoxia [68]. Importantly, since hypoxic HPV-positive cancer 
cells only enter a reversible dormant state, they may form a reservoir for recurring tumors 
that can develop after reoxygenation [71]. Deciphering the molecular mechanism underlying 
hypoxia-induced repression of E6/E7 expression should therefore yield important insights to 
increase our current understanding of HPV-associated tumorigenesis and to provide a 
foundation for future design of therapeutic approaches.  
1.4 Regulatory mechanisms and cellular pathways under hypoxia 
Limited oxygen supply poses a fundamental challenge on the survival of cells. Thus, to 
successfully adapt to hypoxia, cells have to undergo a series of regulatory alterations.  
1.4.1 Metabolic adaptations 
Under conditions of sufficient oxygen supply, normal cells gain the majority of energy through 
ATP production via mitochondrial oxidative phosphorylation (OXPHOS). Many cancer cells, 
however, shift their metabolism towards enhanced glycolysis with accompanying lactate 
production, even under aerobic conditions. This aerobic glycolysis (also termed ‘Warburg 
effect’) provides a fast supply of ATP, although with a lower yield per molecule of glucose 
compared to energy production via OXPHOS, and allows the production of many cellular 
building blocks. Under hypoxia, cells are even more dependent on glycolysis since OXPHOS 
is downregulated to reduce the amount of O2 molecules that are consumed. This metabolic 
reprogramming is mediated in part by increased expression of glycolytic enzymes and 
glucose transporters [73]. Moreover, transporters that excrete lactate from the cell are 
upregulated to prevent intracellular acidification by enhanced lactate production from 
glycolysis [74]. 
Another noteworthy key feature of hypoxic cells is an increase in the intracellular cytosolic 
calcium (Ca2+) concentration that is involved in the regulation of the cellular adaptation to 
hypoxia [75].  
Apart from regulation of Ca2+ homeostasis and glucose metabolism, cellular modifications 
concerning, amongst others, fatty acid metabolism, glutamine metabolism and maintenance 
of adequate redox balance are carried out in hypoxic cells to cope with the demanding nature 
of O2 deprivation [76].  
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1.4.2 Hypoxia-inducible factors (HIFs) 
Hypoxia-inducible factors (HIFs) are transcription factors that are considered master 
orchestrators of the cellular adaptation to hypoxia. If O2 levels are high, prolyl hydroxylases 
(PHDs) hydroxylate proline residues on the HIF-α subunits (HIF-1α and HIF-2α) in an O2- 
and α-ketoglutarate-dependent manner. Hydroxylated HIF-α is recognized by the von Hippel-
Lindau (pVHL) protein that functions as E3 ubiquitin ligase and targets HIF-α for proteasomal 
degradation. Upon hypoxia, PHDs are less active and HIF-α is stabilized. The HIF-α subunits 
each form an obligatory heterodimer with the stably expressed HIF-1β, also termed ARNT. 
The HIF heterodimer then regulates gene expression by binding to DNA sequences termed 
hypoxia-responsive elements (HREs) with the consensus sequence G/ACGTG. Another 
mechanism of O2-dependent regulation of HIF is mediated by factor-inhibiting HIF-1α (FIH1), 
an asparaginyl hydroxylase. FIH1 hydroxylates HIF-α and thereby inhibits recruitment of HIF 
transcriptional coactivators p300 and CREB-binding protein (CBP) [77]. Additionally, it has 
been proposed that increased production of reactive oxygen species (ROS) by the 
mitochondrial electron transport chain under hypoxia are required for stabilization of HIF-α 
[78]. However, HIF-α can also be regulated independently of O2, for instance by oncogenic 
signaling [77].  
HIFs are critically involved in regulating most of the aforementioned metabolic adaptations to 
hypoxia (see chapter 1.4.1). Despite having some overlapping functions, HIF-1α and HIF-2α 
can also regulate unique target genes. HIF-1α is ubiquitously expressed, whereas 
expression of HIF-2α is more restricted, but can still be detected in many cell types [79]. 
Expression of glycolytic genes is largely regulated via HIF-1α, which for instance activates 
hexokinase 1 and 2 (HK1, HK2), phosphofructokinase (PFK) or lactate dehydrogenase A 
(LDHA). While HIF-1α and HIF-2α have both been reported to induce expression of glucose 
transporters, several enzymes involved in redox homeostasis are uniquely regulated by 
HIF-2α such as heme oxygenase 1 (HMOX1) or superoxide dismutase 1 (SOD1) [77, 79]. 
HIFs also regulate the activity of various oncogenes or tumor suppressors. Activity of the pro-
proliferative oncogenic transcription factor MYC and the pro-growth kinase complex 
mTORC1 are negatively regulated by HIF-1α and positively by HIF-2α. Such an opposing 
regulation has also been described for the p53 pathway with an activating effect of HIF-1α 
and a repressive function of HIF-2α. Thus, HIF-1α and HIF-2α often function in a balancing 
manner to regulate the cellular response to hypoxia [77, 79]. 
Apart from HIF-1α and HIF-2α, a third O2-labile HIF-α subunit is described: HIF-3α. Several 
variants of HIF-3α with putatively varying functions exist, generated by alternative splicing or 
usage of different transcription start sites. Studies addressing HIF-3α are limited, but there 
are indications for a role of HIF-3α in hypoxia-induced transcriptional regulation [80]. 
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1.4.3 Epigenetic alterations  
While HIF transcription factors are key drivers of hypoxia-induced alterations in gene 
expression, they are supported by many epigenetic modifications induced under hypoxia 
[81]. These can occur independently of HIF and contribute to global transcriptional 
repression, but also to activation of specific genes [82].  
DNA hypermethylation to silence tumor suppressor genes is commonly found in hypoxic 
tumor cells. This was proposed to be largely caused by reduced activity of O2-dependent ten-
eleven translocation (TET) enzymes that are required for DNA demethylation [83]. 
Hypoxia has a significant impact not only on the methylation of DNA, but also on methylation 
of histones. Interestingly, many histone demethylases are described as O2-dependent, 
resulting in overall enhanced levels of trimethylation at lysine 4 of histone 3 (H3K4me3) and 
at lysine 27 of histone 3 (H3K27me3) under hypoxia [84, 85]. Since H3K4me3 and 
H3K27me27 are opposing histone marks being associated with active and silenced gene 
expression, respectively, consequences of hypoxia-induced histone methylation are 
complex, but lead to significant alterations in gene expression depending on the cellular and 
genetic context [84-86].  
1.4.4 The PI3K/AKT signaling pathway 
Activation of the serine/threonine kinase AKT, also known as protein kinase B (PKB), is 
typically induced by growth factors, cytokines or hormones such as insulin that is secreted 
upon high blood glucose [87]. Interestingly, AKT can also be activated by glucose deprivation 
[88-90]. Moreover, there is emerging evidence that AKT is frequently activated under hypoxia 
[91-93]. In this context, there are also reports connecting the AKT pathway to HIF, insofar as 
PI3K/AKT activity has been described to contribute to increased levels of HIF-1α [91, 94].  
The AKT1-3 proteins are the three distinct isoforms of AKT. They are highly homologous, but 
are each encoded by a separate gene [95]. Belonging to the AGC group of kinases they 
share some structural similarities with protein kinase A, G and C. AKT kinases all consist of 
an N-terminal pleckstrin homology (PH) domain, a central kinase domain and a C-terminal 
hydrophobic regulatory domain. The C-terminal segment is thereby characteristic also for 
other AGC kinases. The three AKT isoforms share approximately 80 % amino acid sequence 
homology with the kinase domain being especially conserved [96, 97]. AKT is fully activated 
when phosphorylated at two specific sites; at T308, T309 or T305 in the kinase domain and 
at S473, S474 or S472 in the C-terminal domain for AKT1, AKT2 or AKT3, respectively [97, 
98]. Hereafter only the phosphorylation sites for AKT1 will be named when referring to all 
AKT isoforms in general. An additional phosphorylation site at a highly conserved threonine 
(T450 in AKT1), phosphorylated by the mTOR complex 2 (mTORC2), was reported to 
contribute to AKT protein stability [99]. 
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AKT is activated downstream of class I phosphoinositide 3-kinases (PI3Ks, see Fig. 5). In 
detail, upon receiving extracellular stimuli, for instance via growth factors or cytokines, 
receptor tyrosine kinases (RTKs) or G protein-coupled receptors (GPCRs) are activated 
leading to recruitment and activation of PI3K, a process that often involves Ras GTPases.  
PI3K phosphorylates the membrane lipid phosphatidylinositol-4,5-bisphosphate (PI4,5P2) to 
generate phosphatidylinositol-3,4,5-trisphosphate (PIP3) that can be further converted to 
phosphatidylinositol-3,4-bisphosphate (PI3,4P2). This can be counteracted by the 
phosphatase PTEN [100]. PIP3 and PI3,4P2 recruit AKT to the membrane by binding to the 
PH domain of AKT. In its inactive state AKT is mainly localized in the cytosol and its PH 
domain closely interacts with its kinase domain. In this conformation, T308 in the kinase 
domain of AKT is inaccessible for phosphorylation. Upon interaction of the PH domain of 
AKT with PIP3 or PI3,4P2, the T308 residue becomes accessible and is phosphorylated by 
phosphoinositide-dependent kinase-1 (PDK1) that is itself recruited to the membrane by 
interaction of its PH domain with phosphoinositides [101]. In a recent report it was proposed 
that translocation of AKT to the plasma membrane is facilitated by calmodulin (CaM) [102]. 
CaM is a Ca2+-sensing protein that can bind to the PH domain of AKT and has been shown 
to colocalize with AKT at the plasma membrane upon growth factor stimulation [103].   
AKT phosphorylated at T308 alone has some enzymatic activity but additional 
phosphorylation at S473 is required for full activation [98].  
The responsible kinase for AKT S473 phosphorylation is mTORC2 [104]. mTORC2 has been 
reported to be activated in a PI3K-dependent manner by being recruited to the membrane via 
PIP3. However, PI3K-independent activity of mTORC2 has been described as well [95]. On a 
side note, AKT S473 phosphorylation has also been described to be carried out by DNA-
dependent protein kinase (DNA-PK) in the context of DNA damage [105]. mTORC2-
mediated phosphorylation at S473 is reported to facilitate T308 phosphorylation and 
suggested to occur prior to T308 phosphorylation [104]. 
AKT signaling is negatively regulated by the phosphoinositide phosphatase PTEN, but also 
by protein phosphatase 2A (PP2A) that dephosphorylates AKT at T308 and by PH domain 
leucine-rich repeat protein phosphatases 1 and 2 (PHLPP1, PHLPP2) that dephosphorylate 
AKT at S473 [95].  
Once phosphorylated at T308 and S473, active AKT dissociates from the membrane and can 
phosphorylate its substrates in the cytoplasm or nucleus [101]. However, it has also been 
reported that AKT activity is dependent on binding to PIP3 or PI3,4P2 and is therefore 
restricted to cellular membranes. Furthermore, activation of AKT has not only been reported 
at the plasma membrane, but also at endomembranes [95].  
The exact mechanism of how AKT is activated under hypoxia is unclear so far. However, 
hypoxia-induced ligand-independent activation of growth factor receptors or modulation of 
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ligand expression resulting in increased AKT activity has been reported for specific 
conditions and cell types [106, 107]. Moreover, in a recent publication it has been suggested 
that AKT is regulated via hydroxylation by the prolyl hydroxylase EgIN1 in an O2-dependent 
manner. Hydroxylated AKT interacts with and is dephosphorylated by PP2A associated with 
pVHL. Since activity of EgIN1 is dependent on O2, hypoxia leads to reduced hydroxylation 
and reduced dephosphorylation of AKT resulting in enhanced AKT activation [108].  
Taken together, despite considerable progress and substantial amounts of data already 
existing in the PI3K/AKT research field, there remain many aspects to be clarified to get a 
more complete picture of AKT signaling.  
 
AKT kinases influence many essential aspects of cell biology by modulating energy 
metabolism and promoting cell survival, growth, proliferation, migration and angiogenesis. In 
line with this, more than 100 proteins have been suggested as AKT substrates [109].  
Amongst the earliest established AKT targets are the two glycogen synthase kinase 3 






















Fig. 5. PI3K-dependent AKT activation. PI3K is activated by RTKs or GPCRS and phosphorylates 
phosphoinositides. AKT and PDK1 are recruited to the membrane via their PH domains. AKT is positively 
regulated by mTORC2 and PDK1. PTEN, PP2A and PHLPP1 and 2 are negative regulators. Simplified 
schematic, for details refer to text. 
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This phosphorylation acts inhibitory by preventing association of GSK3-α/β with their 
substrates. GSK3 has a multitude of targets that are mainly inhibited by GSK3-induced 
phosphorylation. Many of these targets are involved in cell survival and metabolism such as 
c-Myc, HIF-1α or glycogen synthase [95].  
Another important downstream target of AKT is mTORC1. A major function of mTORC1 is 
the promotion of anabolic processes such as protein, lipid and nucleotide synthesis. AKT 
phosphorylates and inhibits TSC2 thereby releasing TSC2-mediated inhibition of mTORC1. 
Additionally, AKT phosphorylates PRAS40, another inhibitor of mTORC1, and induces its 
dissociation from mTORC1 [111, 112]. Moreover, it has been proposed that AKT directly 
phosphorylates and activates mTOR [113]. Hence, via activation of mTORC1, AKT 
contributes to cell growth and survival. AKT-mediated mTORC1 activation is particularly 
interesting considering the induced negative feedback regulation. mTORC1 activation leads 
to enhanced degradation of insulin receptor substrates 1 and 2 (IRS) and consequently 
reduces PI3K activation by insulin and insulin-like growth factor 1 (IGF1) receptors. 
Furthermore, mTORC1 activates p70 S6 kinase (p70S6K), which in turn phosphorylates 
components of the second mTOR-containing complex; mTORC2, resulting in inhibition 
thereof. As a consequence, mTORC2-mediated phosphorylation of AKT at S473 is impaired. 
mTORC1-dependent negative feedback regulation of PI3K/AKT signaling includes further 
mechanisms and is complemented by additional distinct downstream effectors [95]. 
Major outputs of AKT signaling can also be observed at the level of cellular energy 
metabolism. Importantly, AKT stimulates glucose uptake, mainly in response to insulin, by 
inducing translocation of glucose transporters to the plasma membrane [87]. Moreover, AKT 
promotes (aerobic) glycolysis and thus, may be a strong contributor to shifting cellular energy 
metabolism in the context of the Warburg effect (see chapter 1.4.1) [114]. 
Taken together, only a few AKT targets have now been mentioned exemplarily, however, 
those already illustrate how activation of PI3K/AKT can expand to a broad signaling network 
with a multitude of effectors and regulatory mechanisms. This network becomes even more 
complex considering that there exist three distinct isoforms of AKT.     
AKT1 is ubiquitously expressed and AKT2 expression is also found in most tissues, but with 
particularly high levels in insulin-sensitive tissues. Expression of AKT3 is more restricted and 
primarily found in neuronal tissues [95]. Moreover, AKT3 is frequently upregulated in 
melanoma cells [115]. The three AKT isoforms have many overlapping, but also some 
distinct functions. This is clearly demonstrated by comparing phenotypes of isoform-specific 
knockout mice. AKT1-knockout mice have severe growth defects [116], whereas AKT2-
knockout mice show strongly impaired glucose homeostasis with type 2 diabetes-like 
symptoms [117]. Knockout of AKT3 results in impaired brain development in mice [118]. 
These data, together with many other functional studies, indicate that AKT1 is essential for 
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proliferation and cell growth, AKT2 is primarily involved in regulating glucose metabolism and 
AKT3 is crucial for neuronal development. However, combined AKT knockout mice also 
reveal some compensating effects between the isoforms [119, 120]. How isoform-specific 
functions of AKT are regulated is only incompletely understood. Although distinct tissue 
distribution certainly plays a role in isoform-specific effects, expression of more than one AKT 
isoform is frequently found in many tissues. Additionally, subcellular localization, relative 
expression levels, differential activation by diverse stimuli and differences in substrate 
specificity based on molecular distinctions between the individual isoforms may account for 
isoform specificity [95]. 
The PI3K/AKT pathway is aberrantly activated in many cancers and contributes significantly 
to the malignant phenotype of tumor cells and to their resistance towards conventional 
therapies. The most commonly detected alteration in this pathway is an activating mutation in 
the PIK3CA gene, coding for a subunit of class I PI3K. However, alterations in other pathway 
members can also contribute to enhanced AKT activity such as loss of function of the 
negative regulator PTEN or amplifications or activating mutations of RTKs, further PI3K 
subunits or other downstream effectors including AKT isoforms themselves [121]. Thus, the 
PI3K/AKT pathway is subject to intensive investigations as putatively promising therapeutic 
target in cancer therapy. Various small molecule inhibitors targeting PI3K, mTOR or AKT are 
currently tested in the clinic. This includes single-agent studies, but also combinations with 
chemo- and radiotherapy or combination therapies with other targeted drugs [122].  
Cervical cancer belongs to the tumor types frequently associated with aberrant PI3K/AKT 
activation. Mutations in PIK3CA are linked to shorter survival of cervical cancer patients and 
high levels of phosphorylated AKT have been shown to correlate with poor outcome after 
chemoradiation [123, 124]. Hence, the clinical application of PI3K/AKT inhibitors for the 
treatment of cervical cancer is intensely studied [125]. 
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1.5 Research objectives 
Continuous expression of the viral oncogenes E6 and E7 has generally been considered a 
prerequisite for the maintenance of the malignant phenotype of HPV-positive tumor cells 
since silencing of E6 and E7 rapidly induces senescence in these cells. Intriguingly, it was 
recently found that this widely accepted dogma is not valid under hypoxia, a condition that is 
frequently detected in HPV-positive cancers. In specific, hypoxic HPV-positive cancer cells, 
can efficiently and reversibly shut down viral oncogene expression, but evade senescence. 
These surprising findings shed new light on the crosstalk between the viral oncogenes and 
the host cell, which could be of high relevance for both basic research and clinical aspects of 
HPV-linked cancers. To gain mechanistic insights into the underlying regulatory phenomena, 
the following major questions will be addressed: 
(i) At which molecular level are the viral oncogenes downregulated under hypoxia? Is 
the effect linked to changes in E6/E7 promoter activity, to epigenetic modifications of 
the viral transcriptional control region or to alterations in E6/E7 mRNA or protein 
stability? 
(ii) Is HPV oncogene repression linked to the activity of transcription factors which are 
known key regulators for the cellular response towards hypoxia? Analyses will include 
the examination of HIF proteins, considered the master orchestrators of hypoxia-
induced alterations in gene expression. In addition, glucose-responsive factors will be 
investigated since E6/E7 repression under hypoxia is sensitive to glucose. 
(iii) Which signaling cascade is responsible for hypoxic E6/E7 repression? Here, a 
special focus will be put on a detailed analysis of the PI3K/AKT pathway that is 
activated by hypoxia and emerged as a particularly promising candidate. Questions 
that will be addressed include: Is AKT activation required for repression of E6 and E7 
under hypoxia? Is there a connection to the cellular calcium and energy metabolism? 
Can hypoxic regulation of E6 and E7 be affected by inhibitors targeting different 
factors in the PI3K/AKT signaling cascade, including clinically used PI3K/AKT 
inhibitors, and what are the phenotypic consequences of PI3K/AKT inhibitor treatment 
on hypoxic HPV-positive cells? What is the functional role of the individual AKT 
isoforms? Finally, hypoxia-linked alterations in the protein composition of HPV-
positive cancer cells will be analyzed by proteomic studies and the effects of a 
concomitant application of an AKT inhibitor or high glucose supply will be assessed. 
It is the overall aim of the present work to gain a better understanding of the mechanism by 
which HPV-positive cancer cells are able to repress viral oncogene expression under 
hypoxia. The elucidation of the underlying pathway(s) will provide important new insights into 
the host/virus interaction in HPV-positive cancer cells and should be relevant for prospective 
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2. Results 
2.1 Transcriptional regulation of HPV E6/E7 expression under hypoxia  
The expression of HPV E6/E7 is strongly downregulated in cervical cancer cells under 
hypoxic conditions [71]. This repression of E6/E7 is detectable at protein and mRNA level 
raising the question whether transcription of the polycistronic E6/E7 mRNA is impaired under 
hypoxia.  
2.1.1 HPV transcriptional activity is reduced under hypoxia 
To investigate the transcriptional regulation of E6/E7 under hypoxia, the transcriptional 
control region of HPV18 E6/E7 (HPV18 URR), was investigated using luciferase reporter 
assays. More precisely, the HPV18 URR fused to a luciferase gene was transfected into 
HPV18-positive HeLa cells and luciferase activity, representing the transcriptional activity of 
the E6/E7 promoter in the physiological context of the complete HPV18 URR, was 
determined under hypoxia (1 % O2) and normoxia (21 % O2). Activity of the full length 
reporter construct (p18URRL) was significantly impaired under hypoxia with a mean log2 fold 
change of -0.97, which represents a reduction in activity of approximately 50 % (Fig. 6A). A 
similar effect was observed for a 5′-deletion construct that still contains the HPV enhancer 
and the promoter proximal region PPR (p436/L). A further truncated reporter, only consisting 
of the PPR (p232/18L) was no longer repressed by hypoxia indicating a critical role for the 
HPV enhancer region.  
To further investigate whether the PPR is dispensable for hypoxia-mediated repression, 
additional luciferase assays were performed with reporter constructs containing the 230 bp 
HPV18 enhancer region fused to the heterologous HSV TK promoter. Activity of this reporter 
was equally impaired under hypoxia when compared to reporter constructs with the 
homologous HPV E6/E7 promoter indicating that the 230 bp enhancer is sufficient to mediate 
repression of transcriptional activity under hypoxia (Fig. 6B). Likewise, a further 5′-deletion 
construct of the HPV enhancer (p157s/tk*L) still showed significantly reduced activity under 
hypoxia. Contrarily, the activity of a 3′-deletion construct encompassing only 116 bp of the 5′-
enhancer region (p116s/tk*L) was not altered under hypoxia. The activity of the GAPDH 
promoter was measured in parallel as a positive control and showed the expected stimulation 
under hypoxia [126].  
Taken together, the activity of the HPV18 URR under hypoxia was reduced by about 50 % 
with a 157 bp enhancer fragment being sufficient to mediate the repression indicating that 
transcriptional regulation is, at least partially, involved in hypoxic repression of E6/E7.  
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2.1.2 The role of YY1, Brd4 and the BET inhibitor JQ-1 in repression of E6/E7 under 
hypoxia  
Jha and colleagues previously published that the transcription factor YY1 facilitates binding 
of the histone acetyltransferase TIP60 to the HPV URR, which leads to the recruitment of the 
BET family member Brd4 and eventually results in repression of HPV E6/E7 transcription 
[128]. Since the reported binding sites for TIP60 and YY1 overlap with the 157 bp enhancer 


































































































Fig. 6. Reduced activity of the HPV18 URR under hypoxia. Luciferase reporter assays of HeLa cells incubated 
for 24 h under hypoxia (1 % O2) or normoxia (21 % O2). Left panels show a schematic representation of the 
investigated reporter constructs. The full length construct encompasses the 5′ terminal region, the central 
enhancer and the promoter proximal region (PPR). Nucleotide positions according to reference [127]. (A)
Reporter assay with constructs containing the firefly luciferase gene under the control of the complete HPV18 
URR (p18URRL) or deletion constructs thereof (p436/18L, p232/18L), pBL = basic vector. (B) Reporter assay with 
the firefly luciferase gene under the control of the HSV TK promoter fused to the HPV18 enhancer (p230s/tk*L) or 
deletion constructs thereof (p157s/tk*L, p116s/tk*L). pBtk*L = basic vector, pGAPDHLuc = positive control. (A+B)
Shown is the log2 of the relative luciferase activity under hypoxia. Standard deviations are depicted (n = 4 (A), n = 
5 (B)). Asterisks above columns show statistically significant differences from the basic vector control as 
determined by one-way ANOVA (*p<0.05, ***p < 0.001). 
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chapter 2.1.1), it was tested whether YY1 and Brd4 are negative regulators of E6/E7 
expression under hypoxia. However, silencing of YY1 or Brd4 by shRNAs or siRNAs, 
respectively, did not prevent the downregulation of E7 expression under hypoxia as was 
shown by immunoblot analyses (Fig. 7A and B). Moreover, YY1 and Brd4 proteins showed 
no increased expression under hypoxia. In addition to that, ectopic overexpression of YY1 
did not alter E7 expression levels under hypoxia or normoxia (Fig. 7A), all in all arguing 
against a repressive function of YY1 and Brd4 on E6/E7 expression under the investigated 
conditions. Interestingly though, unlike to the shRNA-mediated knockdown of Brd4, treatment 
with the BET inhibitor JQ-1 restored E7, but not E6 expression under hypoxia in HeLa cells 
(Fig. 7C). Noteworthy, treatment with JQ-1 under normoxia slightly decreased E7 expression 
in HeLa cells. However, this latter observation was subject to great variation, thus, two 
representative experiments out of six are shown in this case. By extending the investigations 
to further cell lines, it was revealed that JQ-1-mediated reactivation of E7 expression under 
hypoxia was not observed in HPV18-positive SW756 and HPV16-positive SiHa cells (Fig. 
7D). Downregulation of E6 and E7 expression after JQ-1 treatment under normoxia was on 
the other hand clearly detectable in SW756 and SiHa cells.  
Altogether, YY1 and Brd4 were not confirmed as repressors of HPV E6/E7 expression under 
hypoxia. However, the BET inhibitor JQ-1 was shown to influence E6/E7 expression under 
hypoxia and normoxia in a cell line-dependent manner.  
2.1.3 Trimethylation at H3K4 and H3K27 increases under hypoxia 
Results obtained with luciferase reporter assays indicate that transcriptional regulation plays 
a role in repression of E6/E7 expression under hypoxia. Since epigenetic changes can 
mediate hypoxia-induced alterations in gene expression [81], the epigenetic status of the 
HPV URR was studied next. These investigations were focused on SiHa cells since they 
contain only 1 to 2 HPV16 integrates in contrast to many other cervical cancer cell lines, 
such as HeLa, that harbor a multitude of viral integrates [129].  
The abundancy of H3K4me3 and H3K27me3 at the HPV16 URR in SiHa cells was 
investigated by chromatin immunoprecipitation (ChIP). H3K4me3 is primarily associated with 
active transcription, whereas H3K27me3 is closely linked to inactive genes [130].  
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Fig. 7. Role of YY1 and Brd4 in regulation of E6/E7 under hypoxia. (A) HeLa cells expressing shRNAs
against YY1 (shYY1-1, shYY1-2) or ectopically expressing YY1 (pcDNA3YY1) were cultured for 24 h under 
hypoxia or normoxia. shContr-1 = control shRNA, pcDNA3 = vector control. (B) HeLa and SiHa cells transfected 
with a Brd4 targeting siRNA were cultured for 24 h under hypoxia or normoxia. (C) HeLa cells were treated with 
the indicated concentrations of JQ-1 or DMSO as solvent control and cultured for 24 h under hypoxia or normoxia. 
Shown are two representative experiments out of six. (D) SW756 and SiHa cells were treated and cultured as 
in (C). (A-D) Immunoblot analyses of HIF-1α (hypoxia-linked marker), YY1, HPV16/18 E6 and E7 and Brd4. 
Vinculin, β-actin = loading control. Short exp. = short exposure, long exp. = long exposure. 
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By qPCR analyses of H3K27me3 ChIPs, an increase of H3K27me3 under hypoxia was 
detected at the HPV16 URR (Fig. 8A). However, an increase of H3K27me3 was also 
detected at all other analyzed regions including regulatory regions of VEGF and Glut1, both 
hypoxia-induced proteins [131, 132]. The viral L1 and L2 genes generally exhibited a slightly 
higher occupancy of H3K27me3 compared to the HPV URR and the hypoxia-induced genes. 
qPCR analyses of H3K4me3 ChIPs revealed that the marker for active genes was also 
enriched under hypoxia at all analyzed regions (Fig. 8B). Notably, H3K4me3 signals at the 
L1 and L2 gene were very low under both conditions.  
 
Fig. 8. H3K4 and H3K27 trimethylation under hypoxia. (A+B) SiHa cells were cultured for 24 h under hypoxia 
or normoxia, ChIP against H3K27me3 (A) or H3K4me3 (B) was performed and qRT-PCR analyses were carried 
out using primers located in the HPV16 URR (HPV16URR_1, HPV16_URR2), in the L1 and L2 gene (HPV16L2, 
HPV16L1) and in regulatory regions for VEGF and Glut1 (VEGFprom, Glut1prom). C1orf43 and HOXC13 served 
as control regions. Depicted is the mean percentage of input of 3 independent experiments. Error bars indicate 
standard deviations. ChIP was performed in collaboration with T. Günther and A. Grundhoff (Heinrich-Pette-
Institute, Hamburg). (C) Immunoblot analyses of HeLa and SiHa cells cultured for 24 h under hypoxia or normoxia 
show protein expression of HIF-1α (hypoxia-linked marker), H3K27me3, H3K4me3 and HPV16/18 E7. β-actin = 
loading control. 
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C1orf43 served as control for an actively transcribed region and showed the expected 
enrichment of H3K4me3. The HOXC13 gene served as reference for a transcriptionally 
silenced region and was enriched in H3K27me3. Under hypoxic conditions, a general 
increase of H3K4me3 and H3K27me3 was detected at both control regions (Fig. 8A and B).  
Since the HPV URR was enriched in both, active and repressive histone marks, an effect 
that was mirrored at all other tested genomic regions, global H3K27me3 and H3K4me3 level 
were monitored under hypoxia. In fact, total cell lysates of HeLa and SiHa cells showed 
increased levels of H3K27me3 and H3K4me3 under hypoxia as determined by immunoblot 
(Fig. 8C). Thus, the detected enrichments of the investigated histone marks in ChIP 
experiments go in line with a general increase in cellular H3K27me3 and H3K4me3 level 
under hypoxia.  
2.1.4 DNA methylation is likely not involved in repression of E6/E7 under hypoxia 
Apart from histone modifications, DNA methylation is another epigenetic mechanism that can 
be linked to hypoxic gene silencing [83]. To investigate if DNA methylation is crucial for 
repression of E6/E7 under hypoxia, cells were treated with the global DNA methylation 
inhibitor 5-aza-2’-deoxycytidine (5-Aza) which is a cytidine analog that is incorporated into 
DNA strands during replication. Upon engaging DNA methyltransferases, the enzymes 
become irreversibly bound to DNA resulting in loss of methyltransferase activity [133]. 
However, despite pre-treatment with 5-Aza, E7 expression was still effectively downregulated 
in HeLa and SiHa cells under hypoxia (Fig. 9A) indicating that DNA methylation is not 
required for repression of E6/E7. On a side note, in normoxic SiHa cells, E7 expression was 
slightly reduced upon treatment with 5-Aza when compared to DMSO treated control cells. 
Expression of DNA methyltransferase 1 (Dnmt1) was monitored as a positive control for 
5-Aza treatment since 5-Aza-induced the degradation of Dnmt1 [134]. Indeed, 
downregulation of Dnmt1 expression was observed upon 5-Aza treatment. Noteworthy 
however, under hypoxic conditions, Dnmt1 expression was also strongly impaired.  
In parallel, the DNA methylation status of the HPV16 URR in SiHa cells was investigated via 
qPCR of methylated DNA immunoprecipitation (MeDIP) samples. Methylation levels at the 
analyzed regions in the HPV16 URR were not induced by hypoxia (Fig. 9B) confirming that 
DNA methylation is likely not involved in repression of E6/E7 under hypoxia. In line with 
previous reports [135], the transcriptionally silenced HPV L1 and L2 genes generally 
exhibited higher DNA methylation levels compared to the URR. Interestingly, methylation at 
L1 and L2 slightly decreased under hypoxia. As expected, the hypoxia-induced genes VEGF 
and Glut1 showed low methylation levels that were comparable to the negative control region 
in the human tubulin alpha-1c chain (Tuba1C). A methylated CpG island in the gene 
SHANK1 (CpG 4) served as positive control (Fig. 9B). 
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In conclusion, there were no indications for a role of DNA methylation in repression of E6/E7 
expression under hypoxia since an inhibitor of DNA methylation was not able to alter hypoxic 
E6/E7 expression and, moreover, DNA methylation levels at the HPV16 URR remained low 
under hypoxia. 
 
2.2 Protein and mRNA stability of HPV E6/E7 under hypoxia 
The activity of the E6/E7 transcriptional promoter was reduced under hypoxia, by 
approximately 50 % (Fig. 6). Since hypoxia-induced downregulation of E6/E7 mRNA and 
protein is more pronounced (80 % mRNA reduction in HeLa cells, see [71]), the question 
emerged whether reduced protein or mRNA stability may also contribute to this effect.  
2.2.1 E6 and E7 protein stability is reduced under hypoxia 
To determine E6 and E7 protein stability, HeLa cells were pre-incubated for 4 h under 
hypoxia, thereby ensuring that E6 and E7 protein levels were still detectable under hypoxia. 
Hypoxic and normoxic HeLa cells were then treated with the protein translation inhibitor 
Fig. 9. Role of DNA methylation in regulation of E6/E7 under hypoxia. (A) HeLa and SiHa cells were treated 
with DMSO as solvent control or with 10 µM 5-aza-2’-deoxycytidine (5-Aza) for 3 days. Prior to harvesting, cells 
were cultured for 24 h under hypoxia or normoxia as indicated. Medium with fresh inhibitor was replaced every 
24 h. Immunoblots of HPV18/16 E7 and Dnmt1 are shown. β-actin, α-tubulin = loading control. (B) SiHa cells 
were cultured for 24 h under hypoxia or normoxia, MeDIP was performed and qRT-PCR analyses were carried 
out using primers located in the HPV16 URR (HPV16URR_1, HPV16_URR2), in the L1 and L2 gene (HPV16L2, 
HPV16L1) and in regulatory regions of VEGF and Glut1 (VEGFprom, Glut1prom). Tuba1C = negative control 
region, CpG 4 = positive control region. Depicted is the mean percentage of input of 3 independent experiments. 
Error bars show standard deviations. MeDIP was performed in collaboration with T. Günther and A. Grundhoff 
(Heinrich-Pette-Institute, Hamburg). 
2. Results   
30 
cycloheximide (CHX) and E6 and E7 protein expression was compared over 6 h under 
hypoxia and normoxia. 
Calculation of E6 and E7 protein half-life in Hela cells based on quantification of immunoblots 
and assuming exponential protein decay resulted in the mean half-lives indicated in Tab. 1.  
HeLa 
 Hypoxia Normoxia 
E7 1.94 ± 0.22 h 1.58 ± 0.19 h 
E6 1.99 ± 0.17 h 1.75 ± 0.82 h 
 
In HeLa cells, the half-lives of HPV18 E6 and E7 were slightly reduced under hypoxia as can 
be seen in Fig. 10 showing one representative immunoblot with the corresponding 
quantification. Notably, variations between the individual experiments were detected leading 
to high standard deviations, particularly for E6 expression under normoxia (Tab. 1). However, 
the tendency towards a reduced protein half-life was consistently identified in all 
experiments, suggesting that this effect may contribute to some extent to the downregulation 
of E6 and E7 protein level under hypoxia. 
 
Tab. 1. Mean protein half-lives of E6 & E7 in HeLa cells.
Fig. 10. E6 and E7 protein stability under hypoxia and normoxia. HeLa cells were pre-incubated for 4 h under 
hypoxia or normoxia, treated with 10 µg/ml cycloheximide (CHX) and harvested at the indicated time-points after 
treatment. Upper panels show immunoblot analyses of HPV18 E7 and E6. Vinculin = loading control. Lower 
panels depict quantification of the respective immunoblot relative to vinculin with an exponential decay curve 
determined by non-linear regression. The time point 0 h after CHX treatment was set as 1 under hypoxia and 
normoxia, respectively. 
   2. Results 
31 
2.2.2 E6/E7 mRNA stability is reduced under hypoxia 
The half-life of the E6/E7-encoding mRNAs was assessed by treating normoxic and hypoxic 
HeLa cells with the transcriptional inhibitor actinomycin D (ActD) and E6/E7 mRNA levels 
were measured over 4 h by qRT-PCR. The applied primers recognize all three different 
transcript classes coding for HPV18 E6/E7. Half-life calculation using 5 independent 
experiments and assuming exponential mRNA decay, revealed a half-life of 3.08 h under 
normoxia and 2.48 h under hypoxia (Fig. 11). Notably, half-life measurements were subject 
to strong fluctuations (see discussion, chapter 3.1.2). Nevertheless, the trend consistently 
points towards a reduced E6/E7 mRNA stability under hypoxia, which likely contributes to 
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Fig. 11. E6/E7 mRNA stability under hypoxia and normoxia. HeLa cells were pre-incubated for 4.5 h under 
hypoxia or normoxia, treated with 0.5 µg/ml actinomycin D (ActD) and harvested at the indicated time-points after 
treatment. The mean relative HPV18 E6/E7 mRNA expression (all three transcript classes) of 5 independent 
experiments is depicted. The time point 0 h after ActD treatment was set as 1 under hypoxia and normoxia, 
respectively. Error bars indicate standard deviations. An exponential decay curve was generated by non-linear 
regression.  
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2.3 Candidate transcription factors in regulation of hypoxic E6/E7 expression 
To gain insights into the underlying mechanism of E6/E7 repression under hypoxia, key 
transcriptional regulators mediating the cellular response towards hypoxia were investigated. 
2.3.1 HIF transcription factors in regulation of E6/E7 expression under hypoxia 
HIF transcription factors (HIF-1α and HIF-2α) are major orchestrators of the cellular 
transcriptional response to hypoxia [136]. Thus, it was investigated if hypoxia-induced 
stabilization of HIF-1α or HIF-2α is required to repress E6/E7 under hypoxia. To that end, 
HeLa cells expressing shRNAs targeting HIF-1α or HIF-2α were cultured under hypoxia. 
Immunoblot analyses show that induction of HIF-1α and HIF-2α mediated by hypoxia was 
efficiently blocked by shRNAs (Fig. 12). However, hypoxic repression of E6 and E7 was not 
impaired by silencing HIF-1α and HIF-2α, alone or in combination.  




Fig. 12. HIF transcription factors in repression of E6/E7 under hypoxia. HeLa cells expressing shRNAs 
against HIF-1α and HIF-2α, alone or in combination, were cultured for 24 h under hypoxia or normoxia. 
Immunoblot shows protein expression of HIF-1α, HIF-2α, HPV18 E6 and E7. β-actin = loading control. pSuper = 
basic vector, shContr-1 = control shRNA. Figure is published in reference [71]. 
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2.3.2 The Mlx transcription factor network in regulation of E6/E7 expression under 
hypoxia 
Previously, work of our group showed that downregulation of E6/E7 under hypoxia is 
glucose-sensitive and can be counteracted by an excess of glucose [71]. One major 
orchestrator of glucose-induced gene regulation is the Mlx network of transcription factors. In 
short, high glucose activates transcription factor heterodimers composed of Mlx on the one 
hand and MondoA or ChREBP on the other hand. These dimers then localize to the nucleus 
and bind to carbohydrate response elements to regulate gene expression [137]. Their activity 
has been shown to be inhibited by hypoxia independently of HIF [138]. This raised the 
question whether hypoxia-induced abrogation of Mlx heterodimer activity - which is 
counteracted by artificially high glucose supply - may be linked to hypoxic E6/E7 regulation.  
As demonstrated by immunoblots, repression of E6/E7 protein expression under hypoxia 
was still efficient in HeLa cells expressing Mlx targeting shRNAs (Fig. 13A). Reactivation of 
hypoxic E6/E7 expression induced by high glucose (25 mM) was also not affected by 
silencing Mlx. Knockdown of Mlx was verified by detecting Mlx mRNA expression level (Fig. 
13B) and additionally by measuring mRNA expression of TXNIP (Fig. 13C), which was 
previously reported to be induced by high glucose via the Mlx:MondoA complex [139]. In fact, 
a strong upregulation of TXNIP mRNA expression was observed in HeLa cells cultured with 
high glucose concentrations. This was still detectable, but significantly impaired in Mlx-
silenced cells indicating that Mlx knockdown was successful albeit there may be some 
residual Mlx activity. In contrast to TXNIP, E6/E7 mRNA expression was not affected in Mlx-
silenced cells (Fig. 13C), but followed in line with the pattern observed at protein level. 
On a side note, TXNIP mRNA expression was generally downregulated in hypoxic cells 
cultured under physiological glucose conditions (5.5 mM, Fig. 13C), which is in agreement 
with previous reports [138]. Moreover, this effect was slightly enhanced in Mlx-silenced cells. 
The two possible interaction partners of Mlx are MondoA and ChREBP. Expression of 
ChREBP mRNA in HeLa cells was approaching the detection level and could not be further 
reduced by expression of shRNAs. Thus, further studies were focusing on the second 
potential Mlx interaction partner; MondoA.  
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Results obtained upon shRNA-mediated silencing of MondoA mirrored the effects following 
Mlx silencing. Protein and mRNA expression of E6/E7 were unaffected by MondoA 
knockdown under all experimental conditions including hypoxia and high glucose 
concentrations (Fig. 14A and C). High glucose-induced upregulation of TXNIP mRNA 
expression on the other hand, was severely impaired in cells expressing MondoA targeting 
shRNAs, although a MondoA-knockdown induced enhanced downregulation of TXNIP under 
hypoxia was not detected (Fig. 14C). 
Taken together, the obtained data indicates that hypoxic and glucose-sensitive repression of 
E6/E7 expression occurs in a manner independent of Mlx heterodimers.  
Fig. 13. The Mlx transcription factor in repression of E6/E7 under hypoxia. HeLa cells expressing shRNAs 
against Mlx were cultured for 24 h under hypoxia or normoxia with medium containing 5.5 or 25 mM glucose. 
shContr-1 = control shRNA (A) Immunoblots detecting protein expression of HIF-1α, HPV18 E6 and E7. β-actin =
loading control. (B) qRT-PCR analyses of Mlx mRNA expression showing knockdown efficiency. (C) qRT-PCR 
analyses of E6/E7 and TXNIP mRNA expression. (B+C) Depicted is the log2 of the mean expression relative to 
shContr-1 under normoxia with standard deviations of 3 individual experiments. Asterisks indicate statistically 
significant differences to the respective shContr-1 as determined by one-way ANOVA. (***p < 0.001, *p < 0.05 ). 
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2.3.3 c-Myc in regulation of E6/E7 expression under hypoxia 
The Mlx transcription factor network closely resembles the better characterized Myc network. 
The c-Myc transcription factor is a proto-oncoprotein that dimerizes with its obligatory 
interaction partner Max to regulate gene expression and is known to be a major regulator of 
cellular metabolism as its activity can depend on the cellular nutrient status [140]. Since 
c-Myc was described to be destabilized under hypoxia and glucose-deprived conditions [141, 
142], it was investigated whether c-Myc is involved in glucose-sensitive hypoxia-induced 
downregulation of E6/E7. 
Fig. 14. The MondoA transcription factor in repression of E6/E7 under hypoxia. HeLa cells expressing 
shRNAs against MondoA were cultured for 24 h under hypoxia or normoxia with medium containing 5.5 or 25 mM 
glucose. shContr-1 = control shRNA. (A) Immunoblots of HIF-1α and HPV18 E7 are shown. β-actin = loading 
control. (B) Corresponding qRT-PCR analyses of Mlx mRNA expression showing knockdown efficiency. (C)
Corresponding qRT-PCR analyses of E6/E7 and TXNIP mRNA expression. (B+C) Depicted is the log2 of the 
expression relative to shContr-1 under normoxia. One representative experiment of two is shown. 
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Immunoblot analyses of HeLa cells cultured under hypoxia and normoxia with different 
glucose concentrations revealed that c-Myc protein levels were slightly downregulated under 
hypoxia with physiological glucose concentrations (5.5 mM, Fig. 15). High glucose levels 
(25 mM) counteracted this effect and led to an upregulation of c-Myc protein levels under 
hypoxia. In cells expressing shRNAs targeting c-Myc, c-Myc protein could no longer be 
detected by immunoblot. However, E7 protein expression remained unaltered in c-Myc-
silenced cells and showed the previously described pattern of oxygen- and glucose-
dependent downregulation. In summary, hypoxia-induced downregulation of c-Myc 
expression that can be counteracted by high glucose does likely not affect the regulation of 
E7 under hypoxia. 
 
2.4 A functional role for the PI3K/AKT pathway in repression of E6/E7 under 
hypoxia 
2.4.1 Inverse correlation between activation of AKT and repression of E6/E7 under 
hypoxia 
An important coordinator of cellular signaling that is closely associated with glucose 
metabolism [95] and reported to be activated by hypoxia [92, 93] is the AKT pathway. 
Therefore, the AKT kinase emerged as a putative candidate for hypoxic regulation of E6/E7. 
Indeed, the following experiments revealed an inverse correlation between the activation of 
AKT and the repression of E6/E7 under hypoxia. 
Fig. 15. The c-Myc transcription factor in repression of E6/E7 under hypoxia. HeLa cells expressing an 
shRNA targeting c-Myc were cultured under hypoxia or normoxia for 24 h in medium containing 5.5 or 25 mM 
glucose. shNeg, shContr-1 = control shRNAs. Immunoblot shows protein expression of HPV18 E7 and c-Myc. 
Vinculin = loading control. 
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Time-course experiments of HeLa and SiHa cells showed that phosphorylation of AKT was 
induced by hypoxia at both residues required for full kinase activation [98]. The applied 
Phospho-AKT (P-AKT) specific antibodies detect all three isoforms of AKT phosphorylated at 
T308 (AKT1), T309 (AKT2), T305 (AKT3) or at S473 (AKT1), S474 (AKT2), S472 (AKT3) 
(see also chapter 1.4.3). For simplification, only the residues for AKT1 will be named in the 
following text and figures. The antibody against P-AKT T308 occasionally recognized a band 
of slightly lower molecular weight. By using P-AKT inhibitors and by performing knockdown 
experiments it was shown that only the upper 60 kDa band was specific for P-AKT. 
Increased phosphorylation of AKT at T308 was detectable in HeLa cells after 1 h of hypoxia, 
increased phosphorylation at S473 already after 10 min (Fig. 16A). In Siha cells, induction of 
AKT phosphorylation at both residues was detected after 30 min of hypoxia. Downregulation 
of E6 and E7 protein expression started after 3 h of hypoxia in HeLa cells and after 6-9 h in 
SiHa cells, therefore hypoxia-mediated AKT induction preceded the repression of E6/E7. 
Hypoxic cells that regain access to oxygen start to upregulate E6/E7 expression again after 
several hours ([71], Fig. 16B). Hypoxia-induced upregulation of P-AKT was abolished already 
10 min after reoxygenation as was shown by immunoblot of SiHa cells (Fig. 16B). Hence, like 
repression of E6/E7, activation of AKT by hypoxia was reversible and, furthermore, occurred 
chronologically before reactivation of E6/E7 expression.  
Notably, hypoxia-induced phosphorylation of AKT was only observed in cells cultured in 
medium containing physiological glucose concentrations (5.5 mM) but was abolished when 
cells were cultured under high glucose conditions (25 mM, Fig. 16C). This inversely 
correlated with E6 and E7 expression, which was reactivated under hypoxia by high glucose 
supply. Despite an increase in P-AKT, the expression levels of total AKT protein after 24 h 
hypoxia under physiological glucose conditions were slightly reduced when compared to 
normoxia (Fig. 16C). Since no decline in total AKT protein was detected in the hypoxia time 
kinetic (Fig. 16A), this may be attributed to an increase of AKT over time under normoxia.  
Taken together, hypoxia-mediated activation of AKT was closely connected to repression of 
E6/E7, thereby pointing at AKT as a promising candidate for regulating the repression of 
E6/E7 under hypoxia. 
2. Results   
38 
 
2.4.2 Inhibitors of the PI3K/AKT pathway counteract repression of E6/E7 under 
hypoxia  
The activation status of AKT under hypoxia correlates with repression of E6/E7 providing 
circumstantial evidence for a crosstalk between AKT signaling and the hypoxic repression of 
E6/E7 expression. Consequently, further experiments aimed to elucidate the possible role of 
Fig. 16. AKT phosphorylation is induced under hypoxia in a glucose-dependent manner. (A) Time course 
of HeLa and SiHa cells subjected to hypoxia. Immunoblot shows protein levels of HIF-1α, AKT phosphorylated at 
T308 and S473 (P-AKT T308, P-AKT S473), pan-AKT (AKT), HPV16/18 E6 and E7. Vinculin = loading control. 
(B) Immunoblot of SiHa cells cultured for 24 h under normoxia (N, 21 % O2) or hypoxia (H, 1 % O2) and 
subsequent reoxygenation of hypoxic cells for the indicated time periods. Protein expression of P-AKT T308 and 
S473 and HPV16 E7 was measured. β-actin = loading control. (C) HeLa, SW756 and SiHa cells were cultured for 
24 h under hypoxia or normoxia with medium containing 5.5 or 25 mM glucose. Protein expression was analyzed 
by immunoblot of HIF-1α, P-AKT T308 and S473, pan-AKT, HPV16/18 E6 and E7. β-actin = loading control. 
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the PI3K/AKT pathway in regulation of E6/E7 under hypoxic conditions by functional 
analyses. 
To investigate if hypoxia-induced activation of AKT is required for repression of E6/E7 under 
hypoxia, HeLa, SW756, SiHa and MRI-H-186 cells were treated with the allosteric AKT 
inhibitor AKTi VIII [143] or the PI3K inhibitor LY294002 [144] and cultured under hypoxia. 
Immunoblot analyses showed that phosphorylation of AKT at T308 and S473 was efficiently 
blocked by both inhibitors under normoxia and hypoxia (Fig. 17A). Intriguingly, treatment with 
the PI3K/AKT pathway inhibitors counteracted repression of E7 under hypoxia as was shown 
by immunoblot. E6 expression was also effectively reactivated in HeLa and SW756 cells but 
results were less coherent for E6 in the HPV16-positive SiHa and MRI-H-186 cells where E6 
repression was not or only weakly counteracted by PI3K/AKT inhibitor treatment under 
hypoxia. Notably, protein expression of E6 and E7 was not significantly affected by inhibitor 
treatment in normoxic cells, albeit some minor increases in protein level were detected in 
SW756 and MRI-H-186 cells. 
Based on the fact that PI3K and AKT inhibitors are intensely investigated as anti-cancer 
drugs [121], two agents currently tested in the clinic were included in further studies, namely 
the AKT inhibitor MK-2206 [145] and the PI3K inhibitor PX-866 [146]. Treatment with 
MK-2206 and PX-866 also counteracted repression of E6/E7 protein expression under 
hypoxia in a dose-dependent manner (Fig. 17B). 
qRT-PCR analyses in HeLa cells revealed that this regulation was already detectable at the 
transcript level since all tested inhibitors significantly counteracted hypoxic repression of 
E6/E7 mRNA expression under hypoxia, although E6/E7 mRNA levels did not completely 
return to basal expression levels (Fig. 17C). E6/E7 mRNA expression after inhibitor 
treatment under normoxia showed a small tendency towards an increased expression but no 
major induction was detected.  
These results strongly argue that hypoxia-induced activation of PI3K/AKT signaling is 
necessary for inhibition of E6/E7 expression under hypoxia. 
LY294002, although widely applied to study PI3K signaling, can also inhibit the autokinase 
activity of mTOR [147] and has various other molecular targets [148, 149]. PX-866 is more 
specific but still shows relevant activity towards other kinases such as mTOR [150]. Hence, 
to further corroborate the results above, the highly selective class I PI3K inhibitor GDC-0941 
was also analyzed and showed similar effects on E6 and E7 expression under hypoxia to 
those observed with the other inhibitors (Fig. 17D). Collectively, these findings indicate that 
activation of AKT under hypoxia, mediated via PI3K, is required for the hypoxic repression of 
E6/E7. 
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The PI3K/AKT pathway is closely connected to mTOR signaling in that mTORC2 
phosphorylates AKT at S473 and therefore contributes to activating AKT [151]. To gain a 
deeper understanding of the AKT regulatory pathway under hypoxia, different mTOR 
inhibitors were applied. The inhibitor KU-0063794 inhibits mTORC1 and mTORC2 [152], 
whereas rapamycin almost selectively targets mTORC1, at least during short-term treatment 
[153]. Treatment of HeLa cells with rapamycin only weakly counteracted E7 protein 
repression under hypoxia. However, treatment with KU-0063794 led to a clear reactivation of 
E6 and E7 protein expression under hypoxia (Fig. 18A). This goes in line with effects 
observed for AKT phosphorylation. More precisely, KU-0063794 prevented phosphorylation 
of AKT at S473 under normoxia and hypoxia as was expected due to inhibition of mTORC2. 
Hypoxia-induced phosphorylation of AKT at T308 was only abolished when high 
concentrations (5 µM) of KU-0063794 were applied. As expected, treatment with rapamycin, 
which only targets mTORC1, had no inhibitory effect on hypoxia-induced AKT 
phosphorylation. Hence, reactivation of E6/E7 expression under hypoxia strongly correlated 
with a blockade of AKT S473 phosphorylation via mTORC2. Notably, rapamycin induced 
phosphorylation of AKT at S473 and T308 under normoxia, indicating a feedback mechanism 
on mTORC2 triggered by inhibition of mTORC1.  
In parallel to immunoblot analyses, E6/E7 mRNA expression was measured by qRT-PCR. 
KU-0063794 treatment induced E6/E7 mRNA expression under normoxia and hypoxia (Fig. 
18B). Treatment with rapamycin also induced E6/E7 mRNA expression under normoxia, 
although to a lesser extent than observed for KU-0063794. Under hypoxia, rapamycin weakly 
counteracted repression of E6/E7, albeit much less efficient than KU-0063794. 
 
Fig. 17 (see previous page). Inhibitors of PI3K and AKT counteract repression of E6/E7 under hypoxia. (A)
HeLa, SW756, SiHa and MRI-H-186 cells were treated with 10 µM AKTi VIII, 20 µM LY294002 or DMSO (solvent 
control) and cultured for 24 h under hypoxia or normoxia. Immunoblot analyses show protein expression of 
HIF-1α, P-AKT T308 and S473, HPV18/16 E6 and E7. Vinculin = loading control. (B) HeLa and SW756 cells were 
treated with the indicated concentrations of MK-2206 and PX-866 and cultured for 24 h under hypoxia or 
normoxia. Immunoblot of HIF-1α, P-AKT T308 and S473, HPV18 E6 and E7 is shown. Vinculin = loading control.
(C) qRT-PCR analyses of HeLa cells treated with 3 µM MK-2206, 10 µM AKTi VIII, 3 µM PX-866 or 20 µM 
LY294002 and cultured for 24 h under hypoxia or normoxia. Depicted is the log2 of the mean mRNA expression 
of E6/E7 relative to the DMSO-treated normoxic control. Standard deviations are indicated (n = 3). Asterisks 
indicate statistically significant differences to DMSO treated cells under hypoxia as determined by one-way 
ANOVA (***p < 0.001 ). (D) HeLa cells treated for 24 h with GDC-0941 and cultured under hypoxia or normoxia. 
Immunoblot of HIF-1α, P-AKT T308 and S473, HPV18 E6 and E7 is shown. Vinculin = loading control. 
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To ensure functionality of the mTOR inhibitors, the phosphorylation status of the mTOR 
targets 4E-BP1, S6 and p70S6K was monitored by immunoblot. A general downregulation of 
mTOR target phosphorylation under hypoxia was observed as was reported previously [71]. 
Upon inhibitor treatment they showed the expected effects with a strong downregulation of 
Phospho-S6 and Phospho-p70S6K by both inhibitors (Fig. 18A). Pospho-4E-BP1 was only 
reduced by treatment with KU-0063794 and was insensitive to rapamycin under the applied 
experimental conditions, as expected [154].  
In conclusion, experiments with small molecule inhibitors revealed that hypoxia-induced 
activation of AKT, mediated via the upstream regulators PI3K and mTORC2, is responsible 
for the HPV E6/E7 repression under hypoxia.  
Fig. 18. mTOR inhibitors counteract repression of E6/E7 under hypoxia. (A) HeLa cells were treated with the 
indicated concentrations of rapamycin and KU-0063794 or DMSO as solvent control and cultured for 24 h under 
hypoxia or normoxia. Immunoblot analyses of HIF-1α, P-AKT T308 and S473, phosphorylated 4E-BP1 (P-4E-
BP1, S65), 4-E-BP1, phosphorylated S6 (P-S6, S235/236), phosphorylated p70S6K (P-p70S6K, T389), p70S6K, 
HPV18 E6 and E7 are shown. Vinculin = loading control. (B) E6/E7 mRNA expression of HeLa cells treated as in 
(A) was determined by qRT-PCR. The log2 of the mean expression relative to DMSO treated normoxic control 
cells is shown. Standard deviations are indicated (n = 3). Asterisks indicate statistically significant differences to 
DMSO treated cells under hypoxia as determined by one-way ANOVA (***p < 0.001, **p < 0.01). 
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2.5 Repression of E6/E7 under hypoxia in the context of AKT, calcium and 
energy metabolism 
The observed glucose responsiveness of hypoxic activation of AKT and repression of E6/E7 
suggest a close connection to the cellular metabolism and energy status. Under hypoxia, 
cells are forced to carry out major alterations in their energy metabolism to survive since they 
can no longer rely on mitochondrial oxidative phosphorylation (OXPHOS) as their main 
source of ATP production [73]. Furthermore, oxygen deprivation causes an increase in 
intracellular Ca2+ concentrations. Noteworthy, Ca2+ signaling is important for the regulation of 
mitochondrial energy metabolism [75, 155]. Thus, a potential connection between Ca2+ 
signaling, OXPHOS and E6/E7 repression was investigated, also focusing on AKT which has 
previously been associated with both Ca2+ signaling [102] and metabolic reprogramming 
under hypoxia [156]. 
2.5.1 Calmodulins (CaMs) in regulation of E6/E7 expression under hypoxia 
The ubiquitously expressed Ca2+-binding protein calmodulin (CaM) has been shown to co-
localize with AKT at the plasma membrane and it has been proposed that CaM facilitates 
translocation of AKT to the plasma membrane for activation [102]. Since CaM is dependent 
on Ca2+, it was investigated whether CaM is responsible for increased activation of AKT 
under hypoxia and for a subsequent repression of E6/E7. 
However, HeLa and SiHa cells treated with the CaM antagonist W-7 [157] showed no 
alterations in AKT phosphorylation under hypoxia and normoxia as demonstrated by 
immunoblotting (Fig. 19A). Only SiHa cells treated with a high concentration of W-7 that was 
already lethal for HeLa cells reduced AKT phosphorylation under hypoxia and E7 expression 
levels under normoxia. This may, however, be attributed to high toxicity accompanied by 
extensive side effects.  
HeLa cells expressing shRNAs targeting the three CaM isoforms CaM1, CaM2 and CaM3 
were also not showing any significant alterations in phosphorylation of AKT at T308 (Fig. 
19B). E7 protein and mRNA expression under normoxia and hypoxia was also not affected. 
Knockdown of CaM was assessed by measuring mRNA expression of the three isoforms 
(Fig. 19C).  
Taken together, there were no indications for a connection between the Ca2+-sensing CaM 
on the one hand and repression of E6/E7 or activation of AKT under hypoxia on the other 
hand. 
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Fig. 19. Role of CaMs in hypoxic regulation of E6/E7. (A) Immunoblot analyses of hypoxic and normoxic HeLa 
and SiHa cells treated for 24 h with the indicated concentrations of W-7. DMSO = solvent control. Protein 
expression of HIF-1α, P-AKT T308 and S473 and HPV16/18 E7 is shown. Vinculin = loading control. (B) HeLa 
cells expressing shRNAs against CaM1, CaM2 and CaM3, alone or in combination, were cultured for 24 h under 
hypoxia or normoxia. shContr-1 = control shRNA. Immunoblot of HIF-1α, P-AKT T308 and HPV18 E7.  Vinculin = 
loading control. (C) qRT-PCR analyses of CaM1, CaM2, CaM3 and HPV18 E6/E7 mRNA expression
accompanying to experiment in B. Depicted is the log2 of the mRNA expression relative to shContr-1 under 
normoxia. One representative experiment out of two is shown. 
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2.5.2 Calcium chelation can block repression of E6/E7 under hypoxia  
To gain general insight in whether Ca2+ signaling is required for repression of E6/E7 under 
hypoxia, cells were treated with the Ca2+ chelator BAPTA-AM [158].  
In fact, concomitant treatment with BAPTA-AM during hypoxia counteracted downregulation 
of E6/E7 as was shown by immunoblots of HeLa and SiHa cells (Fig. 20). Notably, HeLa 
cells were more sensitive to BAPTA-AM treatment showing effects already at lower 
concentrations. Hypoxia-induced phosphorylation of AKT was not prevented by treatment 
with BAPTA-AM in HeLa cells, but phosphorylation of S473 was even induced under 
normoxia. Contrarily, in SiHa cells, high concentrations of BAPTA-AM were able to repress 
AKT phosphorylation at both residues under hypoxia and, in case of S473 phosphorylation, 
also under normoxia. Furthermore, treatment with the ionophore A23187 [159], which 
increases membrane permeability for Ca2+, reduced basal E6 expression and inhibited AKT 
S473 phosphorylation in SiHa cells. In HeLa cells, A23187 reduced E6 and E7 level and AKT 
S473 and T308 phosphorylation under normoxia (Fig. 20). 
Hence, results support the notion that Ca2+ plays a crucial role in regulation of E6/E7 
expression. However, a general correlation between Ca2+-dependent E6/E7 regulation and 
AKT activation status was not detected. 
 
Fig. 20. Ca2+ chelation counteracts repression of E6/E7 under hypoxia. HeLa and SiHa cells were treated 
with the indicated concentrations of A23187 and BAPTA-AM and cultured for 24 h under hypoxia or normoxia. 
DMSO = solvent control. Immunoblot shows protein expression of HIF-1α, P-AKT T308 and S473 and HPV16/18 
E6 and E7. Vinculin = loading control. Short exp. = short exposure, long exp. = long exposure. 
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2.5.3 Inhibitors of oxidative phosphorylation repress expression of E6/E7 
To investigate whether hypoxic downregulation of E6/E7 can be linked to alterations in 
mitochondrial activity, cells were treated with OXPHOS inhibitors, namely rotenone, an 
inhibitor of complex I of the mitochondrial electron transport chain or antimycin A, an inhibitor 
of complex III [160].  
Indeed, after treatment with rotenone or antimycin A, repression of E6 and E7 protein 
expression was observed in HeLa and SiHa cells that was counteracted when cells were 
cultured with high concentrations of glucose (Fig. 21A). The phosphorylation status of AKT 
was also affected, however, this was cell line- and inhibitor-dependent. In SiHa cells, both 
inhibitors blocked AKT phosphorylation in a glucose-dependent manner. In HeLa cells, 
treatment with rotenone induced P-AKT, which was counteracted by high glucose. 
Antimycin A rather reduced P-AKT S473, which was reinduced again by high glucose. On a 
side note, phosphorylation of AKT at T308 was not detectable in untreated or Antimycin A-
treated HeLa cells.  
To assess if repression of E6/E7 expression induced by OXPHOS inhibitors is, like hypoxic 
repression of E6/E7, dependent on Ca2+, HeLa cells were treated additionally with BAPTA-
AM. Interestingly, treatment with BAPTA-AM efficiently counteracted repression of E6/E7 
otherwise caused by rotenone or antimycin A (Fig. 21B).  
Previous work of our group showed that the anti-diabetes drug metformin, which is also 
known to, amongst other mechanisms of action, inhibit mitochondrial complex I [161] 
represses E6/E7 expression (A. Däschle, unpublished data). In this context, it was observed 
here that metformin-mediated repression of E6/E7 is not only glucose- but also Ca2+-
dependent (Fig. 21C).  
In conclusion, these results indicate that E6/E7 repression induced by both, hypoxia and 
inhibitors of the mitochondrial electron transport chain, is orchestrated by a glucose-linked 
and Ca2+-dependent mechanism. However, a clear correlation between activation of AKT 
and repression of E6/E7 was not observed in this context. 
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Fig. 21. OXPHOS inhibitors downregulate E6/E7 expression in a glucose- and Ca2+-dependent manner. (A)
HeLa and SiHa cells were treated with the indicated concentrations of rotenone and antimycin A and cultured for 
24 h in medium containing 5.5 or 25 mM glucose. Immunoblot analyses of P-AKT T308 and S473, HPV16/18 E6 
and E7. Vinculin = loading control. DMSO and ethanol (EtOH) are the respective solvent controls. (B) HeLa cells 
were treated with 25 µM BAPTA-AM, 50 nM rotenone and 500 nM antimycin A in the indicated combinations and 
cultured for 24 h before immunoblot analyses of HPV18 E7. Vinculin = loading control. (C) HeLa cells treated with 
2.5 mM metformin were kept in medium containing physiological glucose concentrations (5.5 mM) and treated 
with BAPTA-AM or DMSO (solvent control) or were kept in medium containing 25 mM glucose for 24 h. 
Immunoblot shows expression of HPV18 E7. Vinculin = loading control. 
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2.6 AKT1 and AKT2 mediate repression of E6/E7 under hypoxia 
In the studies described above, a key role of the PI3K/AKT pathway in repression of E6/E7 
under hypoxia was demonstrated by using various small molecule inhibitors targeting this 
pathway. Next, it was aimed at identifying which AKT isoforms are involved in this process. 
AKT1 is ubiquitously expressed and AKT2 expression is also found in most tissues with 
particular high levels in insulin-sensitive tissues [95]. Expression of AKT3, however, is 
described to be more restricted and for instance important in neuronal tissues or frequently 
found to be activated in melanoma cells [115, 162]. The AKT-specific inhibitors applied in the 
present study (AKTi VIII, MK-2206) can target all three AKT isoforms (AKT1, AKT2, AKT3), 
with the highest affinity towards AKT1 and the lowest towards AKT3. 
2.6.1 AKT3 expression in cervical cancer cells 
To investigate whether AKT3 is present in cervical cancer cell lines, immunoblot analyses 
using a polyclonal AKT3-specific antibody (Cell Signaling Technologies, CST) were 
performed. This antibody detected a 60 kDa band that was strongly upregulated in hypoxic 
HeLa, SW756 and SiHa cells (Fig. 22A). Based on this finding, a putative role of AKT3 in 
repression of E6/E7 was assessed by silencing AKT3 via the CRISPR/Cas9 technique in 
HeLa cells. However, no reduction of the hypoxia-induced AKT3 band detected by the CST 
antibody was observed upon application of four different AKT3 targeting guideRNAs (gRNAs, 
Fig. 22B) raising the question of antibody specificity. In contrast to the CST antibody, a 
monoclonal AKT3-specific antibody (Upstate) directed against an N-terminal epitope of AKT3 
revealed no detectable signal for AKT3 in HeLa cells under all investigated conditions. Since 
melanoma cells frequently express increased levels of AKT3, AKT3 knockdown was 
performed in the melanoma cell line MeWo with AKT3 targeting gRNAs. The band detected 
with the monoclonal Upstate antibody was significantly decreased, whereas the signals 
derived from the polyclonal CST antibody remained unaffected (Fig. 22C). This indicates that 
hypoxia-induced immunoblot signals observed with the CST antibody in cervical cancer cell 
lines were most likely not AKT3-specific whereas the Upstate antibody detected AKT3. 
Furthermore, and in stark contrast to melanoma cells, AKT3 is undetectable in HeLa cervical 
carcinoma cells. Thus, further studies were focusing on the two ubiquitously expressed 
isoforms AKT1 and AKT2.  
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2.6.2 Effect of AKT1 and AKT2 modulation on E6/E7 expression under hypoxia 
As illustrated above, AKT inhibitors reactivate expression of E6/E7 under hypoxia. In a next 
step, the question was addressed whether this effect could be counteracted by enhancing 
the activities of AKT1 and AKT2. 
Fig. 22. AKT3 expression in cervical cancer cell lines. (A) Analyses of AKT3 protein expression in HeLa, 
SW756 and SiHa cells cultured for 24 h under hypoxia or normoxia. Immunoblot analyses of HIF-1α, an 
unspecified band detected by an anti-AKT3 antibody (anti-AKT3 (CST)) and HPV16/18 E7. Vinculin = loading 
control. (B) HeLa cells were transfected with AKT3 targeting gRNAs (AKT3 gRNA1-4) and cultured for 24 h under 
hypoxia or normoxia. Empty = empty basic vector. Immunoblot analyses of HIF-1α, anti-AKT3 (CST), AKT3
Upstate antibody) and HPV18 E7. Vinculin, β-actin = loading control. (C) Immunoblot analyses compares AKT3 
expression in MeWo cells that were silenced for AKT3 expression with the CRISPR/Cas9 method using two 
gRNAs (AKT3 gRNA1 and 2), and HeLa cells, incubated for 24 h under hypoxia or normoxia. Empty = empty 
basic vector. Protein expression of AKT3 (Upstate antibody) and unspecified protein detected by anti-AKT3 (CST 
antibody) is shown. β-actin = loading control. 
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To that end, constitutively-active myristoylated forms of AKT1 and AKT2 were overexpressed 
in HeLa cells. Due to myristoylation, AKT is recruited to the plasma membrane and becomes 
constitutively activated [163]. Transfected Hela cells were treated with different 
concentrations of AKTi VIII and cultured under hypoxia or normoxia before protein 
expression was assessed by immunoblot analyses. Successful overexpression of 
constitutively-active AKT was confirmed by detecting P-AKT T308 (Fig. 23). Since ectopically 
expressed AKT has a lower molecular weight due to deletion of its PH-domain, which is 
normally required for regulation of PI3K-dependent membrane recruitment and activation 
[101], it can be distinguished from the much weaker expressed endogenous form. 
Functionality of constitutively-active AKT1 and AKT2 was confirmed by detecting an 
induction of phosphorylation of the well-defined AKT substrate glycogen synthase 
kinase 3-α/β (GSK3-α/β) [110]. Overexpression of either AKT isoform did not affect E6/E7 
expression under normoxia. However, the reactivation of E6/E7 protein expression under 
hypoxia that was observed when cells were treated with AKTi VIII was counteracted by the 
concomitant overexpression of constitutively-active AKT1 or AKT2, alone or in combination. 
Concomitant overexpression of both isoforms together did not further enhance the effect 
observed on E6/E7 expression by the individual isoforms (Fig. 23). 
 
Fig. 23. Overexpression of constitutively-active AKT1 and AKT2 counteracts reactivation of hypoxic E6/E7 
expression induced by AKTi VIII. HeLa cells were transfected with expression vectors for myristoylated AKT1 
(myrAKT1deltaPH) and AKT2 (myrAKT2deltaPH), alone or in combination, treated with 5 and 10 µM AKTi VIII 
and cultured for 24 h under hypoxia or normoxia. Immunoblot of HIF-1α, P-AKT (T308), phosphorylated GSK3-α 
and GSK3-β (P-GSK3-α (S21)/P-GSK3-β (S9)) HPV18 E6 and E7 is shown. Vinculin, β-actin = loading control. 
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Whereas these experiments indicate that AKT activation does not induce repression of 
E6/E7 under normoxia, they further confirmed an involvement of AKT, more precisely AKT1 
and AKT2, in the repression of E6/E7 under hypoxia. Moreover, they suggest a functional 
redundancy of both isoforms in this process. 
2.6.3 Concomitant silencing of AKT1 and AKT2 counteracts repression of E6/E7 under 
hypoxia 
The results obtained after increasing AKT activity via ectopic expression of constitutively-
active isoforms indicate an important role for AKT1 and AKT2 in the hypoxic repression of 
HPV oncogene expression. In this case, silencing of endogenous AKT1 and/or AKT2 
expression should block hypoxia-induced repression of E6/E7.  
To test this hypothesis, HeLa cells were transfected with siRNAs targeting AKT1 and AKT2, 
alone or in combination and cultured under hypoxia or normoxia. Knockdown efficiency was 
monitored by immunoblotting of pan-AKT that showed a significant decrease upon treatment 
with AKT1 targeting siRNAs (Fig. 24A). Upon knockdown of AKT2, expression levels of pan-
AKT were not detectably altered indicating that AKT1 is the predominantly expressed 
isoform. Hence, immunoblot analyses of AKT2 were performed revealing that AKT2 was 
expressed in HeLa cells and that its levels were reduced upon transfection with siRNAs. 
Moreover, it was observed that AKT2 levels remained unaffected by silencing of AKT1 and 
were downregulated under hypoxia similar to what was already observed for general protein 
expression of AKT (Fig. 16C, Fig. 24). Interestingly, hypoxia-induced phosphorylation of AKT 
was not altered upon silencing of AKT2 and diminished, but still detectable, upon silencing of 
AKT1. However, a concomitant silencing of both isoforms very efficiently blocked AKT 
phosphorylation at both investigated residues. Accordingly, repression of E7 was 
counteracted in AKT1 and in AKT1/2 silenced cells with the effect being slightly more 
pronounced upon concomitant knockdown of AKT1 and AKT2. However, reactivation of E6 
expression under hypoxia was not observed upon effective blockade of AKT1/2 expression 
by RNAi (Fig. 24A). 
To obtain more efficient AKT knockdown cells, AKT1 knockdown single cell clones were 
generated by the CRISPR/Cas9 method and subsequently transfected with AKT2 targeting 
siRNAs. AKT1 knockdown clones still showed hypoxia-induced phosphorylation of AKT at 
T308 that was only blocked by additional silencing of AKT2 (Fig. 24B). Phosphorylation of 
AKT at S473 was still detectable in AKT1 knockdown cells, but no induction by hypoxia was 
observed. Importantly, complete disappearance of the P-AKT signal was only observed in 
AKT1 knockdown cell clones in which AKT2 expression was additionally silenced. 
Correspondingly, the reactivation of E7 expression under hypoxia in AKT1 knockdown cells 
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was significantly enhanced when AKT2 was concomitantly blocked. Weak reactivation of E6 
expression under hypoxia was also detectable in the double knockdown cells (Fig. 24B). 
In conclusion, the reactivation of E6/E7 expression under hypoxia that was observed upon 
treatment with PI3K/AKT/mTORC2 inhibitors could be reproduced by silencing AKT1 and 
AKT2 expression. Although the results suggest a predominant role of AKT1, combined 
blockade of AKT1 and AKT2 showed the most efficient effects, indicating functional 
redundancy of the two isoforms in hypoxic regulation of E6/E7 expression. 
 
Fig. 24. Combined silencing of AKT1 and AKT2 counteracts repression of E6/E7 expression under 
hypoxia. (A) HeLa cells were transfected with siRNAs targeting AKT1 (siAKT1) and AKT2 (siAKT2), alone or in 
combination, and incubated for 24 h under hypoxia or normoxia. siContr-1 = control siRNA. (B) AKT1 was 
silenced in HeLa cells using the CRISPR/Cas9 technique. Two single cell clones generated with different gRNAs 
are shown (AKT1 gRNA1#1, AKT1 gRNA4#2). Control cell clone was transfected with the empty basic vector 
(empty#1). Single cell clones were transfected with siRNAs targeting AKT2 (siAKT2) or a control siRNA 
(siContr-1) and cultured for 24 h under hypoxia or normoxia. (A+B) Immunoblot analyses show protein expression 
of HIF-1α, P-AKT T308 and S473, pan-AKT (AKT), AKT2 and HPV18 E6 and E7. β-actin = loading control. 
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2.7 Phenotypic consequences of AKT inhibition on hypoxic cervical cancer 
cells 
2.7.1 PI3K/AKT inhibitors do not induce proliferation in hypoxic cervical cancer cells 
The observation that clinically tested PI3K/AKT inhibitors can reactivate viral oncogene 
expression under hypoxia (Fig. 17) is intriguing and may have clinical consequences, since 
E6/E7 can act pro-proliferative. Thus, the effects of PI3K/AKT inhibitor treatment on the 
proliferation of hypoxic cervical cancer cells were investigated. 
Analysis of cell proliferation by quantification of crystal-violet stained cells revealed that 
treatment with AKTi VIII over a period of 3 days did not reinduce cell growth under hypoxia 
but that cell numbers were slightly lower or remained constant when compared to DMSO 
treated control cells as was shown for HeLa and SiHa cells (Fig. 25A). On a side note, 
treatment of normoxic cells with AKTi VIII led to the expected growth inhibition (Fig. 25B) 
corroborating the well characterized pro-proliferative function of AKT [95]. Moreover, 
comparison of hypoxic and normoxic growth curves of control cells showed the previously 






























































































Fig. 25. AKTi VIII does not induce proliferation under hypoxia. (A+B) Time course of HeLa and SiHa cells 
treated with 10 µM AKTi VIII and cultured under hypoxia (A) or normoxia (B) for 3 days. Crystal violet staining of 
cells was performed every 24 h. Depicted is the relative amount of cells determined by quantification of cell-bound 
crystal violet. The time point 0 h was set as 1 for each condition. Shown is the mean of 3 independent 
experiments with standard deviations.   
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A more detailed analysis was carried out by live cell imaging with acquisition of images every 
2-4 h and subsequent computerized cell quantification. For this purpose, nuclei-labelled 
(H2B-mCherry) cells were used. The resulting growth curves again depicted the anti-
proliferative effects of AKTi VIII on normoxic Hela and SiHa cells (Fig. 26B). Under hypoxia, 
there was no proliferative activity detectable for SiHa cells, with and without AKTi VIII. In 
hypoxic HeLa cells, AKTi VIII further inhibited the already reduced, but still measurable, cell 
growth (Fig. 26B). Moreover, treatment with MK-2206 and PX-866 caused similar effects in 
HeLa cells (Fig. 26C). Appreciable increases in cell death were not observed under any 





























































































































































Fig. 26. AKTi VIII, MK-2206 and PX-866 do not induce proliferation under hypoxia as determined by live 
cell imaging. (A-C) HeLa and SiHa mCherryH2B cells were seeded in 96 well plates. 2 days after seeding cells 
were treated with 10 µM AKTi VIII (A) or 5 µM MK-2206 and 5 µM PX-866 (C) and monitored for the following 72 
h. DMSO served as solvent control. Images were acquired every 2-4 h using an IncuCyte® system and red object 
count (representing cell number) was determined. Shown is the mean of technical triplicates of one representative 
experiment. 
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Collectively, these results indicate that hypoxic cervical cancer cell lines remain growth-
arrested even upon PI3K/AKT inhibitor-induced reactivation of viral oncogene expression 
indicating that the suppression of cell proliferation via inhibition of PI3K/AKT signaling acts 
dominantly over the pro-proliferative stimulus derived from E6/E7 expression. 
2.7.2 PI3K/AKT inhibitors modulate the response of hypoxic HeLa cells to etoposide  
Hypoxic tumors are generally associated with poor patient prognosis that can largely be 
attributed to their high resistance towards radio- and chemotherapy [64]. Since PI3K/AKT 
inhibitors are tested in the clinic not only as single agents, but also to complement 
conventional therapies [121], the effects of such inhibitors on hypoxic cervical cancer cells in 
combination with chemotherapy were investigated. In particular the induction of senescence 
and the clonogenic capacity of treated cells were assessed.  
For this purpose, cells were pre-treated with AKTi VIII, MK-2206 or PX-866, cultured under 
hypoxia or normoxia and 24 hours later treated with the chemotherapeutic drug etoposide. 
Cells were kept under hypoxia for two additional days, then split and cultured further under 
normoxia for colony formation and senescence assays according to the schematic depicted 
in Fig. 27. In normoxic cells, treatment with etoposide led to the induction of senescence, as 
was shown by staining for senescence associated β-galactosidase (SA-β-Gal) activity and by 
the typical morphological signs of senescence that were observed, such as long cytoplasmic 
projections, cell enlargement and flattening (Fig. 27). In contrast, hypoxic cells were better 
able to evade senescence induction resulting in an increased outgrowth of cells after 
subsequent cultivation under normoxia. This was also verified by colony formation assays 
showing a reduced number of outgrowing clones under normoxia (Fig. 28). Interestingly, in 
HeLa cells concomitant treatment with AKTi VIII, MK-2206 or PX-866 abrogated the 
protective effect of hypoxia in that hypoxic cells were no longer able to evade the etoposide-
induced senescence resulting in a significantly diminished number of outgrowing clones (Fig. 
27, Fig. 28). However, in hypoxic SiHa and SW756 cells, senescence induction and number 
of clones was not affected by PI3K/AKT inhibitor treatment. On a side note, in SiHa and 
SW756 cells an increase in the number of clones outgrowing after etoposide treatment was 
observed in normoxic cells that were treated with AKTi VIII (Fig. 27, Fig. 28). 
In conclusion, it was observed that PI3K/AKT inhibitors can modulate the behavior of hypoxic 
cervical cancer cells towards chemotherapy in that they can sensitize cells to etoposide-
induced senescence induction in certain cell lines. 
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Fig. 27. PI3K/AKT inhibitors modulate etoposide-induced senescence under hypoxia in a cell line-
dependent manner. Senescence assay after etoposide (10 µM) treatment of normoxic or hypoxic HeLa, SiHa 
and SW756 cells treated with 10 µM AKTi VIII, 5 µM MK-2206 or 5 µM PX-866. DMSO = solvent control. Scheme 
on top: Treatment protocol, further specified in the text. SA-β-Gal = senescence associated β-galactosidase
assay. CFA = colony formation assay. 
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2.7.3 Knockdown of AKT modulates the response of hypoxic HeLa cells to etoposide  
To further analyze a putative role of AKT in the effects caused by PI3K/AKT inhibitors in 
etoposide treated cells under hypoxia, etoposide treatment was applied to HeLa and SiHa 
cells transfected with siRNAs targeting AKT1 or AKT1 and AKT2 according to the schematic 
in Fig. 29A. Successful knockdown was verified by immunoblotting (Fig. 29B). 
Fig. 28. PI3K/AKT inhibitors modulate etoposide-induced colony forming capacity under hypoxia in a cell 
line-dependent manner. Colony formation assay of hypoxic and normoxic HeLa, SW756 and SiHa cells 
accompanying to senescence assay from Fig. 27. 
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Fig. 29. AKT1/2 silencing modulates etoposide-induced senescence under hypoxia in a cell line-
dependent manner. (A) Senescence assay after etoposide (10 µM) treatment of normoxic or hypoxic HeLa and
SiHa cells either transfected with AKT1 and AKT2 targeting siRNAs (siAKT1, siAKT2) in the indicated 
combinations, or treated with 10 µM AKTi VIII. siContr-1 = control siRNA, DMSO = solvent control. Scheme on 
top: Treatment protocol, further specified in the text. TX = transfection. Eto = etoposide. SA-β-Gal = senescence 
associated β-galactosidase assay. CFA = colony formation assay. (B) Accompanying immunoblot showing 
protein expression of HIF-1α, P-AKT T308, AKT and AKT2. Vinculin = loading control.  
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Knockdown of AKT1 alone rendered hypoxic HeLa cells slightly more vulnerable to etoposide 
treatment as could be observed after subsequent cultivation under normoxia by a lower 
number of cells being able to avoid senescence induction (Fig. 29A) and by the outgrowth of 
fewer cells in colony formation assays (Fig. 30). This effect was further enhanced upon 
concomitant silencing of AKT1 and AKT2. Of note, treatment with AKTi VIII was however still 
more efficient in diminishing the colony forming capacity of etoposide treated hypoxic HeLa 
cells.  
Analogue to the experiments performed with PI3K/AKT inhibitors, AKT knockdown did not 
affect the phenotypic response of hypoxic SiHa cells to etoposide, but an increased 
outgrowth of clones was observed in normoxic SiHa cells transfected with AKT1 or AKT1 and 
AKT2 targeting siRNAs (Fig. 29, Fig. 30).  
Hence, silencing of AKT1 and AKT2 expression sensitized hypoxic HeLa, but not SiHa cells, 
towards etoposide treatment. 
 
Fig. 30. AKT1/2 silencing modulates etoposide-induced colony forming capacity under hypoxia in a cell 
line-dependent manner. (A) Colony formation assay of Hela and SiHa cells accompanying to senescence assay 
from Fig. 29. 
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2.8 Proteome analysis of hypoxic HPV-positive cancer cells 
In summary, the work of the present study revealed that HPV oncogene expression is 
repressed under hypoxia via the PI3K/AKT pathway in a glucose-dependent manner in that 
PI3K/AKT/mTORC2 inhibitors as well as high glucose levels counteract E6/E7 repression. To 
gain further insights into this process, mass spectrometry (MS)-based quantitative proteome 
analyses were performed, with the support of Prof. Dr. Jeroen Krijgsveld’s group at DKFZ, 
using Thermo Scientific’s tandem mass tag (TMT) isobaric labeling approach [164]. The 
cellular proteome of SiHa cells cultured under normoxia, under hypoxia, and under hypoxia 
treated with AKTi VIII or high glucose concentrations (25 mM) was assessed (illustrated in 
Fig. 31A). A representative immunoblot showed the expected E7 and P-AKT T308 
expression under the investigated conditions (Fig. 31B).  
To gain an impression about global alterations in the obtained data sets derived from 3 
individual experiments, volcano plots were generated to visualize relative fold changes in 
relation to statistical significance (Fig. 31C). Comparison of the proteome (5967 measured 
proteins) of differentially treated hypoxic cells to normoxic cells showed that many alterations 
in protein expression were detected. However, significant changes (p < 0.05) with strong 
alterations in expression levels (log2 fold change < -1 or > 1) were limited (Fig. 31C, upper 
panel). Under hypoxia E6/E7 expression is shut down but reactivated again when cells are 
treated with AKTi VIII or with high glucose concentrations. Since high glucose blocks 
hypoxia-induced AKT phosphorylation, repression of E6/E7 could be counteracted by a 
common mechanism under both conditions. Hence, it is particularly interesting to compare 
these two conditions with untreated hypoxic cells, where E6/E7 is downregulated, to identify 
potentially common regulators of E6/E7 expression under hypoxia. Volcano plots of these 
comparisons showed that most of the significantly different expressed proteins were 
upregulated by the treatments relative to the hypoxia control, but some downregulated 
proteins were detected as well (Fig. 31C, lower panel).  
In total, 46 proteins with significant differential expression (p-value < 0.05) between the 
hypoxia and normoxia DMSO-treated controls were detected. These are grouped into two 
main clusters, characterized by upregulation (9 proteins) or downregulation (37 proteins) as 
compared to the normoxia baseline. The alteration of protein expression caused by hypoxia 
was partially or fully reverted by the treatment with AKTi VIII and high glucose for many of 
the candidates (Fig. 32). Proteins with strong deregulation caused by hypoxia and a strong 
normalization effect of the treatments may be promising leads for future investigations of the 
mechanism behind E6/E7 reactivation through AKT inhibition and high glucose 
concentrations. Interesting candidates include, amongst others, metal responsive proteins 
like metallothionein 2A (MT2A) or proteins linked to the Wnt signaling pathway like Wnt5A or 
Dickkopf-related protein 1 (DKK1) (Fig. 32). A putative functional role of these proteins in 
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AKT-dependent repression of E6/E7 under hypoxia awaits further exploration in future 
studies. 
 
Fig. 31. Proteome analysis of hypoxic SiHa cells. TMT mass spectrometry analysis of SiHa cells treated with 
DMSO as solvent control, 10 µM AKTi VIII or kept in medium containing 25 mM glucose (instead of standard 
medium with 5.5 mM glucose) and cultured for 17 h under hypoxia or normoxia as indicated. (A) Scheme 
depicting the four analyzed treatment conditions. (B) Representative immunoblot showing protein expression of 
HIF-1α, P-AKT T308, HPV16 E7. β-actin = loading control. (C) Volcano plots depicting mean log2-fold change of 
protein expression versus adjusted p-value (n = 3). Upper graphs: Fold change of protein expression from hypoxic 
conditions (DMSO as solvent control, AKTi VIII, 25 mM glucose) relative to normoxic condition (DMSO treated). 
Lower graphs: Fold change of protein expression under hypoxia treated with AKTi VIII or cultured under hypoxia 
with 25 mM glucose relative to DMSO-treated hypoxic control. Proteome analyses were performed in 
collaboration with B. Kuhn and J. Krijgsveld (DKFZ).  
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Fig. 32. Heatmap of differentially expressed proteins under hypoxia. Analysis of proteome data derived from 
TMT mass spectrometry described in Fig. 31. It was filtered for differential expression under hypoxia (DMSO-
treated control) compared to normoxia (p < 0.05) and hierarchical clustering was performed. Left three columns: 
Comparisons of the different treatment conditions under hypoxia relative to normoxia. Right two columns: 
Comparisons of hypoxia treated with AKTi III or high glucose (25 mM) relative to DMSO-treated hypoxic control. 
Protein names are indicated on the right. Upregulation is shown in red, downregulation in blue (see color scheme 
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3. Discussion 
Under normoxic conditions, HPV-positive cancer cells rely on sustained expression of the 
two viral oncogenes E6 and E7 and go into senescence when those are silenced. Contrarily, 
under hypoxia, a condition frequently found in subregions of solid tumors, they reversibly 
shut down E6 and E7 expression and enter a dormant state that potentially contributes to 
therapy resistance and tumor recurrences. This thesis aimed at elucidating the mechanism 
which underlies the repression of the HPV oncogenes under hypoxia. The results showed 
that hypoxic E6/E7 repression is regulated at the transcriptional level, but likely also at the 
level of protein and mRNA stability. Moreover, the critical signal cascade responsible for 
hypoxic E6/E7 downregulation was identified and functionally characterized, revealing that 
E6/E7 repression under hypoxia is dependent on the activity of the PI3K/AKT signaling 
pathway. 
3.1 Level of E6/E7 repression under hypoxia 
3.1.1 Transcriptional regulation contributes to repression of E6/E7 under hypoxia 
Repression of E6/E7 mRNA expression under hypoxia is, at least partially, caused by 
inhibition of transcription as was demonstrated by reporter assays revealing that the activity 
of the HPV18 URR coding for E6/E7 transcripts was significantly reduced by approximately 
50 % under hypoxia. 
DNA methylation is unlikely to play a role in this context since no major alterations in 
methylation pattern at investigated (CpG-containing) sites in the HPV16 URR were detected 
and treatment with the demethylating agent 5-Aza did not prevent repression of E6/E7 under 
hypoxia. DNA methylation has previously been reported to be important for expression of 
E6/E7 in HPV-positive cancer cell lines since treatment with 5-Aza led to diminished E6/E7 
mRNA and protein expression level [165]. This was only partially confirmed in the present 
studies where 5-Aza downregulated E6/E7 expression under normoxia in SiHa, but not in 
HeLa cells although higher concentrations of 5-Aza were applied compared to the 
aforementioned study. The suggested mechanism for downregulation of E6/E7 expression in 
SiHa cells upon DNA demethylation involves the microRNA miR-375. The promoter of 
miR-375 is methylated under normal conditions and treatment with 5-Aza reactivates 
miR-375 expression resulting in reduced levels of E6/E7 [165]. In HeLa cells, which were not 
included in the original study, this regulation was not observed, possibly due to cell line-
dependent differential regulatory mechanisms. Hypoxia-induced reduction in DNA 
methylation at the L1 and L2 genes may be attributed to the observed downregulation of 
Dnmt1 expression, which was already previously reported for colorectal cancer cells [166]. 
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Whereas the results indicate that DNA methylation plays no direct role in repression of E6/E7 
under hypoxia, the data regarding the methylation status of histones was more complex. 
Total cellular levels of H3K4me3 and H3K27me3 were increasing under hypoxia, most likely 
due to diminished activity of O2-dependent histone demethylases. Hypoxia-induced inhibition 
has for instance been reported for the H3K4me3 demethylase JARID1A or the H3K27me3 
demethylase JMJD3 [84, 167]. This also goes in line with recent reports that describe 
increased bivalent epigenetic marking with H3K4me3 and H3K27me3 under hypoxia [85, 86]. 
Bivalently marked chromatin is characteristic, but not entirely exclusive, for embryonic stem 
cells. In many developmental genes the repressive mark H3K27me3 silences the gene, 
whereas the presence of H3K4me3 allows rapid activation when required [168]. In a 
comprehensive analysis, it was previously shown that although transcription is primarily 
determined by H3K4me3, the exact loci of the H3K4me3 and H3K27me3 marks is an 
additional decisive factor for transcriptional activity. For instance, increased H3K27me3 at 
the transcription start site (TSS) under hypoxia was closely associated with gene repression 
despite the presence of H3K4me3 [85]. Thus, increased enrichment of H3K27me3 (and 
H3K4me3) at the HPV16 URR in hypoxic SiHa cells may indicate transcriptional repression, 
especially since one of the applied primers (HPV16URR_2) spans a region close to the TSS 
of E6/E7. Primers for the hypoxia-activated genes VEGF and Glut1 were in regulatory 
regions more distant to the TSS. H3K4me3 and H3K27me3 detected at these sites may 
therefore rather be associated with transcriptional activation under hypoxia although an 
increase in both histone marks was detected here as well. Nevertheless, to adequately 
associate the detected chromatin marks with transcriptional activity of genes a better 
resolution (obtainable by ChIP-sequencing) would be required to gain information about the 
exact localization of H3K4me3 and H3K27me3 marks among the genome. Additionally, the 
data obtained in the present study cannot distinguish if enhanced signals from H3K4me3 and 
H3K27me3 at the same locus are caused by bivalent chromatin or by chromatin that harbors 
different epigenetic marks among the cell population. To gain information about putative co-
localization of both histone marks, sequential ChIP assays would be required. Hence, the 
results obtained in the present work revealed alterations in histone marks at the HPV16 URR 
and raise the possibility that transcription of E6/E7 is repressed by bivalent epigenetic 
marking with H3K4me3 and H3K27me3 but requires further detailed analyses to allow a final 
conclusion in this context.  
Deletion analyses of the HPV18 URR revealed that hypoxic repression could be mediated by 
a 157 bp fragment of a 3’-portion of the HPV18 enhancer, even when fused to a 
heterologous promoter. Binding of YY1, a potential repressor of HPV transcription [169], was 
reported for this cis-regulatory element [128], leading to the recruitment of Brd4 to this site. 
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Yet, a role for YY1 in regulation of E6/E7 expression was not detected in the present studies 
-neither under normoxia nor hypoxia.  
Interestingly however, treatment with the BET inhibitor JQ-1 led to downregulation of E6/E7 
expression. JQ-1 binds to the bromodomain of BET family members, namely Brd2, Brd3, 
Brd4 and Brdt, and prevents their binding to acetylated histone lysines and the subsequent 
recruitment of transcriptional regulators [170]. BET inhibitors are currently undergoing clinical 
trials to investigate their anti-cancer activities and thus, are of substantial clinical significance 
[171]. In the context of YY1, Brd4 was described as negative regulator of E6/E7 expression 
[128]. In contrast, the JQ-1 induced repression of E6/E7 observed in the present experiments 
argues for an activating function of Brd4. However, since knockdown of Brd4 had no 
consequences on E6/E7 expression under the investigated conditions, this effect could also 
be attributable to the other Bet family members or be caused by a small amount of residual 
Brd4. JQ-1-dependent repression of HPV transcription has previously been reported, but 
only in the context of E2 [172], whose ORF gets disrupted upon integration of the viral DNA 
into the host cell genome in many cervical cancers including the here investigated HeLa, 
SW756 and SiHa cell lines [165, 173]. Thus, JQ-1 induced repression of E6/E7 can also 
occur independently of E2. During the course of this thesis, a paper was published 
describing an E2-independent mechanism of Brd4-mediated activation of E6/E7 transcription 
that can be abolished by BET inhibitors such as JQ-1 [174]. More precisely, Brd4 was 
described to bind to super-enhancer-like-elements at tandemly integrated copies of the HPV 
genome that drive expression of E6/E7 [174, 175]. In the present work, BET-inhibitor 
mediated downregulation of E6/E7 expression was observed in SiHa cells that are 
characterized by only 1-2 viral integrates [129]. Hence, BET family members may also 
activate E6/E7 transcription without the formation of super-enhancers at tandem repeats of 
viral DNA. 
Remarkably, while JQ-1 treatment downregulated E6/E7 expression under normoxia, it 
counteracted repression of E7 under hypoxia in HeLa cells. JQ-1-mediated reactivation was 
not observed for E6 raising the possibility that differential regulation of protein stability of E6 
and E7 or alternative splicing events are involved. However, since these phenomena were 
exclusively observed in HeLa cells, they are likely cell line-specific and were not further 
analyzed in the present work. 
Apart from reported binding of YY1, binding sites for AP1, Oct1 and NF1 [36] have been 
described in the 157 bp fragment sufficient to mediate repression of transcriptional activity 
under hypoxia. Unpublished results from the group of Prof. Dr. Frank Rösl (DKFZ, 
Heidelberg) indicated that AP1, a major driver of HPV transcription [40], is probably not 
responsible for downregulation of E6/E7 under hypoxia (A. Hitschler et al., unpublished 
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data). A potential involvement of Oct1 or NF1 in hypoxic regulation of E6/E7 expression 
remains to be elucidated. 
Taken together, transcription of the HPV E6/E7 mRNA is reduced under hypoxia by a 
mechanism independent of DNA methylation but possibly influenced by alterations in 
H3K4me3 and H3K27me3. In addition, histone-binding BET proteins may play a direct or 
indirect role in hypoxic regulation of E6/E7 expression in a cell line dependent manner.  
Notably, HPV promoter activity under hypoxia was reduced by half, whereas downregulation 
of E6/E7 mRNA was more pronounced (80 % in HeLa cells, see [71]). Thus, effects 
observed in the reporter assays may only partially explain the repression of E6/E7 under 
hypoxia. This may be due to experimental limitations; in luciferase reporter assays the 
activity of the HPV URR was not assessed in the endogenous chromosomal context but with 
a transiently transfected episomal plasmid that may not be subject to all regulatory events 
occurring at the integrated viral promoter. Furthermore, effects on protein and mRNA stability 
of E6 and E7 under hypoxia could contribute to the downregulation. 
3.1.2 Protein and mRNA stability of E6/E7 are reduced under hypoxia 
In fact, E6 and E7 showed slightly reduced protein half-lives under hypoxia. Moreover, 
downregulation of E6/E7 under hypoxia was already detectable at the mRNA level and 
E6/E7 mRNA half-life was shortened under hypoxia. Measurements of both, mRNA and 
protein stability were subject to variations between individual experiments. This suggests that 
protein and mRNA half-lives are likely to be very sensitive to minor fluctuations in the 
experimental conditions such as slight variations in cell density that in turn affect, for 
instance, glucose concentrations in the cell culture medium. However, the detected 
tendencies consistently revealed a reduction of protein and mRNA half-lives. This data 
suggests that E6/E7 downregulation under hypoxia is mediated not only by the repression of 
the E6/E7 transcriptional promoter but also supported by a reduction of E6/E7 mRNA and 
protein half-lives. 
3.2 Candidate transcription factors that are likely not involved in hypoxic 
repression of E6/E7 
Since E6/E7 repression occurs to a substantial part at the transcriptional level and is 
glucose-sensitive, several strong candidates for hypoxic and glucose-dependent regulation 
of gene expression were investigated. In particular, HIF transcription factors are directly and 
indirectly involved in transcriptional regulation of many genes under hypoxia [77]. Although, 
as expected, a strong induction of HIF-1α and HIF-2α was observed under hypoxic 
conditions, E6/E7 repression was not prevented upon efficient knockdown of HIF-1α or 
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HIF-2α, alone or in combination. Work from our group additionally showed that induction of 
HIF-1α under normoxia using the HIF mimetics CoCl2, mimosine and DMOG did not alter E7 
expression [71]. Hence, HIF transcription factors likely neither directly nor indirectly affect 
E6/E7 expression indicating that repression of E6/E7 under hypoxia occurs via a HIF-
independent mechanism.  
Repression of E6/E7 under hypoxia was counteracted by high glucose concentrations raising 
the possibility that glucose-sensitive transcription factors are involved. The Mlx network 
emerged as a prime candidate involved in this regulation since it is an important coordinator 
of gene expression in response to glucose [137]. However, no experimental evidence linking 
Mlx to the regulation of E6/E7 expression was obtained. In specific, whereas the previously 
described Mlx-dependent upregulation of TXNIP by high glucose [139] was impaired upon 
silencing of Mlx and MondoA, neither the repression of E6/E7 nor the glucose-dependent 
reactivation of E6/E7 under hypoxia was affected under the same experimental conditions.  
The c-Myc oncoprotein, which is part of a transcription factor network similar to the Mlx 
network, was found to be downregulated by hypoxia in a glucose-dependent manner thereby 
correlating with E6/E7 expression. This finding is corroborated by previous reports [141, 
142]. Moreover, a positive correlation between E6/E7 and c-Myc expression has been 
described in that E6 is known to stabilize c-Myc [53, 54] and that silencing of E6/E7 
expression in HeLa cells decreases c-Myc level [55, 56]. However, while E6/E7 are likely to 
positively regulate c-Myc expression under the conditions investigated in the present study, a 
reciprocal mechanism of c-Myc-dependent E6/E7 regulation was not detected since silencing 
of c-Myc had no impact on E6/E7 expression under hypoxia or normoxia. 
Taken together, the cellular mechanism causing downregulation of viral oncogene 
expression under hypoxia appears to be independent of HIF transcription factors, the Mlx 
network and the c-Myc oncoprotein.  
3.3 AKT-dependent repression of E6/E7 under hypoxia 
However, evidence for a possible role for the AKT kinase in the process of hypoxic E6/E7 
repression emerged in the present studies. Specifically, activating phosphorylation of AKT 
was induced under hypoxia in a glucose-dependent manner, thereby inversely correlating 
with E6/E7 expression. Moreover, time course experiments revealed that hypoxia-induced 
activation of AKT and reoxygenation-induced inactivation of AKT precede downregulation 
and reactivation of E6/E7 expression, respectively. These circumstantial evidences would be 
consistent with a role for AKT in hypoxic E6/E7 repression, but required experimental proof 
to demonstrate a functional connection. 
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3.3.1 Signaling via the PI3K/AKT pathway is required for repression of E6/E7 under 
hypoxia 
In the PI3K/AKT pathway, PI3K is an upstream regulator being essential for activation of AKT 
and described to be important for activation of mTORC2 as well. mTORC2 phosphorylates 
AKT at S473, one of the two residues phosphorylated in fully activated AKT [95] (see also 
Fig. 5). Chemical inhibitors targeting AKT, PI3K or mTORC2 all counteracted repression of 
E6/E7 under hypoxia, providing strong experimental evidence that this signaling axis is 
crucial for downregulation of E6/E7 expression. 
More detailed analyses revealed that PI3K and AKT inhibitors prevented phosphorylation of 
AKT at both amino acid residues (T308 and S473). Notably, blockade of S473 
phosphorylation alone by targeting mTORC2 with KU-0063794 was sufficient to counteract 
repression of E6/E7 under hypoxia as well. A second mTOR inhibitor, rapamycin, did not 
block AKT S473 phosphorylation since it primarily targets mTORC1 [153], but not mTORC2 
which is the responsible kinase for AKT S473 phosphorylation. Instead, treatment with 
rapamycin enhanced S473 phosphorylation since mTORC1-mediated feedback inhibition on 
mTORC2 was blocked. Phosphorylation of AKT at S473 by mTORC2 was described to 
facilitate T308 phosphorylation [104], which may explain the observation that T308 
phosphorylation under hypoxia is reduced by high concentrations of KU-0063794 as well. 
Taken together, it was shown here that S473 phosphorylation of AKT is a prerequisite for 
repression of E6/E7 under hypoxia. Although unique blockade of T308 phosphorylation was 
not performed in the present work, results indicate that dual phosphorylation of AKT at T308 
and S473 is required for hypoxia-induced downregulation of E6/E7 since AKT 
phosphorylated at S473 alone has no kinase activity [98]. Collectively, these results showed 
that E6/E7 repression under hypoxia is dependent on fully activated AKT, which is induced 
via PI3K and mTORC2. 
AKT is a known activator of mTORC1 (see chapter 1.4.4). However, despite induction of 
AKT, phosphorylation of the mTORC1 targets p70S6K, S6 and 4E-BP1 was found to be 
downregulated in hypoxic cervical cancer cell lines, as was described before [71]. mTORC1, 
which induces protein synthesis and cell growth, can be inactivated by hypoxia in many cell 
types via multiple pathways [176]. One mechanism implicated in hypoxic mTORC1 regulation 
in cervical cancer cell lines involves the REDD1/TSC2 axis. Increased expression of REDD1, 
stimulated by hypoxia, reactivates TSC2, an inhibitor of mTORC1 [71, 177]. The reduced 
phosphorylation of mTORC1 targets in hypoxic cervical cancer cells indicates that this effect 
is dominant over AKT-induced inhibition of TSC2 and allows repression of growth promoting 
signals under hypoxic conditions. 
Repression of E6/E7 under hypoxia was already detectable at the mRNA level and could be 
counteracted by PI3K/AKT/mTOR inhibitors at this level as well. Rapamycin also 
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counteracted E6/E7 mRNA repression under hypoxia to some extent. While primarily 
targeting mTORC1, rapamycin can, upon prolonged treatment, also inhibit mTORC2 [178], 
which may explain the weak reactivation of hypoxic E6/E7 expression observed upon 
rapamycin treatment. Interestingly, E6/E7 mRNA expression was induced by mTOR 
inhibitors and showed a tendency to slightly increase after treatment with AKT inhibitors 
under normoxia. At the protein level this could only be observed in some cell lines. This 
further corroborates a negative regulation of E6/E7 expression via the PI3K/mTORC2/AKT 
pathway, but also shows that AKT-mediated regulation of E6/E7 expression primarily occurs 
under hypoxic conditions whereas normoxic E6/E7 expression is only weakly influenced by 
inhibiting AKT activity.  
Noteworthy, while E7 protein expression was efficiently reactivated under hypoxia by 
PI3K/AKT/mTORC2 inhibitors in all investigated cells lines, results for E6 were less coherent 
with reactivated E6 protein expression in HPV16-positive SiHa and MRI-H-186 being only 
weakly or not detectable. E6 and E7 are translated from alternatively spliced transcripts [21]. 
Thus, hypoxia-induced alterations in the relative abundance of the different transcript classes 
or effects of PI3K/AKT inhibitors on E6/E7 splicing events under hypoxia could represent a 
mechanism of differential regulation of E6 and E7 levels under hypoxia. Another, yet to be 
investigated potential explanation may be given by alterations of E6 protein stability in 
HPV16-positive cells under hypoxia that counteract PI3K/AKT-inhibitor induced reactivation 
of E6/E7 mRNA expression. 
Notwithstanding some discrepancies in regulation of HPV16 E6, it was clearly shown that 
pharmacological inhibition of the AKT pathway counteracts repression of viral oncogene 
expression in hypoxic cervical cancer cell lines. Particularly the investigation of a series of 
inhibitors targeting different steps in the signaling cascade that all result in comparable 
output on E6/E7 expression argues for a specific effect of the PI3K/mTORC2/AKT axis in 
regulation of E6/E7 under hypoxia. 
3.3.2 Regulation of E6/E7 in the context of Ca2+, energy metabolism and AKT activation 
Increased cytosolic Ca2+ concentrations are a characteristic feature of hypoxic cells [75]. 
Interestingly, it was demonstrated that repression of E6/E7 under hypoxia was dependent on 
Ca2+ since downregulation of E6/E7 was prevented by treatment with the Ca2+ chelator 
BAPTA-AM. In line with a possible role of Ca2+ in the regulation of HPV oncogene 
expression, treatment with the Ca2+ ionophore A23187 that increases intracellular Ca2+ levels 
led to downregulation of E6/E7 expression under normoxia. However, this effect was weaker 
in comparison to hypoxic downregulation of E6/E7 and furthermore, A23187-mediated 
downregulation of E7 in normoxic SiHa cells was not detected at all. This may indicate that 
Ca2+ is essential for repression of E6/E7 under hypoxia, but that further hypoxia-induced 
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cellular alterations are required for an efficient downregulation. However, it is also possible 
that increases in cytosolic Ca2+ induced by treatment with A23187 were not sufficiently high. 
Another key characteristic of hypoxic cells is enhanced glycolysis and reduced OXPHOS to 
cope with limited O2 supply [73]. Intriguingly, blockade of OXPHOS using inhibitors for 
complexes I or III of the mitochondrial electron transport chain repressed E6/E7 under 
normoxia in a glucose-dependent manner. This is interesting in the light of the finding of our 
group that high glucose concentrations also counteracted hypoxia-induced repression of 
E6/E7 [71]. Thus, under conditions of reduced OXPHOS, generated either by hypoxia or by 
inhibitor treatment, E6/E7 expression was strongly downregulated which could be prevented 
by an excess of glucose. Moreover, E6/E7 expression was reactivated by BAPTA-AM 
treatment in hypoxic and OXPHOS inhibitor-treated cells indicating that repression occurs in 
a related Ca2+-dependent manner under both conditions.  
However, not only inhibition of OXPHOS but also inhibition of glycolysis using 
2-deoxyglucose (2-DG) can induce downregulation of E6/E7 expression as was previously 
reported [179]. Like glucose, 2-DG is phosphorylated by hexokinase, the first and rate-
limiting glycolytic enzyme. This phosphorylated intermediate, 2-DG-6-phosphate, cannot be 
further metabolized, accumulates and as a feedback mechanism inhibits hexokinase [180]. 
2-DG-mediated repression of E6/E7 was also found to be counteracted by the intracellular 
Ca2+ chelator TMB-8 [179] and by high glucose concentrations that compete with 2-DG 
(K. Hoppe-Seyler, unpublished data).  
Taken together, these results showed that cells cultured under hypoxia or treated with 
OXPHOS or glycolysis inhibitors downregulate E6/E7 expression which is counteracted by 
high glucose levels and Ca2+ chelators. These cells are in a state of energy shortage due to 
impaired ATP production, which can be counteracted by high glucose levels that cells can 
use to fuel ATP synthesis. Hence, results indicate that E6/E7 is downregulated under energy 
deprived conditions in a Ca2+-dependent manner. Notably however, work from our group has 
revealed that E6/E7 expression was not diminished upon treatment with 3-bromopyruvate 
(K. Hoppe-Seyler, S. Adrian, unpublished data). This alkylating agent leads to rapid depletion 
of cellular ATP and was reported to inhibit both, glycolysis and OXPHOS [181], indicating 
that downregulation of E6/E7 upon energy shortage is more complex and not exclusively 
triggered by low ATP levels.  
Since activation of AKT by phosphorylation was established as being essential for repression 
of E6/E7 under hypoxia, it was of great interest whether phosphorylation of AKT was also 
associated with increases in intracellular Ca2+ or with OXPHOS inhibition. AKT activation has 
been described to be facilitated by Ca2+-dependent CaMs [102]. However, since 
phosphorylation of AKT and regulation of E6/E7 expression was neither influenced by 
silencing of CaM1-3 nor by treatment with the CaM inhibitor W-7, AKT activation by hypoxia 
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is likely mediated via a different, CaM-independent, mechanism. Moreover, hypoxia-induced 
phosphorylation of AKT was abrogated by treatment with the Ca2+ chelator BAPTA-AM only 
in SiHa, but not in HeLa cells. Hence, BAPTA-AM induced reactivation of E6/E7 expression 
under hypoxia cannot generally be attributed to an inhibition of AKT activation. The here 
obtained results in HeLa cells are in contrast to publications reporting an inhibitory effect of 
BAPTA-AM on AKT phosphorylation [182, 183]. Since BAPTA-AM mediated attenuation of 
AKT phosphorylation was described to occur transiently [182], it may be possible that AKT 
phosphorylation in HeLa cells was only impaired at earlier time-points. However, analyses of 
earlier time-points also did not show reduced AKT activation upon BAPTA-AM treatment in 
hypoxic HeLa cells (data not shown). Hence, although it is still possible that the critical time-
point of BAPTA-AM induced modulation of AKT phosphorylation was missed, it is more likely 
that the applied BAPTA-AM concentrations that are sufficient to reactivate E6/E7 expression 
under hypoxia in HeLa cells do not significantly repress AKT. This could mean that Ca2+-
dependent E6/E7 regulation does not occur upstream of AKT signaling but rather 
downstream or that these mechanisms act cooperatively in E6/E7 repression. 
Furthermore, E6/E7 repression induced by treatment with OXPHOS inhibitors was not 
associated with an activation of AKT in all cases. Instead opposing regulation of P-AKT was 
partially detected. Rotenone, for instance, induced AKT phosphorylation in a glucose-
dependent manner in HeLa cells but abolished AKT activation in SiHa cells. Consequently, 
E6/E7 repression mediated by OXPHOS inhibitors does not generally act via induction of 
AKT. 
3.3.3 Repression of E6/E7 under hypoxia is mediated by AKT1 and AKT2 
AKT has three isoforms (AKT1-3) that all can be activated via PI3K/mTORC2 [95] and that 
are all targeted by the AKT-specific inhibitors applied in the present study (AKTi VIII, 
MK-2206), albeit with decreasing affinity from AKT1 to AKT3. The present work revealed that 
AKT1 and AKT2 are involved in hypoxic regulation of E6/E7 expression. Expression of AKT3 
was not detected in HeLa cells, which fits to the described rather restricted expression of 
AKT3 to neuronal cells or specific cancer types such as melanoma [95, 115]. A hypoxia-
induced signal obtained with a polyclonal AKT3 antibody (CST) was identified by knockdown 
experiments as being likely not specific for AKT3. This notion is further supported by the 
observation that total AKT protein levels as determined with a pan-AKT antibody showed no 
increase under hypoxia, but rather declined when compared to cells cultured in parallel under 
normoxia. 
Overexpression studies of AKT1 and AKT2 revealed that both isoforms can, in principle, 
repress E6/E7 expression under hypoxia. Their involvement in hypoxic E6/E7 repression was 
further corroborated by knockdown experiments of endogenous AKT1 and AKT2. More 
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precisely, it was shown that combined blockade of AKT1 and AKT2 was required to 
efficiently counteract repression of E6/E7 under hypoxia. Together with the finding that 
ectopically expressed constitutively-active AKT1 and AKT2 together did not further diminish 
AKTi VIII-mediated reactivation of hypoxic E6/E7 expression compared to individual 
overexpression of the two isoforms, this strongly indicates functional redundancy of AKT1 
and AKT2 in hypoxic E6/E7 repression. 
The levels of P-AKT showed no detectable alterations upon silencing of AKT2 and were only 
weakly diminished upon transient silencing of AKT1 but were strongly repressed when both 
isoforms are shut down. This suggests that AKT1 and AKT2, respectively, compensate for 
loss of the other isoform allowing constant high levels of active AKT under hypoxia as long 
as one of the isoforms is still expressed. Nonetheless, AKT1 is likely the most strongly 
expressed isoform in HeLa cells as can be concluded from signals derived from a pan-AKT 
antibody that were strongly downregulated upon silencing of AKT1 and not visibly affected by 
silencing of AKT2. In the AKT1 silenced single cell clones, phosphorylation of AKT at S473 
was equally high under normoxic and hypoxic conditions. This may be caused by an 
upregulation of S473 phosphorylation of AKT2 already in normoxic cells to compensate for 
loss of AKT1 expression which was not detected in cells where AKT1 was only transiently 
silenced for a shorter time period. Since this effect was only observed for S473 but not for 
T308 phosphorylation, an overall induction of fully activated AKT under hypoxia can still be 
assumed.  
Counteraction of hypoxic E6 repression was observed upon combined silencing of AKT1 and 
AKT2, although to a weaker extent than observed for E7. This indicates that, like E7 
expression, E6 expression under hypoxia is repressed by AKT1/2 but also that reactivation of 
E6 upon blockade of AKT1/2 is likely to require more effective AKT1/2 inhibition. This is in 
line with results obtained by treatment with PI3K/AKT inhibitors where counteraction of E6 
repression under hypoxia was not or only weakly detected in certain cell lines. The 
underlying mechanism resulting in partial differences in the dimension of AKT-dependent E6 
and E7 regulation under hypoxia is still unclear. 
Notably, under normoxia, knockdown of AKT1 and AKT2, alone or in combination, as well as 
AKT pathway inhibitors did not appreciably enhance E6/E7 expression. Vice versa, ectopic 
expression of constitutively-active AKT1 and AKT2 did not repress E6/E7 expression under 
normoxia. Collectively these results indicate that activation of AKT alone is not sufficient to 
significantly diminish E6/E7 expression levels but that additional cellular alterations that 
occur under hypoxia and that cooperate with AKT, are necessary for efficient repression of 
viral oncogene expression. 
The PI3K/AKT cascade has the potential to regulate the activity of transcription factors [95] 
and to modulate the stability of mRNAs [184, 185]. It will be interesting for future studies to 
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identify the downstream factors linking hypoxic AKT1/2 activation to repression of E6/E7, 
which was found to be linked to inhibition of HPV transcription and reduction of the E6/E7 
mRNA half-life.  
3.3.4 Therapeutic implications of AKT inhibition in hypoxic cervical cancer cells 
Aberrant activation of the PI3K/AKT pathway is a common feature of many tumors. This also 
applies to cervical cancer patients whose prognosis and response to conventional treatments 
is closely associated with the status of PI3K/AKT signaling [124]. In line with this, the most 
frequently mutated gene in cervical cancer patients is PIK3CA that encodes a subunit of 
PI3K. Apart from activating mutations, PIK3CA activity is also found to be enhanced in many 
cervical cancer cases due to genomic amplifications [123, 186]. Cervical cancer is therefore 
subject to trials using PI3K/AKT/mTOR inhibitors as therapeutic agents [125, 187]. Thus, the 
observation that clinically tested PI3K/AKT/mTORC2 inhibitors can reactivate viral oncogene 
expression in hypoxic cells is extremely interesting. The downregulation of E6/E7 in hypoxic 
cells likely serves as a protective mechanism for the tumor. The cells are not proliferating, do 
not express any viral antigens and are protected from therapeutic interventions such as 
chemotherapy [71]. This raised the question how these cells cope with the proliferative 
impulse induced by E6/E7 when reactivated by PI3K/AKT/mTORC2 inhibitors under oxygen-
deprived conditions, which – as an undesired scenario – may lead to increased growth of 
tumor cells. Time-course experiments revealed, however, that hypoxic cells treated with 
PI3K/AKT inhibitors did not start to proliferate again despite E6/E7 expression. This indicates 
that the hypoxic state of the cell, which is often linked to inhibition of cell proliferation [67], 
and the anti-proliferative effects of AKT inhibition are dominant above the growth-promoting 
signals exerted by the re-induced viral oncogenes. 
Hypoxic HPV-positive cancer cells are able to reactivate E6/E7 expression and resume 
proliferation when they are reoxygenated [71]. This observation could be of clinical 
relevance, for instance when hypoxic tumor cells regain improved access to O2 after therapy-
induced tumor shrinkage, which possibly could enable tumor recurrence [71]. Hence, in the 
present thesis it was also investigated how hypoxic HPV-positive cancer cells alter their 
response to chemotherapy when treated with PI3K/AKT inhibitors. Compared to normoxic 
cells, hypoxic cells were shown to be more protected from etoposide-induced senescence 
allowing the outgrowth of many cell clones during subsequent cultivation under normoxia. 
Additionally, it was observed that treatment with AKTi VIII or silencing of AKT1 and AKT2 
allowed the outgrowth of a higher number of colonies after etoposide treatment of HPV-
positive cancer cells under normoxia. The latter may be explained by the reduced 
proliferation induced by AKT inhibition since highly proliferating cells are more vulnerable to 
chemotherapeutic agents.  
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Interestingly, treatment with PI3K/AKT inhibitors sensitized hypoxic HeLa cells to etoposide-
induced senescence induction. The specificity of the inhibitor-mediated effects was verified in 
knockdown experiments revealing that single knockdown of AKT1 weakly reduced the 
number of outgrowing cells and that combined silencing of AKT1 and AKT2 more strongly 
prevented the outgrowth of cells. This demonstrated that, apart from redundantly repressing 
E6/E7 expression under hypoxia, AKT1 and AKT2 also protect hypoxic HeLa cells from 
etoposide-induced senescence in a functionally redundant manner. Experiments with ectopic 
overexpression of E6/E7 under hypoxia would possibly yield further information whether the 
AKT-induced repression of E6/E7 is a contributing factor to AKT-mediated evasion from 
chemotherapy-induced senescence.  
Reduced outgrowth of etoposide-treated cells after concomitant treatment with PI3K/AKT 
inhibitors under hypoxia was exclusively observed in HeLa, but not in SiHa or SW756 cells. 
In line with this, silencing of AKT1 and AKT2 did not influence chemotherapy response of 
hypoxic SiHa cells (SW756 cells were not investigated) indicating involvement of a cell type-
dependent mechanism. Since HeLa has been established from a cervical adenocarcinoma, 
whereas all other cell lines were derived from squamous cell carcinomas [56], it will be 
interesting to extent further studies to other cell lines derived from cervical adenocarcinomas. 
Nonetheless, the ability of PI3K/AKT inhibitors to enhance the therapeutic effects of 
chemotherapy is not a peculiarity of hypoxic HeLa cells but is in line with AKT-associated 
increased therapy resistance and has also been described for other cancer cell types [121, 
145, 188]. 
In conclusion, it was shown that while inhibition of the PI3K/AKT pathway counteracted 
repression of the HPV oncogenes under hypoxia in all investigated cell lines, it influenced the 
behavior of HPV-positive cells towards chemotherapy in a cell line dependent manner. 
Importantly, PI3K/AKT inhibitor-induced reactivation of viral oncogene expression in hypoxic 
cervical cancer cells did not induce proliferation and had either no or beneficial effects on the 
therapeutic outcome after etoposide treatment in hypoxic cells. Further detailed 
investigations regarding the effects of PI3K/AKT pathway inhibitors on hypoxic HPV-positive 
cancers are required to fully evaluate the clinical implications thereof. However, given the 
results of the present study it is plausible that reactivation of viral oncogene expression in 
hypoxic HPV-positive cancer cells has no detrimental effects on treatment outcome. It may 
even be possible that such cells would be more vulnerable to various therapeutic approaches 
and to the host’s immune system since they are no longer able to downregulate viral antigen 
expression.  
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3.4 Proteome analyses as starting point for future investigations 
The cornerstones of the regulatory phenomena observed in the present studies are: (i) 
hypoxia blocks HPV oncogene expression, an effect that can be counteracted by (ii) AKT 
inhibition and by (iii) high glucose supply. To gain further insights into the underlying 
regulatory circuits and the resulting phenotypic consequences, proteome analyses were 
performed in SiHa cells by comparing normoxic and hypoxic conditions and assessing the 
response of hypoxic SiHa cells towards AKTi VIII and 25 mM glucose. These experiments 
provide information about cellular proteins and pathways that are regulated in parallel or 
inversely with HPV E6/E7. In principle, these pathways could underly a common regulation 
as E6/E7 expression or, alternatively, could themselves act as upstream regulators of E6/E7 
under hypoxia or as downstream regulators which mediate E6/E7-dependent cellular effects 
in hypoxic cells. Thus, the proteomic analyses performed here should serve as an important 
experimental basis to address these issues in future studies. 
Interestingly, two members of the Wnt signaling pathway, Wnt-5a and DKK1, were amongst 
the top hits of differentially expressed proteins under hypoxia. Both proteins were 
downregulated under hypoxia in an AKT- and glucose-dependent manner. Wnt signaling has 
important functions in embryonic development and adult stem cell biology, cell proliferation 
and migration. Deregulated Wnt signaling is therefore associated with cancer and metabolic 
diseases [189]. Wnt ligands induce cellular responses by binding to members of the Frizzled 
receptor family. Three different branches of the Wnt pathway have been identified so far: 
canonical Wnt signaling via β-catenin, the noncanonical planar cell polarity pathway and the 
noncanonical Wnt/Ca2+ pathway [190]. Wnt5a is characterized for activating noncanonical 
Wnt signaling but has also been implicated in antagonizing the canonical Wnt/β-catenin 
pathway [190-192]. DKK1, a member of the Dickkopf family, is an inhibitor of canonical Wnt 
signaling that binds to low-density lipoprotein receptor-related protein 6 (Lrp6), a coreceptor 
of Frizzled, and blocks signal transduction [193]. Hence, the results from the proteomics 
screen revealed the hypoxia-induced downregulation of two factors that negatively regulate 
canonical Wnt/β-catenin signaling which argues for an induction of this pathway under 
hypoxia. Since Wnt/β-catenin signaling has been linked to active PI3K/AKT signaling [194, 
195], it will be interesting to investigate a functional role of this pathway as upstream 
regulator of AKT-dependent hypoxic repression of E6/E7. 
A very prominently regulated protein identified in the proteome analyses is MT2A, which was 
downregulated under hypoxia and reinduced again under the treatment conditions that also 
counteracted hypoxic E6/E7 repression. MT2A belongs to the family of metallothioneins that 
bind heavy metals, have been reported to protect against oxidative stress and to be 
associated with cellular proliferation [196]. Apart from MT2A two additional metallothioneins 
were detected in the proteome screen (MT1X, MT1F) that showed a similar, only less 
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pronounced, pattern of regulation to what was observed for MT2A. Metallothionein 
expression has previously been described to be negatively regulated by the PI3K/AKT 
pathway in human hepatocellular carcinoma cells [197]. Thus, MT2A, MT1X and MT1F 
represent candidates that could be commonly regulated with E6/E7 or could also play a 
functional role in AKT-linked upstream regulation of E6/E7. Moreover, since metallothionein 
expression is associated with cellular proliferation another possible scenario would be that 
metallothioneins are downstream targets of E6/E7 that are involved in E6/E7-linked 
proliferation under normoxia. 
The here described candidates represent examples for differentially regulated proteins linked 
to E6/E7 expression in hypoxic HPV-positive cells. Since the performed proteome analyses, 
at current, offer only circumstantial evidence, validation experiments addressing a functional 
role differentially expressed proteins, will hopefully provide additional insights into pathways 
involved in hypoxic E6/E7 repression and, moreover, could delineate novel downstream 
targets for the viral oncoproteins. 
3.5 Conclusions and perspectives 
Due to the disappointingly low vaccination rates as well as to the lengthy natural course of 
disease development, HPV-linked cancers are expected to remain an important medical 
challenge for many decades to come. It is therefore of high importance to improve the clinical 
management of these devastating tumors and to develop novel therapeutic strategies. To 
approach this goal from a rational basis, a better understanding of the crosstalk between 
oncogenic HPVs and their host cell is an important prerequisite. 
Hypoxic tumor cells pose a major therapeutic problem also in HPV-positive cancers. 
Recently, it was found that hypoxic cells strongly repress HPV E6/E7 oncogene expression. 
This is linked to the induction of a reversible dormant state which could contribute to 
therapeutic resistance, immune evasion and tumor recurrence. The present work provides 
now first insights into the regulatory mechanisms of hypoxic repression of HPV oncogene 
expression. 
Firstly, hypoxic inhibition of E6/E7 protein and mRNA expression is carried out by a 
combination of transcriptional repression and reduced mRNA and protein stabilities. 
Secondly, a series of factors were excluded as likely candidates mediating E6/E7 repression 
under hypoxia. These include YY-1, HIF-1/2α, the Mlx:MondoA transcription factor network 
and c-Myc. Thirdly, repression of E6/E7 expression is dependent on Ca2+ metabolism in that 
chelation of intracellular Ca2+ functions in a counteractive manner. Fourthly, the work 
identified the PI3K/AKT pathway as key mediator of hypoxic E6/E7 repression. Further 
functional analyses revealed that downregulation of the HPV oncogenes is redundantly 
mediated by AKT1 and AKT2 that are activated via PI3K and mTORC2 under hypoxia (see 
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model in Fig. 33). In this regard, pharmacological inhibitors of the PI3K/mTORC2/AKT 
pathway were shown to reactivate E6/E7 expression in hypoxic cells. However, this is not 
associated with viral oncogene-induced proliferation and moreover, can sensitize hypoxic 
cells to therapeutic effects of etoposide in a cell line-dependent manner. Under normoxia, 
activation of AKT1 and AKT2, alone or together, was not sufficient to repress E6/E7 but 
required the cellular background of hypoxic cells.  
 
In conclusion, with the delineation of the AKT pathway as key regulator for hypoxic E6/E7 
repression, interesting new insights into the crosstalk between virus and host cell have been 
gained. Considering the highly therapy resistant nature of hypoxic tumor cells, the present 
findings may create a basis for future studies addressing the development of novel treatment 
strategies. Ongoing work of our group and collaboration partners suggests that P-AKT is 
enriched in hypoxic tumor regions in biopsies derived from cervical cancer patients 
(immunofluorescence stainings, Arnulf Mayer, University Hospital Mainz, Germany) 
supporting the clinical relevance of the here obtained in vitro data. Mechanistically, the direct 
















Fig. 33. Model of AKT-dependent E6/E7 regulation under hypoxia in HPV-positive cancer cells. AKT1 and 
AKT2 are activated under hypoxia. As an upstream regulator PI3K is required for activation of AKT, PDK1 and 
mTORC2. PDK1 and mTORC2 phosphorylate AKT at the residues S473 and T308, respectively, which leads to 
the repression of E6/E7 under hypoxia. Treatment with the indicated inhibitors interferes with AKT1/2 activation 
and counteracts hypoxic repression of E6/E7. The direct link between AKT and E6/E7 repression and potential
further required hypoxic alterations are still unclear. 
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performed in this work provide a promising foundation to further investigate this issue and to 
identify relevant AKT-regulated downstream acting factors and additional cellular circuits 
modified under hypoxia in a glucose-dependent manner. Based on the proteome data, an 
important pathway which warrants further investigation is the Wnt signaling cascade which is 
hypoxia sensitive and functionally linked to AKT signaling [194, 195, 198]. It should also be 
noted that the present study focused on regulation of E6/E7 under chronic hypoxia. However, 
intermittent or acute hypoxia, mainly generated by defective tumor vessels, is likewise a key 
feature of solid tumors that has a high clinical impact [66]. Analyses of E6/E7 regulation 
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4. Materials and Methods 
4.1 Reagents 
Molecular biology grade reagents were applied where possible. All standard reagents for 
buffers and media were supplied by AppliChem (Darmstadt, Germany), BD Biosciences 
(Heidelberg, Germany), Bio-Rad (Munich, Germany), Carl Roth (Karlsruhe, Germany), Enzo 
Life Sciences (Lörrach, Germany), New England Biolabs (NEB, Frankfurt, Germany), 
Promega (Madison, WI, USA), Merck (Darmstadt, Germany), Sigma-Aldrich (St. Louis, M, 
USA) and Thermo Fisher Scientific (Waltham, MA, USA). Manufacturers of non-standard 
reagents are specified in the text.  
All buffers and solutions were prepared with H2O if not stated otherwise. 
4.2 Cellular biology techniques 
4.2.1 Cultivation of cell lines 
HeLa, SiHa, SW756 and MeWo cells were cultured in Dulbecco’s minimal essential medium 
(DMEM, Gibco, Thermo Fisher Scientific, USA). MRI-H-186 cells were cultured in RPMI 1640 
medium (Gibco). The standard medium was supplemented with 10 % fetal calf serum (FCS, 
Gibco), 100 U/ml penicillin, 100 µg/ml streptomycin, 2mM L-glutamine (all from Sigma-
Aldrich) and contained 1g/L (5.5 mM) glucose. For cell growth analyses, HeLa and SiHa cells 
that were transduced with a pMOWS hH2B mCherry expression vector to generate cells with 
red fluorescent histone H2B were provided (transduction was kindly performed by 
Dr. Joschka Willemsen, group of Dr. Marco Binder, DKFZ, Heidelberg). The stock cultures of 
the transduced HeLa mCherry H2B and SiHa mCherry H2B were kept under selection by 
using medium additionally supplemented with 1 µg/ml puromycin (Sigma-Aldrich). For 
experiments medium without puromycin was applied.   
Standard cultivation of human cell lines was performed at 37 °C and 5 °CO2 in a humidified 
incubator at 21 % O2 (=normoxia). Incubation under hypoxia (= 1 % O2, 5 % CO2) was 
performed in a hypoxic incubator or in the InvivO2 400 physiological oxygen workstation 
(Ruskinn Technology Ltd, Bridgend, UK). To ensure a continuous adequate atmosphere, 
time course experiments were all performed in the InvivO2 workstation.  
For routine passage, cells were split every 3-4 days before reaching full confluency using 
0.25 % Trypsin-EDTA solution (Gibco).  
Prior to experiments number of viable cells was determined using the trypan blue method 
with the CountessTM Automated Cell Counter (Invitrogen, Carlsbad, CA, USA).    
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4.2.2 Cryopreservation and thawing of cells 
For long-term storage of cells, cryopreservation was used. Cells were trypsinized, pelleted by 
centrifugation for 3 min at 800 g, resuspended in culture medium containing 30 % FCS and 
10 % DMSO and aliquoted into cryotubes. The cryotyubes were transferred into an 
isopropanol-filled freezing container (Nalgene, Thermo Fisher Scientific) and kept for several 
days at -80 °C and finally stored in liquid nitrogen. 
For thawing, cells were rapidly warmed to 37 °C in a water bath, resuspended in fresh culture 
medium and transferred into a new cell culture flask. Medium was removed and replenished 
the following day. 
4.2.3 Treatment of cells with chemical compounds 
Cells were treated with inhibitors or small molecule compounds (see Tab. 2) 1-2 days after 
seeding. The compounds were added directly into the medium and the appropriate volume of 
the solvent was applied to control cells.  
Compound Solvent Final concentration Supplier 
5-Aza-2’-deoxycytidine 
(Decitabine) DMSO 10 µM Sigma-Aldrich 
A23187 DMSO 5 µM Enzo Life Science 
AKT inhibitor VIII/ AKT1/2-
inhibitor (AKTi VIII) DMSO 5-10 µM Sigma-Aldrich 
Antimycin A Ethanol 0.2-5 µM Sigma-Aldrich 
BAPTA-AM DMSO 20-50 µM Enzo Life Science 
Etoposide DMSO 10 µM Enzo Life Science 
GDC-0941 DMSO 5-10 µM Selleck Chemicals (Houston, USA) 
JQ1 DMSO 1-20 µM Cayman Chemical (Ann Arbor, USA) 
KU-0063794 DMSO 1-5 µM Sigma-Aldrich 
LY294002 DMSO 20 µM Cayman Chemical 
Metformin DMEM 2.5 mM Enzo Life Science 
MK-2206 DMSO 1-10 µM AdipoGen (San Diego, USA) 
PX-866 DMSO 1-10 µM Focus Biomolecules 
Rapamycin DMSO 50 nM AdipoGen 
Rotenone DMSO 10-500 nM Sigma-Aldrich 
W-7 DMSO 10-50 µM Cayman Chemical 
 
 
4.2.4 Transfection of synthetic siRNAs 
For transfection of synthetic siRNAs (Ambion, Thermo Fisher Scientific), cells were seeded in 
6cm dishes and transfection was performed on the following day when cells had reached 30-
40 % confluency. Prior to transfection, standard cell culture medium was replaced by 1.6 ml 
of cell culture medium lacking penicillin and streptomycin. For each dish 4 or 6 µl of the 
Tab. 2. Chemical compounds.
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transfection reagent DharmaFECT1, for HeLa or SiHa cells respectively, were pre-incubated 
in a final volume of 200 µl of reduced serum medium Opti-MEM I (Gibco) for 5 min at room 
temperature (RT). In parallel, 2-4 µl of the 10 µM siRNA stock solution were equally pre-
incubated with Opti-MEM I in a final volume of 200 µl. Both solutions were then mixed and 
incubated for 20 min at RT. Subsequently, the 400 µl transfection mix was added dropwise to 
the cells to reach a final siRNA concentration of 10 or 20 nM as indicated in Tab. 3. The 
medium was replaced with standard cell culture medium 24 h after transfection. Harvesting 
of cells for downstream analyses was carried out 72 h after transfection. 
Stock solutions of lyophilized synthetic siRNAs (10 µM) were prepared with nuclease-free 
H2O. For transfection of AKT1- and AKT2-targeting siRNA, a pool of several siRNAs 
(referred to as siAKT1 and siAKT2) in equimolar concentrations was used. As a negative 
control, an siRNA that contains at least four mismatches to all known human genes was 
applied (siContr1). 
Target 
transcript siRNA siRNA sequence Final concentration 
AKT1 
siAKT1 #1 5′-GCGUGACCAUGAACGAGUU-3’ 
20 nM 
siAKT1 #2 5′-CGGUAGCACUUGACCUUUU-3’ 
AKT2 
siAKT2 #1 5′-UGACUUCGACUAUCUCAAA-3’ 
20 nM 
siAKT2 #2 5′-CAACUUCUCCGUAGCAGAA-3’ 
BRD4 siBrd4 5′-AGAUUGAAAUCGACUUUGA-3’ 10 nM 
- siContr-1 5′-CAGUCGCGUUUGCGACUGG-3’ 10-20 nM 
 
4.2.5 Transfection of plasmid DNA and generation of single cell clones 
Transfection of plasmid DNA was performed by means of the calcium phosphate 
coprecipitation technique according to Chen and Okayama [199]. In brief, cells were seeded 
in 6cm dishes in 3 ml of standard culture medium and DNA was transfected the next day 
when cells were 30 % confluent. Prior to transfection, plasmid DNA of interest was adjusted 
with pBluescript II vector (Stratagene, Heidelberg, Germany) to a final amount of 6 µg DNA 
per dish, if necessary. DNA was mixed with 150 µl of 0.25 M CaCl2 and then with 150 µl 2x 
BES buffer (50 mM BES, 280 mM NaCl, 1.5 mM Na2HPO4, pH 6.95). The transfection mix 
was incubated for 10-20 min at RT and afterwards added dropwise to the cells. Cells were 
kept in a humidified incubator at 35 °C and 3 % CO2 for 16-18 h. Medium was then removed, 
cells were washed once with medium and fresh medium was added for further incubation 
under standard conditions if not indicated otherwise. Harvesting of cells was usually 
performed 48 h after transfection or 72 h after transfection in the case of shRNA expressing 
pSuper plasmids. 
Tab. 3. Synthetic siRNAs.
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Transfection of CRISPR plasmids was performed as described above. Standard culture 
medium was replaced 36 h after transfection with medium containing 1 µg/ml puromycin to 
select for successfully transfected cells. Cells were kept under selection medium for up to 5 
days until all cells of a mock transfected plate were dead. Cells were then cultured in 
standard medium and either used directly as a pool for further experiments or seeded for 
generating single cell clones. To that end, cells were seeded in 96 well plates by performing 
serial dilution. Single cell clones were identified by eye using light microscopy and cultured 
until a sufficient number of cells were available. Efficiency of the knockdown was evaluated 
by detecting protein expression using immunoblot analyses. 
4.2.6 Luciferase reporter assay 
The activity of the HPV transcriptional control region, also designated upstream regulatory 
region (URR), under hypoxia was investigated by means of luciferase reporter assays with 
reporter plasmids that express firefly luciferase under the control of different elements of the 
HPV URR. All vectors for luciferase assays were kindly provided by Karin Hoppe-Seyler. All 
reactions were performed in duplicates for each individual experiment. 
Transfection of plasmid DNA by the calcium phosphate coprecipitation technique was 
performed as described in chapter 4.2.5. The transfection mix for each sample contained 
additionally 0.2 µg pCMV-Gal plasmid as an internal standard to adjust for variations in the 
transfection efficiency by measuring β-galactosidase activity. Lysis of cells for luciferase and 
β-galactosidase activity measurements was carried out 48 h after transfection and 24 h after 
incubation under hypoxia. Cells were first washed with ice-cold PBS and then scraped in 
200 µl triton lysis buffer (25 mM glycylglycine pH 7.8, 15 mM MgSO4, 4 mM EGTA, 1 mM 
DTT, 10 % glycerol, 1 % Triton X-100). Samples were kept on ice during this procedure. 
Cellular debris was pelleted by centrifugation at 12,000 g and 4 °C for 5 min. For 
determination of luciferase activity, 30 µl of the supernatant were transferred into a 96 well 
plate. Measurement was carried out with a luminometer (LB943 Mithras2, Berthold 
Technologies, Bad Wildbad, Germany). The luminometer injects 150 µl luciferase reaction 
buffer (25 mM glycylglycine pH 7.8, 15 mM MgSO4, 5 mM ATP) and 50 µl luciferin solution 
(0.25 M luciferin in luciferase reaction buffer devoid of ATP) to each sample.  
The luciferase that is expressed from the transfected reporter constructs catalyzes the ATP-
dependent oxidation of luciferin to oxyluciferin and CO2 whilst emitting light at 562 nm. The 
detected light is proportional to the expression of luciferase and thus allows to assess the 
transcriptional activity. To account for the transfection efficiency, luciferase values were 
normalized to the respective values of the β-galactosidase activity.   
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Vector designation  Comment Source 
pCMV-Gal β-galactosidase expression [200] 
pBluescript II (pBL) empty vector Stratagene 
HPV18URRL luciferase reporter construct [36] 
p438/18L luciferase reporter construct [36] 
p232/18L luciferase reporter construct [36] 
pBtk*L basis vector HSV TK promoter [36] 
p230s/tk*L luciferase reporter construct [36] 
p116s/tk*L luciferase reporter construct [36] 
pGAPDHLuc luciferase reporter construct (1112 bp of the GAPDH promoter driving firefly luciferase) [201] 
 
4.2.7 β-galactosidase assay 
To determine transfection efficiency of luciferase reporter assays, β-galactosidase activity 
was measured in parallel. 20-50 µl of the cell lysate were pipetted in a clear 96-well plate and 
200 µl galactosidase reaction buffer (60 mM Na2HP04, 40 mM NaH2PO4, 10 mM KCl, 1 mM 
MgSO4, 1mg/ml ortho-nitrophenyl-β-galactoside (ONPG)) were added. Due to the hydrolysis 
of ONPG catalyzed by β-galactosidase, the yellow-coloured o-nitrophenol is produced and 
absorbance can be measured at 405 nm with an ELISA plate reader (Multiskan Ex, Thermo 
Electron, Karlsruhe, Germany). To account for unspecific absorbance, an additional 
measurement at 620 nm is performed and subtracted from values obtained at 405 nm.   
4.2.8 Colony formation assay  
A colony formation assay (CFA) is a landmark technique that was initially established to 
study the effects of radiation or chemotherapeutic drugs on the reproductive viability of cells 
by determining their clonogenic capabilities.  
To investigate the effects of etoposide in combination with PI3K/AKT inhibitors under hypoxia 
and normoxia, cells were seeded in 6cm dishes and treated with PI3K/AKT inhibitors before 
incubation under normoxia or hypoxia as indicated. For CFAs of AKT1/2-silenced cells, cells 
were treated with DMSO or AKTi VIII 24 h after siRNA transfection and kept under hypoxia or 
normoxia. Etoposide (10 µM) was added 24 h after inhibitor treatment. For hypoxic cells, 
etoposide treatment was performed in the hypoxia workstation to ensure a constant oxygen 
concentration of 1 %. Cells were removed from the hypoxia workstation 48 h after etoposide 
treatment, split into new 6 cm dishes in ratios ranging from 1:2 to 1:200 and further kept in 
standard cell culture medium under normoxia.  
The 1:2, 1:5 and 1:10 splits were used for senescence assays (SAs, see chapter 4.2.9)  
Fixing and staining of the colonies was performed 9-12 days after splitting. For this purpose, 
medium was discarded, and cells were washed with phosphate-buffered saline (PBS 137 
mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, pH 7.4). 350 µl of a 
Tab. 4. Plasmids for Luciferase assays. 
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formaldehyde-crystal violet solution (12 mM crystal violet, 29 mM NaCl, 3.7 % formaldehyde, 
22 % ethanol) were added per 6cm dish and incubated for 5 min. Dishes were then washed 
with H2O and dried at 37 °C before taking images with the Epson Perfection 4990 Photo 
Scanner. 
4.2.9 Senescence assay 
To identify senescent cells, senescence associated β-galactosidase (SA-β-Gal) activity was 
detected. The enzymatic activity of SA-β-Gal is detectable at pH 6.0 using the chromogenic 
substrate X-Gal (5-bromo-4-chloro-3-indolyl β D-galactopyranoside) [202]. This enzymatic 
reaction eventually yields an insoluble blue product (5,5’-dibromo-4,4’-dichloro-indigo) that 
can be visualized by bright field microscopy.  
For senescence assays (SAs) cells were treated and split as described for CFAs (see 
chapter 4.2.8) Staining of senescent cells was performed 5-6 days after splitting. First, cells 
were washed with PBS. Next, they were fixed in 1 ml fixation buffer (2 % formaldehyde, 
0.2 % glutaraldehyde in PBS) per dish for 3 min at RT. After removing the fixation buffer and 
additional washing with PBS, 1.5 ml senescence assay buffer (40 mM citric acid, 150 mM 
NaCl, 2 mM MgCl2, adjusted to pH 6.0 with Na2HPO4 and freshly supplemented with 5 mM 
K3[Fe(CN)6], 5 mM K4[Fe(CN)6] and 1 mg/ml X-Gal) were added and cells were incubated in 
a wet chamber for 16-24 h at 37 °C. Senescence assay buffer was then removed and PBS 
was added to the 6 cm dishes.  Images of representative cells were taken with a brightfield 
microscope (EVOS XL Core Cell Imaging System, Life Technologies, Calsbad, CA, USA).  
4.2.10 Cell growth analyses 
Cell growth was assessed by staining with crystal violet. To this end, HeLa and SiHa cells 
were seeded in 96-well plates at a density of 3x103 cells per well. One plate was used for 
each time point. 24 h after seeding, medium was replenished (100 µl per well) and cells were 
treated with inhibitors or solvent control and cultured under hypoxia or normoxia as indicated. 
All treatments were performed in quadruplicates. Cells were stained 0, 24, 48 and 72 h after 
treatment. For this purpose, medium was removed, cells were washed with 200 µl PBS and 
30 µl formaldehyde-crystal violet solution (see chapter 4.2.8) were added per well. After 
5 min of incubation, plates were washed with H20, dried at 37 °C and stored in the dark at RT 
until further processing. For quantification of cells, 30 µl 33 % acetic acid per well were 
added to dilute cell-bound crystal violet. After 5 min incubation, absorbance was measured at 
570 nm with a SPECTROstar Nano Absorbance Reader (BMG Labtech, Ortenberg, 
Germany).  
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Alternatively, cell growth was assessed using the IncuCyte® S3 Live-Cell Analysis System 
under normoxia or the IncuCyte® ZOOM Live-Cell Analysis System (both Essen BioScience, 
Ann Arbor, USA) under hypoxia. For IncuCyte® analyses, nuclei-labelled HeLa mCherry H2B 
and SiHa mCherry H2B cells were seeded in 96 well plates in triplicates and number of cells 
was determined as red object count.  
4.3 Chromatin-based techniques 
4.3.1 Methylated DNA immunoprecipitation (MeDIP) 
Methylated DNA immunoprecipitation (MeDIP) was performed in cooperation with 
Dr. Thomas Günther and Prof. Dr. Adam Grundhoff (Heinrich-Pette Institute, Hamburg).  
SiHa cells were seeded in 10 cm plates. 2 days after seeding medium was replenished and 
cells were incubated for 24 h under hypoxia or normoxia. Cells were washed once with PBS 
supplemented with 2 mM EDTA and afterwards lysed directly on the plate in 1 ml 3x DNA 
lysis buffer (70 mM Tris, 2.5 mM EDTA, 3 % sarcosyl) and 2 ml PBS plus EDTA. Lysate was 
transferred in a 15 ml falcon and 200 µg/ml proteinase K was added. To allow digestion of 
cellular proteins, lysate was incubated for 7 h at 55 °C in a water bath and then stored at 
4 °C. Isolation of genomic DNA was performed by phenol extraction. To that end one volume 
of phenol:chloroform:isoamyl alcohol (25:24:1) was added per sample, incubated for 15 min 
while rotating and centrifuged for 10 min at 850 g at RT. Supernatant was transferred to a 
new tube and one volume of chloroform:isoamyl alcohol (24:1) was added. After incubation 
for 30 min while rotating, sample was centrifuged again and the supernatant was transferred 
to a new tube. To precipitate DNA, one volume of isopropanol and 0.1 volume of 3 M sodium 
acetate (pH 5.2) was added and DNA was pelleted by centrifugation for 1 h at 2000 g at 
4 °C. DNA pellet was washed once with 70 % ethanol and air-dried before resuspending in 
1 ml nuclease-free H2O. 
Immunoprecipitation of methylated DNA and following qPCRs were carried out by Dr. 
Thomas Günter (Heinrich-Pette Institute, Hamburg) as previously described [203]. Primer 
sequences are indicated in Tab. 5. 
4.3.2 Chromatin immunoprecipitation (ChIP) 
H3K4me3 and H3K27me3 at the HPV URR was assessed by chromatin immunoprecipitation 
(ChIP) in a cooperation with Dr. Thomas Günther and Prof. Dr. Adam Grundhoff (Heinrich-
Pette Institute, Hamburg).  
SiHa cells were seeded in 10 cm plates and 2 days later medium was replenished, and cells 
were incubated for 24 h under hypoxia or normoxia. Proteins were cross-linked with DNA by 
adding 1 % formaldehyde to the cell culture medium. Fixation was carried out for 10 min at 
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RT before reaction was stopped by applying 125 mM glycine solution for 5 min. Medium was 
then removed, cells were washed two times with ice-cold PBS, scraped from the plate in 2 ml 
ice-cold PBS and transferred to a 15 ml falcon tube. Cells were pelleted by centrifugation for 
3 min at 200 g and 4 °C. Supernatant was removed and the cell pellet was stored at -80 °C 
until further use.  
The following ChIP and qPCRs were performed by Dr. Thomas Günter (Heinrich-Pette 
Institute, Hamburg) according to a recently published protocol [204]. Primer sequences for 
qPCRs are given in Tab. 5 
Genomic target 




for: 5’-AGTGGGTGGAGAATGCAGAC -3’ 










HPV16 L1 HPV16L1 
for: 5’-GTCGTGGTCAGCCATTAGGT-3’ 
89 bp rev: 5’-TGCTGCATAAGCACTAGCATTT-3’ 








HPV16 URR HPV16URR_2 
for: 5’-ACTGCTTGCCAACCATTCCA-3’ 
107 bp rev: 5’-TAAGGCGTTGGCGCATAGTG-3’ 
SHANK1 (CpG 











for: 5’-CTCTGGACAGAGTTTCCGGG-3’ 79 bp 
rev: 5’-CAATGAAGGGGAAGCTCGAC-3’ 
 
4.4 DNA-based techniques 
4.4.1 Transformation of bacteria 
Transformation of bacteria with plasmid DNA was performed according to the protocol of 
Hanahan [205].  
Competent bacteria of the E.coli strain TG2 were used for transformation. They were 
generated by growing the bacteria overnight at 37 °C in Lysogeny Broth (LB) medium (1% 
Bacto trypton, 0.5% yeast extract, 170 mM NaCl, pH 7.0). Bacteria were then pelleted and 
resuspended in transformation buffer (10% polyethylene glycol 8000, 5% DMSO, 50 nM 
MgCl2, 15% glycerol in LB medium, pH 6.5). Bacteria were frozen in liquid nitrogen and 
stored at -80 °C.  
Tab. 5 Primer for MeDIP and histone ChIPs.
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For transformation, competent TG2 bacteria were thawed on ice. 100 µl of bacteria 
suspension was mixed with 50-100 ng plasmid DNA and incubated for 30 min on ice. A heat-
shock at 42 °C in a water bath was carried out for 45 sec, followed by incubation on ice for 
3 min. 800 µl LB medium was added to the bacteria mixture and they were incubated at 
37 °C while shaking for 45 min. The transformation reaction or a fraction thereof was then 
streaked on an LB agar plate (1.5 % agar agar for bacteriology (Gerbu, Heidelberg, 
Germany)) in LB medium and grown overnight at 37 °C. The LB agar plate was 
supplemented with the appropriate antibiotic (100 µg/ml ampicillin). Alternatively, the 
transformation mixture was used to inoculate an overnight culture of LB medium 
supplemented with ampicillin. 
4.4.2 DNA preparation and enzymatic modification 
Isolation of plasmid DNA  
Cultures of transformed bacteria in LB medium supplemented with ampicillin, shaken at 
37 °C overnight, were used for isolation of plasmid DNA. The PureLink™ Quick Plasmid 
Miniprep Kit (Invitrogen) or the PureLink™ HiPure Plasmid Filter Midiprep Kit (Invitrogen) 
were applied according to the manufacturer’s protocol for the preparation of small and 
medium amounts of plasmid DNA.  
The preparation of larger amounts of plasmid DNA was performed by the maxipreparation 
protocol based on Sambrook and Russell [206]. To that end, transformed bacteria were 
pelleted, resuspended in solution I (50 mM glucose, 25 mM Tris, 10 mM EDTA, pH 6.7), 
lysed in freshly prepared solution II (0.2 M NaOH, 1% SDS) and neutralized with solution III 
(3 M potassium acetate, 11.5% acetic acid). After briefly chilling on ice, lysate was 
centrifuged at 5,500 g and 4 °C for 10 min to pellet cellular debris. The plasmid-containing 
supernatant was transferred to a fresh tube and 20 ml isopropanol was added to precipitate 
DNA. After incubation for 30 min on ice, plasmid DNA was pelleted at 5,500 g and 4°C for 
30 min. The pellet was resuspended in 4 ml TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0) 
supplemented with 100 µl ethidium bromide solution (10 mg/ml). Samples were transferred to 
6 ml PA Ultraclimp tubes (Sorvall, Asheville, NC, USA) and filled up with with CsCl solution 
(44 g CsCl, 41 ml TE, 1 ml ethidium bromide (10 mg/ml)). Ultracentrifugation was then 
carried out at 220000 g at 20 °C for 16 h in an OTD75B Sorvall Ultracentrifuge. The 
supercoiled plasmid DNA, visible through incorporation of ethidium bromide, was extracted 
and transferred to a 50 ml falcon tube. To remove ethidium bromide from plasmid DNA, 
extraction with water-saturated 1-butanol was performed several times. Precipitation of 
plasmid DNA was then carried out by adding 2 volumes of ethanol and incubating at -20 °C 
for 1 h. Following centrifugation at 5500 g and 4 °C for 30 min, DNA was resuspended in 4ml 
TE buffer supplemented with 160 µl of a 5 M NaCl solution. DNA was again precipitated with 
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ethanol and pelleted by centrifugation. Purified plasmid DNA was finally resuspended in 200-
-500 µl TE buffer and concentration was determined with the NanoDrop ND-100 
spectrophotometer (Peqlab, Erlangen, Germany). 
Restriction digestion 
Restriction endonucleases from NEB or Fermentas were applied according to the 
manufacturer’s protocol. For analytical digestion 0.5-1 µg of DNA was used in final volume of 
20 µl and incubated for 1 h at 37 °C in a water bath. Preparative digestion was performed 
with 20 µg of plasmid DNA in a final volume of 50 µl and incubation for 2 h at 37 °C in a 
water bath. Preparative digestion of pLentiCRISPRempty with BsmBI was performed at 
55 °C in a water bath for 1 h. 
Dephosphorylation of 5’ termini 
The 5’-terminal phosphates of linearized plasmids were hydrolyzed to avoid recirculation. For 
this purpose, digested plasmid DNA was incubated with 5-30 units of calf intestinal alkaline 
phosphatase (CIP, NEB) in a final volume of 50 µl for 1 h at 37 °C in a water bath. 
DNA precipitation with ethanol 
To precipitate plasmid DNA from aqueous solutions, 2.5 volumes of ice-cold ethanol and 0.1 
volume of 3 M sodium acetate (pH 5.2) were added and incubated at - 20 °C for 30-60 min. 
DNA was pelleted by centrifugation and washed once with 70 % ethanol. The pellet was then 
air-tried before dissolving in TE buffer. 
Agarose gel electrophoresis and purification of DNA fragments 
DNA fragments were separated according to their size by horizontal agarose gel 
electrophoresis. Dependent on the expected fragment size 1-2 % of agarose were dissolved 
by boiling in electrophoresis buffer (40 mM Tris, 5 mM sodium acetate, 1 mM EDTA, pH 7.8). 
PeqGREEN non-toxic DNA/RNA dye (Peqlab) was added at a dilution of 1:20,000 and the 
solution poured into a gel chamber (Peqlab). After allowing it to cool down, the gel was put 
into an electrophoresis chamber (Peqlab) that was filled with electrophoresis buffer. DNA 
samples were mixed with 6x DNA loading buffer (0.25 % bromphenol blue, 0.25 % 
xylencyanol, 30 % glycerol) and loaded on the gel. 5 µl of SmartLadder (Eurogentec, 
Seraing, Belgium) were applied as size marker. The gel was run at 80-100 V for 30-90 min. 
DNA was visualized via UV transillumination in a gel documentation system (Intas Science 
Imaging Instruments, Göttingen, Germany).    
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If DNA fragments were to be extracted from the agarose gel for cloning purposes, the 
QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) was applied according to the 
manufacturer’s instructions. 
Ligation 
DNA fragments were inserted into linearized and 5’-dephosphorylated vectors. For the 
ligation procedure, 50-100 ng of vector were mixed with a 3-7 fold molar excess of the insert, 
2 units of T4 DNA Ligase (Life Technologies) and the supplied reaction buffer in a final 
volume of 10-20 µl. The ligation reaction was incubated for 2 h at 21 °C or overnight at 16 
°C. The T4 DNA ligase was then heat-inactivated for 10 min at 65 °C.  
For amplification, TG2 bacteria were transformed with the ligation mixture as described. 
Success of cloning was confirmed by analytical digest followed by agarose gel 
electrophoresis and by sequencing. Sequencing services were provided by MWG-Biotech. 
Analysis of the sequences was performed using the Basic Local Alignment Search Tool 
provided by the National Center for Biotechnology Information. 
4.4.3 Plasmids and cloning strategy  
pSuper plasmids 
shRNAs (short hairpin RNAs) were transcribed from pSuper (suppression of endogenous 
RNA) plasmids by the H1 RNA polymerase III promoter [207]. The pSuper transcript consists 
of a 19nt siRNA sequence directed against the target transcript in sense and antisense 
orientation separated by a hairpin that is processed to a functional siRNA upon expression in 
mammalian cells. The applied pSuper plasmids and their shRNA target sequences are listed 
in Tab. 6. The shRNA target sequences for Mlx were designed using an online tool provided 
by the Hannon lab (Cold Spring Harbor Laboratory, USA, 
http://cancan.cshl.edu/RNAi_central/RNAi.cgi?type=siRNA). All other target sequences are 
derived from the sources indicated in Tab. 6. All shRNAs were tested individually and then, if 
available, pooled at equimolar concentrations for further experiments.  
To clone a specific shRNA into pSuper, the synthetic sense and antisense shRNA 
oligonucleotides (Eurofins Genomics, Ebersberg, Germany) were mixed and incubated for 5 
min at 95 °C. To achieve annealing, the oligonucleotide mix was then incubated for 10 min at 
70 °C in a water bath and slowly cooled down in the water bath until reaching 30 °C. 
Annealing of the oligonucleotides resulted in sticky ends required for. The 5’-termini of the 
double stranded oligonucleotides were phosphorylated using T4 polynucleotide kinase (PNK, 
NEB) in the supplied buffer supplemented with 1 mM ATP for 30 min at 37 °C followed by 
enzyme inactivation for 10 min at 70 °C in a water bath. The reaction was slowly cooled 
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down in the water bath to RT and subsequently ligated into Bgl II- and Hind III-digested and 
5’-dephosphorylated pSuper. 
Vector target transcript shRNA target sequence 
source for target 
sequence 
pSuper shCalm1-1 CALM1 5′-AGGCAUUCCGAGUCUUUGA-3′ Ambion 
pSuper shCalm1-2 CALM1 5′-GCCUUCUCCCUAUUUGAUA -3′ Ambion 
pSuper shCalm2 CALM2 5′-GCACAAUUGACUUCCCUGA -3′ Ambion 
pSuper shCalm3-1 CALM3 5′-AGAUGAUCAGGGAGGCUGA -3′ Ambion 
pSuper shCalm3-2 CALM3 5′-GACUUCCCGGAGUCCUGA -3′ Ambion 
pSuper shHif-1α-1 HIF-1α 5′-CUAACUGGACACAGUGUGU-3′ [208] * 
pSuper shHif-1α-2 HIF-1α 5′-CUGAUGACCAGCAACUUGA-3′ [209] * 
pSuper shHif-2α-1 HIF-2α 5′-GCGACAGCUGGAGUAUGAA-3′ [208] * 
pSuper shHif-2α-2 HIF-2α 5′-CAGCAUCUUUGAUAGCAGU-3′ [210] * 
pSuper shMlx-2 MLX 5′-UCAUGAAAGUGAACUAUGA-3′ online tool Hannon lab 
pSuper shMlx-3 MLX 5′-CUGACCAGGUCAAGUUCAA-3′ online tool Hannon lab 
pSuper shMondoA MONDOA 5′-GAACAACUGCUCAGGGAAA-3′ [211] 
pSuper shMyc c-MYC 5′-CGAUGUUGUUUCUGUGGAA-3′ [212] 
pSuper shYY1-1 YY1 5′-GCAAGAAGAGUUACCUCAG-3′ [213] * 
pSuper shYY1-2 YY1 5′-GGCAGAAUUUGCUAGAAUG-3′ [213] * 
pSuper  -  empty vector [207] 
pSuper shContr-1 -  5′-CAGUCGCGUUUGCGACUGG-3′ * 
pSuper shNeg - 5′-UACGACCGGUCUAUCGUAG-3′ * 
* Plasmids were kindly provided by Karin Hoppe-Seyler & Claudia Lohrey 
 
CRISPR plasmids 
For generating AKT1 and AKT3 knockdown cells, the CRISPR/Cas9 (CRISPR = clustered 
regularly interspaced short palindromic repeats, Cas = CRISPR-associated) system was 
used. This technique is based on findings of an acquired defense mechanism of bacteria 
against phage infections [214]. To generate knockdowns in mammalian cell lines we exploit 
the type II CRISPR system [215]. In brief, a Cas9 endonuclease is guided to the target site in 
the gene of interest by an artificially designed guideRNA (gRNA), which combines features of 
the CRISPR RNA (crRNA) and the trans-activating RNA (tracrRNA). The gRNA contains a 
20 nt sequence complementary to a sequence in the target gene that is located next to a so-
called protospacer adjacent motif (PAM, 5’-NGG-3’ for Cas9 from Streptococcus pyogenes). 
The Cas9 induces a DNA double-strand break at the target site and due to error-prone non-
homologous end joining repair (NHEJ) small insertions or deletions (indels) are generated 
leading to a disruption of the reading frame. 
The here applied vector LentiCRISPRv1 (Addgene, USA, plasmid #49535) contains an 
expression cassette for Cas9 and a second cassette for the gRNA. Single gRNAs were 
designed using the online tool E-CRISP (http://www.e-crisp.org/E-CRISP/, version 5.3) 
Tab. 6. pSuper plasmids.
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provided by the Boutros lab (DKFZ, Heidelberg) or were taken from Doench et al. [216]. The 
20 nt sequence was complemented with CACC at the 5’-termini of the sense strand and with 
AAAC at the 5’-termini of the reverse strand to create overhangs for the cloning site. Cloning 
of the gRNAs into the LentiCRISPRv1 was performed according to the protocol developed by 
the Zhang lab [217]. The single gRNAs were phosphorylated using T4 PNK in the supplied 
buffer supplemented with 1 mM ATP for 30 min at 37 °C, followed by 5 min at 95 °C. To 
anneal the single gRNAs, the reaction mix was cooled down to 25 °C in steps of 5 °C per min 
in the MJ Research PTC-200 thermal cycler (Global Medical Instrumentation, Ramsey, USA) 
LentiCRISPRv1 vector was linearized by digestion with BsmBI, cutting out a 1885 nt filler 
sequence. The linearized vector was then 5’-dephosphorylated and purified by agarose gel 
electrophoresis before the dimerized gRNA was ligated into it.  
Vector Target transcript gRNA target sequence 
Source for target 
sequence 
LentiCRISPRv1 - (no gRNA inserted)  
LentiCRISPRv1 AKT1 gRNA1 AKT1 5′-GACGTGGCTATTGTGAAGGA-3′ [216] 
LentiCRISPRv1 AKT1 gRNA4 AKT1 5′-TGTCATGGAGTACGCCAACG-3′ [216] 
LentiCRISPRv1 AKT3 gRNA1 AKT3 5′-GAGAATATATAAAAAACTGG-3′ www.e-crisp.org 
LentiCRISPRv1 AKT3 gRNA2 AKT3 5′-GCCACTGAAAAGTTGTTGAG-3′ www.e-crisp.org 
LentiCRISPRv1 AKT3 gRNA3 AKT3 5′-GTCGTTCTGTTTTCATTAAC-3′ www.e-crisp.org 
LentiCRISPRv1 AKT3 gRNA4 AKT3 5′-ATTTCATGTAGATACTCCAG-3′ [216] 
 
Protein expression vectors 
Protein expression vectors were obtained from the sources indicated in Tab. 8. pLNCX1 
basic vector was generated by cutting out the insert from the Addgene vectors #15989. This 
was performed by restriction digestion with Hind III/Cla I. Blunt ends were generated using 
T4 DNA polymerase (NEB) according to the manufacturer’s instructions, followed by re-




this thesis Expressed protein Source 
pcDNA3 pcDNA3 - Invitrogen 
pcDNA3 YY1 pcDNA3 YY1 YY1 kindly provided by N. Lützner (Group of Prof. Dr. Frank Rösl, DKFZ, Heidelberg) 
pLNCX1 pLNCX1 - cloned from Addgene #15989 
pLNCX1 myrAKT1 
delta4-129 myrAKT1 deltaPH 
myristoylated AKT1, 
deletion4-129 (HA tagged) Addgene #15989 [218] 
pLNCX1 myrAKT2 
deltaPH myrAKT2 deltaPH 
myristoylated AKT2, 
deletion1-107 (HA tagged) 
Addgene #27294 (kind gift from Morris 
Birnbaum) 
pLNCX1 myr HA 
AKT1 K179M AKT1 K179M 
myristoylated AKT1, 
mutation K179M (HA tagged) Addgene #9006 [219] 
Tab. 7. CRISPR plasmids.
Tab. 8. Further protein expression vectors.
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4.5 Protein-based techniques 
4.5.1 Protein extraction from cells 
To generate protein extracts for immunoblot analyses, cells were usually seeded in 6 cm 
dishes and treated according to the experimental setup. At the time point of harvesting, cells 
were washed with ice-cold PBS and 150 µl ice-cold CSK-1 lysis buffer (10 mM PIPES pH 
6.8, 300 mM NaCl, 1mM EDTA, 300 mM sucrose, 1 mM MgCl2, 0.5% Triton X-100) was 
added. The lysis buffer was freshly supplemented with 100 µl PhosSTOP phosphatase 
inhibitor cocktail (Roche Diagnostics, Risch-Rotkreuz, Switzerland), 25 µl Pefabloc (Merck, 
Darmstadt, Germany) and 10 µl P8340 protease inhibitor cocktail (Sigma-Aldrich) per 900 µl 
CSK-1 buffer. Cells were scrapped from the dish using a rubber cell scraper and transferred 
into a 1.5 ml tube.  
For time course experiments, cells were washed and scraped in ice-cold PBS. The cell 
suspension was centrifuged for 10 s at 13000 g and the supernatant was removed. The cell 
pellet was stored at - 20 °C until all samples were collected. Sample preparation was then 
continued by lysing the pellets in an appropriate volume of CSK-1 buffer, freshly 
supplemented with phosphatase and protease inhibitors as described before. 
Cell lysates (derived from frozen pellets or from directly lysed cells) were incubated for 
30 min on ice to allow proper cell lysis before cellular debris was removed by centrifugation 
for 5 min at 13000 g and 4 °C. The supernatant was transferred to a fresh 1.5 ml tube. 
Protein concentration of the cell lysate was determined by the Bradford assay. To this end, 1-
3 µl of the cell lysate was mixed with 1ml of the 1:5 diluted protein assay dye reagent 
concentrate (BioRad) in a disposable cuvette (BRAND® semi-micro disposable cuvettes, 
Sigma-Aldrich). After incubation for 5 min at RT, absorption at 595 nm was measured with a 
photometer (BioPhotometer D30, Eppendorf, Hamburg, Germany). Protein concentration 
was calculated by comparison to a BSA standard curve. Protein lysates were then adjusted 
to the desired concentration by diluting with 4x loading buffer (8 % SDS, 250 mM Tris-HCl, 
20 % β-mercaptoethanol, 40 % glycerol, 0.008 % bromphenol blue). Samples were boiled for 
5 min at 96 °C and further used for immunoblot analyses or kept at -80 °C for long-term 
storage.  
4.5.2 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein lysates were separated according to their molecular weight by sodium 
dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Polyacrylamide gels were 
cast according to Tab. 9 using gel cassettes (NuPAGE empty gel cassettes mini, Life 
Technologies) or glass plates sealed with 1 % agarose. 
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Components for stacking gel  For 2 gels (5 %) Components for resolving gel 
For 2 gels (12.5 
%) 
H20 3.5 ml H20 4.5 ml 
30% Acrylamide/ bisacrylamide 830 µl 30% Acrylamide/ bisacrylamide 4.2 ml 
0.47 M Tris-HCl (pH 6.7) 620 µl 3 M Tris-HCl (pH 8.9) 1.2 ml 
10 % SDS 50 µl 10 % SDS 100 µl 
10 % APS 100 µl 10 % APS 10 µl 
TEMED 5 µl TEMED 50 µl 
 
Gels were installed into the XCell SureLockTM Mini-Cell Electrophoresis System (Life 
Technologies). Equal amounts of protein extract (15-30 µg) per lane were loaded on the gel. 
Additionally, 2 µl peqGOLD Protein-marker IV (PeqLab) was applied. Using tris-glycine SDS 
running buffer (2.5 mM Tris, 19.2 mM glycin, 0.1 % SDS), gels were run at 90-120 V for 
1-2 h.  
4.5.3 Western transfer and immunodetection of proteins 
Proteins were transferred from the gel to Immobilon-P PVDF membrane (Millipore, Bedford, 
MA, USA) by semi-dry blotting procedure. For this purpose, the PVDF membrane that was 
activated in methanol and eight Whatman paper (GE Healthcare, Buckinghamshire, UK) per 
gel were soaked in Towbin transfer buffer (2.5 mM Tris, 19.2 mM glycine, 20 % methanol, 
pH 8.3). Then, a sandwich with four Whatman paper at the bottom (anode), then the 
membrane, the protein gel and four Whatman paper at the top (cathode) was assembled into 
a Trans-Blot® SD Semi-Dry Electrophoretic Transfer Cell (Bio-Rad). Routinely, 1 to 4 gels 
were assembled into one semi-dry transfer cell. Electrotransfer of proteins was performed for 
1 h at 20 V. 
After blotting, the membrane was incubated with Blocking solution (5 % skim milk powder, 
1 % BSA, 0.2 % Tween-20 in PBS) for 1 h at RT to saturate unspecific binding sites. Next, 
the membrane was incubated with the primary antibody (Tab. 10) diluted in blocking solution 
overnight at 4 °C. Prior to incubation with the secondary antibody the membrane was 
washed three times for 10 min with PBS-T (0.2 % Tween-20 in PBS). Incubation with the 
appropriate secondary antibody, diluted in blocking solution, was carried out for 1 h at RT. 
Afterwards, the membrane was washed again three times for 10 min with PBS-T. Finally, 
signals were detected by means of enhanced chemiluminescence (ECL). To that end, ECL™ 
Prime Western Blotting Detection Reagent (GE Healthcare) or SuperSignal West Pico 
Luminol/Enhancer Solution (Thermo Fisher Scientific) was applied to the membrane 
Tab. 9. Recipe for SDS polyacrylamide gels.
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according to the manufacturer’s instructions and images were acquired with the Fusion SL 
Detection System (Vilber Lourmat, Eberhardzell, Germany).  
Primary antibodies 
Specificity Source Dilution Supplier 
anti-4E-BP1 rabbit 1:1000 Cell Signaling Technology #9452 
anti-4E-BP1 Phospho (S65) rabbit 1:1000 Cell Signaling Technology #9451 
anti-AKT rabbit 1:1000 Cell Signaling Technology #9272 
anti-AKT2 (F-7) mouse 1:500 Santa Cruz sc-5270 
anti-AKT3 rabbit 1:1000 Cell Signaling Technology #4059 
anti-AKT3 (clone GMA104) mouse 1:2000 EMD Millipore, Upstate 05-780 
anti-AKT Phospho (S473) rabbit 1:1000 Cell Signaling Technology #4058 
anti-AKT Phospho (T308) rabbit 1:1000 Cell Signaling Technology #9275 
anti-Brd4 (EPR5150(2)) rabbit 1:500 Abcam ab128874  
anti-c-Myc mouse 1:250 BD Pharmingen #551102 
anti-Dnmt1 (H-12) mouse 1:500 Santa Cruz sc-271729 
anti-GSK3-α/β Phospho (S21/S9) rabbit 1:1000 Cell Signaling Technology #9331 
anti-H3K4me3 (Tri-Methyl-Histone H3 
Lys4 (C42D8)) 
rabbit 1:1000 Cell Signaling Technology #9751 
anti-H3K27me3 (Tri-Methyl-Histone H3 
Lys27 (C36B11)) 
rabbit 1:1000 Cell Signaling Technology #9733 
anti-Hexokinase 2 (HK2) goat 1:200 Santa Cruz sc-6521 
anti-HIF-1α mouse 1:500 BD Pharmingen #610959 
anti-HIF-1β rabbit 1:500 Novus Biologicals 100-122SS 
anti-HPV16E6 (clone 849) mouse 1: 3000 Arbor Vita Corporation (Sunnyvale, CA, 
USA) 
anti-HPV16E7 (NM2) mouse 1:1000 Kind gift of Dr. Müller, DKFZ, Heidelberg 
anti-HPV18E6 (clone 399) mouse 1: 2000 Arbor Vita Corporation 
anti-HPV18E7 chicken 1:1000 Zentgraf, DKFZ, Heidelberg; ID: B (28) 
#47 31.10-11.11.95 
anti-p70 S6 Kinase (p70S6K) rabbit 1:1000 Cell Signaling Technology #9202 
anti-p70 S6 Kinase Phospho (T389) rabbit 1:1000 Cell Signaling Technology #9234 
anti-PTEN rabbit 1:2000 Cell Signaling Technology #9552 
anti-S6 Phospho (S235/236) rabbit 1:1000 Cell Signaling Technology #2211 
anti-Vinculin mouse 1:4000 Santa Cruz sc-73614 
anti-YY1 mouse 1:500 Santa Cruz sc271134 
anti-α-tubulin mouse 1:5000 Merck CP06 
anti-β-actin mouse 1:50000 Sigma-Aldrich A2228 
Secondary antibodies (HRP-coupled) 
Specificity Dilution Supplier 
anti-chicken IgG 1:5000 Santa Cruz sc-2428 
anti-goat IgG 1:5000 Santa Cruz sc-2020 
anti-mouse IgG 1:5000 Santa Cruz sc-2005 
anti-rabbit IgG 1:5000 Santa Cruz sc-2004 
 
  
Tab. 10. Antibodies for immunoblotting.
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4.5.4 Determination of protein half-life 
To compare the stability of proteins under hypoxia and normoxia, 4x105 HeLa cells were 
seeded per 6 cm dish. Medium was replenished the following day and 2 days after seeding 
cells were pre-incubated for 4 h under hypoxia. To stop de novo protein translation, 10 µg/ml 
cycloheximide (CHX, Sigma-Aldrich) was added to the cells in the hypoxia workstation and 
cells were harvested for protein extraction at the indicated time-points after CHX treatment. 
Normoxic cells were kept in a standard incubator at 21 % O2 and treated and harvested in 
parallel. Immunoblot analyses of protein lysates were performed and images were acquired. 
Band densities of E6 and E7 signals were quantified using Bio1D image analysis software 
(Vilber Lourmat) and normalized to the band densities of the respective loading control (β-
actin, α-tubulin or vinculin). Half-life of E6 and E7 was calculated from an exponential decay 
curve that was generated by non-linear regression using SigmaPlot software. 
4.5.5 Tandem mass tag (TMT) mass spectrometry (MS) 
Mass spectrometry (MS)-based quantitative proteome analysis was performed in cooperation 
with Bianca Kuhn and Prof. Dr. Jeroen Krijgsveld (DKFZ, Heidelberg). For this purpose, an 
isobaric labeling approach using Thermo Fisher Scientific’s tandem mass tags (TMTs) was 
applied. TMTs are isobaric tags, hence they share the same overall mass but differ in the 
distribution of heavy and light isotopes. They generally consist of an amine-reactive region, a 
mass normalization (balance) region and a reporter region. The light and heavy isotopes are 
distributed between the balance group and the reporter group yielding an overall identical 
mass but a unique reporter ion generated by the reporter region. Up to 10 samples (TMT 
10plex) can be combined for analysis via liquid chromatography (LC)-MS/MS. By comparing 
the intensities of the unique reporter ions, a relative quantification of protein abundances can 
be performed. Thus, this multiplex technique allows the integrated analysis of up to 10 
samples simultaneously [164]. 
For proteome analyses 1x106 SiHa cells were seeded in 6 cm dishes. After two days, 
medium was replenished (5.5 mM or 25 mM glucose as indicated), cells were treated with 
10 µM AKTi VIII or DMSO and cultured for 17 h under hypoxia or normoxia. For harvesting, 
cells were immediately put on ice, washed once with ice-cold PBS, scraped in 500 µl PBS 
and transferred in a 1.5 ml tube. Cells were pelleted by centrifugation, supernatant was 
removed and cell pellets were stored at -80 °C until further processing. 
The following protocol describing sample preparation and mass spectrometry analysis was 
provided and the procedure performed by Bianca Kuhn (Group of Prof. Dr. Jeroen Krijgsveld, 
DKFZ, Heidelberg). 
Cell pellets were resuspended in 70-300 µl 0.1 % (w/v) RapiGest SF Surfactant (Waters, 
Milford, USA) that was reconstituted in 100 mM triethylammonium buffer (TEAB). To 
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complete lysis and to share chromatin, sonication was performed at 4 °C using a Bioruptor 
Pico sonication device (Diagenode) with 30 sec on/off-pulses for 15-20 cycles. Determination 
of protein concentration was carried out using the PierceTM BCA protein assay kit (Thermo 
Fisher Scientific) according to the manufacturer’s protocol. 50 µg per sample was adjusted to 
100 µl with 100 mM TEAB. Proteins were reduced by adding 5 mM dithiothreitol and 
incubation for 60 min at RT. To perform alkylation, 15 mM 2-chloroacetamide was added and 
samples were incubated for 30 min at RT. For proteolytic digestion modified trypsin (gold 
grade, Promega) was added in a 1:50 trypsin to protein ratio and incubated overnight at 
37 °C while shaking. The next day, 1% trifluoroacetic acid (pH<2) was added to stop the 
reaction and break RapiGest SF. Samples were incubated at 37 °C for 30-45 min before 
centrifugation at 20000 g for 10 min. The supernatant was transferred to a new 1.5 ml tube 
and the sample was dried using a speed vacuum concentrator. 
Isobaric labeling of the peptides was accomplished with 10plex TMT reagents (Thermo 
Fisher Scientific). 10 µg of each sample was dissolved in 100 mM TEAB buffer to obtain a 
concentration of 1 μg/µl, vortexed and incubated for 10 min at RT. TMT10plex reagents 
(0.8 mg) were dissolved in 41 μl of acetonitrile. 4.1 µL of one of the 10 TMT labels (TMT-126, 
TMT-127N, TMT-127C, TMT-128N, TMT-128C, TMT-129N, TMT-129C, TMT-130N, TMT-
130C, and TMT-131) was combined with 10 µg of the corresponding peptide samples and 
incubated for 1 h at RT. The reaction was then quenched for 15 min by adding 8 µl of 5 % 
hydroxylamine. The labeled samples were pooled in equal amounts. The sample mix was 
vacuum dried and subsequently filled up to 90 µL with 0.1% formic acid in H2O. For high pH 
LC fractionation, the sample mix was pwith ammonium formate (200 mM, pH 10) to reach a 
final concentration of 20 mM ammonium formate.  
The sample mix was fractionated by high pH reverse-phase LC. Here, peptides were 
fractionated on a 1200 Infinity HPLC system (Agilent, Santa Clara, CA, USA) with a Gemini 
C18 column (3 µm, 110 Å, 100 × 1.0 mm; Phenomenex, Torrance, CA, USA) using a linear 
60 min gradient from 0 % to 35 % (v/v) acetonitrile in 20 mM ammonium formate (pH 10) at a 
flow rate of 0.1 ml/min. Peptide elution was detected with a variable wavelength UV detector 
set to 254 nm. Sixty 1 min fractions were collected and pooled into 12 fractions. Fractions 
were then analyzed using LC-MS on an Orbitrap Fusion™ Tribrid™ (Thermo Fisher 
Scientific) mass spectrometer coupled to an Easy-nLC 1000 (Thermo Fisher Scientific) 
ultrahigh pressure liquid chromatography pump. Peptides were loaded onto an Acclaim 
PepMapTM 100 C18 Nano-Trap (100 μm x 2cm, nanoViper, C18, 5 μm 100Å pores) and 
separated over 50 cm Acclaim PepMapTM RSLC analytical columns (75 μm × 50 cm, 
nanoViper, C18, 2 µM, 100Å). For mobile phase Solvent A (0.1% formic acid in H2O) and 
Solvent B (0.1 % formic acid in 80 % acetonitrile in H2O) were used in the following gradient: 
3–8 % B over 4 min, 8–10 % B over 2 min, 10-32 % over 68 min, 32–50 % B over 12 min 
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and 50-100 % B in 1 min, holding at 100 % B for 7 min. The gradient returned to 3 % B in 
1 min and held there for 10 min to prepare for the next injection. The flow rate throughout the 
runs was 300 nl/min. Eluting samples were injected by electrospray ionization (ESI) using a 
10 µm Picotip coated fused silica emitter and a nanospray-Flex ion source (Thermo Fisher 
Scientific) connected to an Orbitrap-Fusion. The Orbitrap Fusion mass spectrometer was 
operated in data-dependent mode using vendor supplied default setting for synchronous 
precursor selection (SPS) MS3 fragmentation. 
Analysis of MS spectra was performed using Proteome Discoverer 2.1 (Thermo Fisher 
Scientific) and the proteins were identified using MASCOT search engine 2.3.2. (Matrix 
Science) against the Swissprot Homo sapiens proteome (21.06.2018). Percolator algorithm 
was used as the false discovery rate calculator, and all peptides were filtered at the strict 
target false discovery rate level of 0.01. 
For the identification of the differentially expressed proteins under the described conditions, 
Linear Models for Microarray Data (limma, Version 3.36.2; RStudio, Version 1.1.456) were 
applied for all biological replicates. P-values were adjusted using Benjamini-Hochberg 
correction. Volcano plots were generated using GraphPad Prism software. 
The heatmap of the proteins showing differential expression between hypoxia and normoxia 
was generated with support of Stephen Krämer (DKFZ, Heidelberg) using the pandas 
(0.23.3) and seaborn (0.9.0) python packages. Hierarchical clustering was performed using 
scikit-learn, using Euclidean distance and the average linkage method. 
4.6 RNA-based techniques 
4.6.1 RNA extraction from cells 
To analyze mRNA expression under varying experimental conditions, RNA was usually 
harvested from 6 cm dishes. Cells were washed once with PBS and 600 µl RNA lysis buffer 
(Invitrogen, freshly supplemented with β-mercaptoethanol) per 6 cm dish was added to the 
cells. The lysate was resuspended, transferred to a 1.5 ml tube and either stored at -20 °C or 
directly further processed for RNA extraction. Isolation of total RNA was performed with the 
column-based PureLink RNA Mini Kit (Invitrogen) according to the manufacturer’s 
instructions. To remove unwanted DNA from the sample PureLink DNase Set (Invitrogen) 
was applied. The purified RNA was diluted in 40-80 µl RNAse-free H2O and concentration 
was determined with the NanoDrop ND-1000 spectrophotometer (Peqlab). Purified RNA was 
stored at -80 °C. 
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4.6.2 Reverse transcription (RT) and quantitative real-time PCR (qRT-PCR) 
For cDNA synthesis the ProtoScript® II First Strand cDNA Synthesis Kit (NEB) was used. In 
brief, 500 ng of purified RNA was adjusted to a volume of 3 µl with RNAse-free H2O and 
mixed with 1 µl of random primer. The mix of primer and RNA was denatured for 5 min at 
70 °C and immediately put on ice. 5 µl of the 2x reaction mix and 1 µl of the 10x enzyme mix 
were added per sample. The 10 µl reaction mix was then incubated first for 5 min at 25 °C, 
followed by 1 h incubation at 42 °C and finally for 5 min at 80 °C in a thermal cycler. The 
cDNA product was stored at -20 °C.  
Expression of mRNA was finally determined by quantitative real-time PCR (qPCR). Before 
using the cDNA for qRT-PCR, 40 µl of nuclease-free H2O was added to the 10 µl cDNA 
reaction mix and then further diluted in a ratio of 1:10. For each primer pair that was to be 
analyzed, one reaction mix was prepared. The reaction mix for one sample was comprised of 
10 µl SYBR™ Green PCR Master Mix (Applied Biosystems, USA), 0.4 µl forward primer, 0.4 
µl reverse primer and 7.2 µl nuclease-free H20 resulting in a final volume of 18 µl. The final 
concentration of the forward and reverse primers was 100 nM each for detection of mRNAs 
and 50 nM for detection of 18S rRNA. The reaction mix was pipetted in the well of a 96-well 
plate (MicroAmpTM Optical 96-Well Reaction Plate, Life Technologies) and 2 µl of the diluted 
cDNA was added. To control for contaminations a no template control containing 2 µl H2O 
instead of cDNA was included for each reaction mix. All reactions were run as duplicates. 
The qRT-PCR was run on a 7300 Real Time PCR System (Applied Biosystems, Invitrogen) 
according to the following program.  
Initiation:   50 °C  2 min 
Polymerase activation: 95 °C  10 min 
Denaturation:   95 °C  15 sec     40 cycles 
Annealing and elongation: 60 °C  1 min 
Dissociation curves:  95 °C  15 sec 
    60 °C  1 min 
    95 °C  15 sec 
    60 °C  15 sec 
The generation of dissociation curves allowed detection of unspecific amplification artefacts. 
Calculation of mRNA expression was performed according to the comparative Ct (2-ΔΔCt) 
method [220] with normalization to 18S rRNA as internal reference. Statistical analyses of 
fold change values were carried out after logarithmic transformation.  
All primers were initially tested for sufficient efficiency (80-110 %) by generating a standard 
curve using serial dilutions. 
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Target RNA Sequence of forward (for) and reverse (rev) primer  amplicon length 





































4.6.3 Determination of mRNA half-life 
To assess E6/E7 mRNA stability under hypoxia and normoxia, HeLa cells were treated with 
the transcriptional inhibitor Actinomycin D (ActD, Sigma-Aldrich) 2 days after seeding at a 
density of 5x105 cells per 6 cm dish. Prior to ActD treatment, cells were pre-incubated for 4.5 
h under hypoxia. Treatment with 0.5 µg/ml ActD was carried out inside the hypoxia 
workstation. Harvesting for mRNA isolation was performed at the indicated time points after 
ActD treatment. Normoxic cells were treated and harvested in parallel. RNA extraction, cDNA 
synthesis and qRT-PCR with primers, detecting all three transcript classes coding for E6/E7, 
was performed. Based on the results from the qRT-PCR an exponential decay curve was 
generated by non-linear regression to calculate the mRNA half-life using SigmaPlot software. 
4.7 Statistical analyses 
All experiments were performed at least in three biological replicates, if not indicated 
otherwise. Mean values and standard deviations were calculated using Microsoft Excel 
(Microsoft Office 2010) or SigmaPlot software. Analyses of fold change values were carried 
out following logarithmic transformation. Statistical significance was determined by one-way 
ANOVA using SigmaPlot software. P-values of ≤0.05 (*), ≤0.01 (**), or ≤0.001 (***) were 
considered statistically significant. 
Statistical analysis of MS-data is described in chapter 4.5.5. 
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CRISPR  clustered regularly interspaced short palindromic repeats 
DKK1   Dickkopf-related protein 1 
DMEM   Dulbecco’s minimal essential medium 
DMOG   dimethyloxaloylglycine 
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DNA   deoxyribonucleic acid 
Dnmt1   DNA methyltransferase 1 
e. g.   exempli gratia 
E6-AP   E6-associated protein 
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et al.   et alii 
FCS   fetal calf serum 
Fig.   figure 
FIH   factor-inhibiting HIF-1α 
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Glut1   glucose transporter 1 
GPCR   G protein-coupled receptor 
gRNA   guide RNA 
GSK3   glycogen synthase kinase 3 
H3K4me3  trimethylation at lysine 4 of histone 3 
H3K27me3  trimethylation at lysine 27 of histone 3 
HAP   hypoxia-activated prodrug 
HDAC   histone deacetylase 
HIF   hypoxia-inducible factor 
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hTERT  human telomerase reverse transcriptase 
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kDa   kilo dalton 
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log2   binary logarithm 
MeDIP   methylated DNA immunoprecipitation 
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Mlx   Max-like protein X 
mRNA   messenger RNA 
MS   mass spectrometry 
MT2A   metallothionein 2A 
mTOR   mechanistic target of rapamycin 
mTORC1/mTORC2 mTOR complex 1/mTOR complex 2 
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O2   oxygen 
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OXPHOS  mitochondrial oxidative phosphorylation 
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ROS   reactive oxygen species 
RT   room temperature 
   Indexes 
111 
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Tab.   table 
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Prefixes 
Symbol  Prefix   Factor 
k   kilo   103 
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µ   micro   10-6 
n   nano   10-9 
 
References 
1. Torre, L.A., et al., Global cancer statistics, 2012. CA Cancer J Clin, 2015. 65(2): p. 
87-108. 
2. Vogelstein, B. and K.W. Kinzler, The multistep nature of cancer. Trends in Genetics, 
1993. 9(4): p. 138-141. 
3. Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. Cell, 
2011. 144(5): p. 646-74. 
4. Katzke, V.A., R. Kaaks, and T. Kuhn, Lifestyle and cancer risk. Cancer J, 2015. 21(2): 
p. 104-10. 
5. Peto, J., Cancer epidemiology in the last century and the next decade. Nature, 2001. 
411: p. 390. 
6. Plummer, M., et al., Global burden of cancers attributable to infections in 2012: a 
synthetic analysis. The Lancet Global Health, 2016. 4(9): p. e609-e616. 
7. de Martel, C., et al., Worldwide burden of cancer attributable to HPV by site, country 
and HPV type. Int J Cancer, 2017. 141(4): p. 664-670. 
8. de Villiers, E.-M., Cross-roads in the classification of papillomaviruses. Virology, 
2013. 445(1): p. 2-10. 
9. Doorbar, J., et al., The biology and life-cycle of human papillomaviruses. Vaccine, 
2012. 30 Suppl 5: p. F55-70. 
10. Durst, M., et al., A papillomavirus DNA from a cervical carcinoma and its prevalence 
in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S 
A, 1983. 80(12): p. 3812-5. 
11. Bouvard, V., et al., A review of human carcinogens--Part B: biological agents. Lancet 
Oncol, 2009. 10(4): p. 321-2. 
12. Smith, J.S., et al., Human papillomavirus type distribution in invasive cervical cancer 
and high-grade cervical lesions: a meta-analysis update. Int J Cancer, 2007. 121(3): 
p. 621-32. 
13. Vaccarella, S., et al., Worldwide trends in cervical cancer incidence: impact of 
screening against changes in disease risk factors. Eur J Cancer, 2013. 49(15): p. 
3262-73. 
14. Lowy, D.R. and J.T. Schiller, Preventing Cancer and Other Diseases Caused by 
Human Papillomavirus Infection: 2017 Lasker-DeBakey Clinical Research Award. 
Jama, 2017. 318(10): p. 901-902. 
15. Schiffman, M., et al., Carcinogenic human papillomavirus infection. Nat Rev Dis 
Primers, 2016. 2: p. 16086. 
16. Castle, P.E. and M. Maza, Prophylactic HPV vaccination: past, present, and future. 
Epidemiol Infect, 2016. 144(3): p. 449-68. 
   Indexes 
113 
17. Lehtinen, M. and J. Dillner, Clinical trials of human papillomavirus vaccines and 
beyond. Nature Reviews Clinical Oncology, 2013. 10: p. 400. 
18. Bruni, L., et al., Global estimates of human papillomavirus vaccination coverage by 
region and income level: a pooled analysis. Lancet Glob Health, 2016. 4(7): p. e453-
63. 
19. Schiller, J.T. and M. Muller, Next generation prophylactic human papillomavirus 
vaccines. Lancet Oncol, 2015. 16(5): p. e217-25. 
20. zur Hausen, H., Papillomaviruses and cancer: from basic studies to clinical 
application. Nat Rev Cancer, 2002. 2(5): p. 342-50. 
21. Doorbar, J., Molecular biology of human papillomavirus infection and cervical cancer. 
Clin Sci (Lond), 2006. 110(5): p. 525-41. 
22. Doorbar, J., The E4 protein; structure, function and patterns of expression. Virology, 
2013. 445(1-2): p. 80-98. 
23. Doorbar, J., et al., Human papillomavirus molecular biology and disease association. 
Rev Med Virol, 2015. 25 Suppl 1: p. 2-23. 
24. DiMaio, D. and D. Mattoon, Mechanisms of cell transformation by papillomavirus E5 
proteins. Oncogene, 2001. 20: p. 7866. 
25. Schiffman, M. and N. Wentzensen, Human papillomavirus infection and the 
multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev, 
2013. 22(4): p. 553-60. 
26. Westrich, J.A., C.J. Warren, and D. Pyeon, Evasion of host immune defenses by 
human papillomavirus. Virus Res, 2017. 231: p. 21-33. 
27. Moody, C.A. and L.A. Laimins, Human papillomavirus oncoproteins: pathways to 
transformation. Nat Rev Cancer, 2010. 10(8): p. 550-60. 
28. Egawa, N., et al., Human Papillomaviruses; Epithelial Tropisms, and the 
Development of Neoplasia. Viruses, 2015. 7(7): p. 3863-90. 
29. Wentzensen, N., S. Vinokurova, and M. von Knebel Doeberitz, Systematic review of 
genomic integration sites of human papillomavirus genomes in epithelial dysplasia 
and invasive cancer of the female lower genital tract. Cancer Res, 2004. 64(11): p. 
3878-84. 
30. Romanczuk, H. and P.M. Howley, Disruption of either the E1 or the E2 regulatory 
gene of human papillomavirus type 16 increases viral immortalization capacity. Proc 
Natl Acad Sci U S A, 1992. 89(7): p. 3159-63. 
31. Herfs, M., et al., A discrete population of squamocolumnar junction cells implicated in 
the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A, 2012. 109(26): p. 
10516-21. 
32. Hoppe-Seyler, K., et al., The HPV E6/E7 Oncogenes: Key Factors for Viral 
Carcinogenesis and Therapeutic Targets. Trends Microbiol, 2018. 26(2): p. 158-168. 
33. Goodwin, E.C., et al., Rapid induction of senescence in human cervical carcinoma 
cells. Proc Natl Acad Sci U S A, 2000. 97(20): p. 10978-83. 
34. Wells, S.I., et al., Papillomavirus E2 induces senescence in HPV-positive cells via 
pRB- and p21(CIP)-dependent pathways. Embo j, 2000. 19(21): p. 5762-71. 
35. Magaldi, T.G., et al., Primary human cervical carcinoma cells require human 
papillomavirus E6 and E7 expression for ongoing proliferation. Virology, 2012. 422(1): 
p. 114-24. 
36. Butz, K. and F. Hoppe-Seyler, Transcriptional control of human papillomavirus (HPV) 
oncogene expression: composition of the HPV type 18 upstream regulatory region. J 
Virol, 1993. 67(11): p. 6476-86. 
37. Bernard, H.U., Regulatory elements in the viral genome. Virology, 2013. 445(1-2): p. 
197-204. 
38. McBride, A.A. and A. Warburton, The role of integration in oncogenic progression of 
HPV-associated cancers. PLoS Pathog, 2017. 13(4): p. e1006211. 
39. Hoppe-Seyler, F. and K. Butz, Activation of human papillomavirus type 18 E6-E7 
oncogene expression by transcription factor Sp1. Nucleic Acids Res, 1992. 20(24): p. 
6701-6. 
Indexes     
114 
40. Thierry, F., et al., Two AP1 sites binding JunB are essential for human papillomavirus 
type 18 transcription in keratinocytes. J Virol, 1992. 66(6): p. 3740-8. 
41. Scheffner, M., et al., The E6 oncoprotein encoded by human papillomavirus types 16 
and 18 promotes the degradation of p53. Cell, 1990. 63(6): p. 1129-36. 
42. Huibregtse, J.M., M. Scheffner, and P.M. Howley, Cloning and expression of the 
cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus 
E6 oncoprotein with p53. Mol Cell Biol, 1993. 13(2): p. 775-84. 
43. Scheffner, M., et al., The HPV-16 E6 and E6-AP complex functions as a ubiquitin-
protein ligase in the ubiquitination of p53. Cell, 1993. 75(3): p. 495-505. 
44. Frolov, M.V. and N.J. Dyson, Molecular mechanisms of E2F-dependent activation 
and pRB-mediated repression. J Cell Sci, 2004. 117(Pt 11): p. 2173-81. 
45. Munger, K., et al., Complex formation of human papillomavirus E7 proteins with the 
retinoblastoma tumor suppressor gene product. Embo j, 1989. 8(13): p. 4099-105. 
46. Dyson, N., et al., Homologous sequences in adenovirus E1A and human 
papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. 
J Virol, 1992. 66(12): p. 6893-902. 
47. Boyer, S.N., D.E. Wazer, and V. Band, E7 protein of human papilloma virus-16 
induces degradation of retinoblastoma protein through the ubiquitin-proteasome 
pathway. Cancer Res, 1996. 56(20): p. 4620-4. 
48. Jones, D.L., D.A. Thompson, and K. Munger, Destabilization of the RB tumor 
suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced 
apoptosis. Virology, 1997. 239(1): p. 97-107. 
49. Hawley-Nelson, P., et al., HPV16 E6 and E7 proteins cooperate to immortalize 
human foreskin keratinocytes. Embo j, 1989. 8(12): p. 3905-10. 
50. Thomas, M., et al., Human papillomaviruses, cervical cancer and cell polarity. 
Oncogene, 2008. 27(55): p. 7018-30. 
51. Klingelhutz, A.J., S.A. Foster, and J.K. McDougall, Telomerase activation by the E6 
gene product of human papillomavirus type 16. Nature, 1996. 380: p. 79. 
52. Veldman, T., et al., Transcriptional activation of the telomerase hTERT gene by 
human papillomavirus type 16 E6 oncoprotein. J Virol, 2001. 75(9): p. 4467-72. 
53. Veldman, T., et al., Human papillomavirus E6 and Myc proteins associate in vivo and 
bind to and cooperatively activate the telomerase reverse transcriptase promoter. 
Proc Natl Acad Sci U S A, 2003. 100(14): p. 8211-6. 
54. Zeng, Q., et al., O-linked GlcNAcylation elevated by HPV E6 mediates viral 
oncogenesis. Proc Natl Acad Sci U S A, 2016. 113(33): p. 9333-8. 
55. Kuner, R., et al., Identification of cellular targets for the human papillomavirus E6 and 
E7 oncogenes by RNA interference and transcriptome analyses. J Mol Med (Berl), 
2007. 85(11): p. 1253-62. 
56. Hoppe-Seyler, K., et al., Viral E6/E7 oncogene and cellular hexokinase 2 expression 
in HPV-positive cancer cell lines. Oncotarget, 2017. 8(63): p. 106342-106351. 
57. Gewin, L. and D.A. Galloway, E box-dependent activation of telomerase by human 
papillomavirus type 16 E6 does not require induction of c-myc. J Virol, 2001. 75(15): 
p. 7198-201. 
58. Hwang, S.G., et al., Human papillomavirus type 16 E7 binds to E2F1 and activates 
E2F1-driven transcription in a retinoblastoma protein-independent manner. J Biol 
Chem, 2002. 277(4): p. 2923-30. 
59. Brehm, A., et al., The E7 oncoprotein associates with Mi2 and histone deacetylase 
activity to promote cell growth. Embo j, 1999. 18(9): p. 2449-58. 
60. Hurlin, P.J., et al., Progression of human papillomavirus type 18-immortalized human 
keratinocytes to a malignant phenotype. Proc Natl Acad Sci U S A, 1991. 88(2): p. 
570-4. 
61. Smith, P.P., et al., Cytogenetic analysis of eight human papillomavirus immortalized 
human keratinocyte cell lines. Int J Cancer, 1989. 44(6): p. 1124-31. 
62. Duensing, S. and K. Munger, Centrosomes, genomic instability, and cervical 
carcinogenesis. Crit Rev Eukaryot Gene Expr, 2003. 13(1): p. 9-23. 
   Indexes 
115 
63. Klingelhutz, A.J. and A. Roman, Cellular transformation by human papillomaviruses: 
lessons learned by comparing high- and low-risk viruses. Virology, 2012. 424(2): p. 
77-98. 
64. McKeown, S.R., Defining normoxia, physoxia and hypoxia in tumours-implications for 
treatment response. Br J Radiol, 2014. 87(1035): p. 20130676. 
65. Vaupel, P., M. Hockel, and A. Mayer, Detection and characterization of tumor hypoxia 
using pO2 histography. Antioxid Redox Signal, 2007. 9(8): p. 1221-35. 
66. Vaupel, P. and A. Mayer, Hypoxia in cancer: significance and impact on clinical 
outcome. Cancer Metastasis Rev, 2007. 26(2): p. 225-39. 
67. Brown, J.M., Tumor Hypoxia in Cancer Therapy, in Methods in Enzymology. 2007, 
Academic Press. p. 295-321. 
68. Noman, M.Z., et al., Hypoxia: a key player in antitumor immune response. A Review 
in the Theme: Cellular Responses to Hypoxia. Am J Physiol Cell Physiol, 2015. 
309(9): p. C569-79. 
69. Wilson, W.R. and M.P. Hay, Targeting hypoxia in cancer therapy. Nat Rev Cancer, 
2011. 11(6): p. 393-410. 
70. Hunter, F.W., B.G. Wouters, and W.R. Wilson, Hypoxia-activated prodrugs: paths 
forward in the era of personalised medicine. Br J Cancer, 2016. 114(10): p. 1071-7. 
71. Hoppe-Seyler, K., et al., Induction of dormancy in hypoxic human papillomavirus-
positive cancer cells. Proc Natl Acad Sci U S A, 2017. 114(6): p. E990-e998. 
72. Blagosklonny, M.V., Geroconversion: irreversible step to cellular senescence. Cell 
Cycle, 2014. 13(23): p. 3628-35. 
73. Bensaad, K. and A.L. Harris, Hypoxia and metabolism in cancer. Adv Exp Med Biol, 
2014. 772: p. 1-39. 
74. Ullah, M.S., A.J. Davies, and A.P. Halestrap, The plasma membrane lactate 
transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-
dependent mechanism. J Biol Chem, 2006. 281(14): p. 9030-7. 
75. Toescu, E.C., Hypoxia sensing and pathways of cytosolic Ca2+ increases. Cell 
Calcium, 2004. 36(3-4): p. 187-99. 
76. Nakazawa, M.S., B. Keith, and M.C. Simon, Oxygen availability and metabolic 
adaptations. Nat Rev Cancer, 2016. 16(10): p. 663-73. 
77. Majmundar, A.J., W.J. Wong, and M.C. Simon, Hypoxia-inducible factors and the 
response to hypoxic stress. Mol Cell, 2010. 40(2): p. 294-309. 
78. Klimova, T. and N.S. Chandel, Mitochondrial complex III regulates hypoxic activation 
of HIF. Cell Death And Differentiation, 2008. 15: p. 660. 
79. Keith, B., R.S. Johnson, and M.C. Simon, HIF1alpha and HIF2alpha: sibling rivalry in 
hypoxic tumour growth and progression. Nat Rev Cancer, 2012. 12(1): p. 9-22. 
80. Duan, C., Hypoxia-inducible factor 3 biology: complexities and emerging themes. Am 
J Physiol Cell Physiol, 2016. 310(4): p. C260-9. 
81. Watson, J.A., et al., Epigenetics, the epicenter of the hypoxic response. Epigenetics, 
2010. 5(4): p. 293-6. 
82. Johnson, A.B., N. Denko, and M.C. Barton, Hypoxia induces a novel signature of 
chromatin modifications and global repression of transcription. Mutat Res, 2008. 
640(1-2): p. 174-9. 
83. Thienpont, B., et al., Tumour hypoxia causes DNA hypermethylation by reducing TET 
activity. Nature, 2016. 537: p. 63. 
84. Chang, S., et al., Hypoxic reprograming of H3K27me3 and H3K4me3 at the INK4A 
locus. FEBS Lett, 2016. 590(19): p. 3407-3415. 
85. Prickaerts, P., et al., Hypoxia increases genome-wide bivalent epigenetic marking by 
specific gain of H3K27me3. Epigenetics Chromatin, 2016. 9: p. 46. 
86. Adriaens, M.E., et al., Quantitative analysis of ChIP-seq data uncovers dynamic and 
sustained H3K4me3 and H3K27me3 modulation in cancer cells under hypoxia. 
Epigenetics Chromatin, 2016. 9: p. 48. 
87. Hajduch, E., G.J. Litherland, and H.S. Hundal, Protein kinase B (PKB/Akt)--a key 
regulator of glucose transport? FEBS Lett, 2001. 492(3): p. 199-203. 
Indexes     
116 
88. von der Crone, S., et al., Glucose deprivation induces Akt-dependent synthesis and 
incorporation of GLUT1, but not of GLUT4, into the plasma membrane of 3T3-L1 
adipocytes. Eur J Cell Biol, 2000. 79(12): p. 943-9. 
89. Roberts, H.R., et al., Colon tumour cells increase PGE(2) by regulating COX-2 and 
15-PGDH to promote survival during the microenvironmental stress of glucose 
deprivation. Carcinogenesis, 2011. 32(11): p. 1741-7. 
90. Gao, M., et al., Site-specific activation of AKT protects cells from death induced by 
glucose deprivation. Oncogene, 2014. 33(6): p. 745-55. 
91. Zundel, W., et al., Loss of PTEN facilitates HIF-1-mediated gene expression. Genes 
Dev, 2000. 14(4): p. 391-6. 
92. Beitner-Johnson, D., et al., Hypoxia activates Akt and induces phosphorylation of 
GSK-3 in PC12 cells. Cell Signal, 2001. 13(1): p. 23-7. 
93. Stegeman, H., et al., Activation of AKT by hypoxia: a potential target for hypoxic 
tumors of the head and neck. BMC Cancer, 2012. 12: p. 463. 
94. Jiao, M. and K.J. Nan, Activation of PI3 kinase/Akt/HIF-1alpha pathway contributes to 
hypoxia-induced epithelial-mesenchymal transition and chemoresistance in 
hepatocellular carcinoma. Int J Oncol, 2012. 40(2): p. 461-8. 
95. Manning, B.D. and A. Toker, AKT/PKB Signaling: Navigating the Network. Cell, 2017. 
169(3): p. 381-405. 
96. Bellacosa, A., et al., Activation of AKT Kinases in Cancer: Implications for 
Therapeutic Targeting, in Advances in Cancer Research. 2005, Academic Press. p. 
29-86. 
97. Osorio-Fuentealba, C. and A. Klip, Dissecting signalling by individual Akt/PKB 
isoforms, three steps at once. Biochem J, 2015. 470(2): p. e13-6. 
98. Alessi, D.R., et al., Mechanism of activation of protein kinase B by insulin and IGF-1. 
Embo j, 1996. 15(23): p. 6541-51. 
99. Facchinetti, V., et al., The mammalian target of rapamycin complex 2 controls folding 
and stability of Akt and protein kinase C. Embo j, 2008. 27(14): p. 1932-43. 
100. Vanhaesebroeck, B., et al., The emerging mechanisms of isoform-specific PI3K 
signalling. Nature Reviews Molecular Cell Biology, 2010. 11: p. 329. 
101. Calleja, V., et al., Intramolecular and intermolecular interactions of protein kinase B 
define its activation in vivo. PLoS Biol, 2007. 5(4): p. e95. 
102. Agamasu, C., et al., The Interplay between Calmodulin and Membrane Interactions 
with the Pleckstrin Homology Domain of Akt. J Biol Chem, 2017. 292(1): p. 251-263. 
103. Agamasu, C., R.H. Ghanam, and J.S. Saad, Structural and Biophysical 
Characterization of the Interactions between Calmodulin and the Pleckstrin Homology 
Domain of Akt. J Biol Chem, 2015. 290(45): p. 27403-13. 
104. Sarbassov, D.D., et al., Phosphorylation and Regulation of Akt/PKB by the Rictor-
mTOR Complex. Science, 2005. 307(5712): p. 1098-1101. 
105. Bozulic, L., et al., PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-
strand break response and promotes survival. Mol Cell, 2008. 30(2): p. 203-13. 
106. Chen, E.Y., et al., Hypoxia activates a platelet-derived growth factor 
receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase 
kinase-3 inactivation. Cancer Res, 2001. 61(6): p. 2429-33. 
107. Zhang, J., et al., Apelin/APJ signaling promotes hypoxia-induced proliferation of 
endothelial progenitor cells via phosphoinositide-3 kinase/Akt signaling. Mol Med 
Rep, 2015. 12(3): p. 3829-3834. 
108. Guo, J., et al., pVHL suppresses kinase activity of Akt in a proline-hydroxylation-
dependent manner. Science, 2016. 353(6302): p. 929-32. 
109. Manning, B.D. and L.C. Cantley, AKT/PKB signaling: navigating downstream. Cell, 
2007. 129(7): p. 1261-74. 
110. Cross, D.A., et al., Inhibition of glycogen synthase kinase-3 by insulin mediated by 
protein kinase B. Nature, 1995. 378(6559): p. 785-9. 
111. Saxton, R.A. and D.M. Sabatini, mTOR Signaling in Growth, Metabolism, and 
Disease. Cell, 2017. 168(6): p. 960-976. 
   Indexes 
117 
112. Laplante, M. and D.M. Sabatini, mTOR signaling in growth control and disease. Cell, 
2012. 149(2): p. 274-93. 
113. Nave, B.T., et al., Mammalian target of rapamycin is a direct target for protein kinase 
B: identification of a convergence point for opposing effects of insulin and amino-acid 
deficiency on protein translation. Biochem J, 1999. 344 Pt 2: p. 427-31. 
114. Elstrom, R.L., et al., Akt stimulates aerobic glycolysis in cancer cells. Cancer Res, 
2004. 64(11): p. 3892-9. 
115. Madhunapantula, S.V. and G.P. Robertson, Targeting protein kinase-b3 (akt3) 
signaling in melanoma. Expert Opin Ther Targets, 2017. 21(3): p. 273-290. 
116. Cho, H., et al., Akt1/PKBalpha is required for normal growth but dispensable for 
maintenance of glucose homeostasis in mice. J Biol Chem, 2001. 276(42): p. 38349-
52. 
117. Cho, H., et al., Insulin resistance and a diabetes mellitus-like syndrome in mice 
lacking the protein kinase Akt2 (PKB beta). Science, 2001. 292(5522): p. 1728-31. 
118. Tschopp, O., et al., Essential role of protein kinase B gamma (PKB gamma/Akt3) in 
postnatal brain development but not in glucose homeostasis. Development, 2005. 
132(13): p. 2943-54. 
119. Peng, X.D., et al., Dwarfism, impaired skin development, skeletal muscle atrophy, 
delayed bone development, and impeded adipogenesis in mice lacking Akt1 and 
Akt2. Genes Dev, 2003. 17(11): p. 1352-65. 
120. Dummler, B., et al., Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are 
viable but display impaired glucose homeostasis and growth deficiencies. Mol Cell 
Biol, 2006. 26(21): p. 8042-51. 
121. Mayer, I.A. and C.L. Arteaga, The PI3K/AKT Pathway as a Target for Cancer 
Treatment. Annu Rev Med, 2016. 67: p. 11-28. 
122. Lim, H.J., P. Crowe, and J.L. Yang, Current clinical regulation of 
PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. J Cancer Res Clin 
Oncol, 2015. 141(4): p. 671-89. 
123. Wright, A.A., et al., Oncogenic mutations in cervical cancer: genomic differences 
between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer, 
2013. 119(21): p. 3776-83. 
124. Schwarz, J.K., et al., Pathway-specific analysis of gene expression data identifies the 
PI3K/Akt pathway as a novel therapeutic target in cervical cancer. Clin Cancer Res, 
2012. 18(5): p. 1464-71. 
125. Hou, M.M., et al., Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the 
cervix: A phase I clinical experience. Oncotarget, 2014. 5(22): p. 11168-79. 
126. Zhong, H. and J.W. Simons, Direct comparison of GAPDH, beta-actin, cyclophilin, 
and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. 
Biochem Biophys Res Commun, 1999. 259(3): p. 523-6. 
127. Cole, S.T. and O. Danos, Nucleotide sequence and comparative analysis of the 
human papillomavirus type 18 genome. Phylogeny of papillomaviruses and repeated 
structure of the E6 and E7 gene products. J Mol Biol, 1987. 193(4): p. 599-608. 
128. Jha, S., et al., Destabilization of TIP60 by human papillomavirus E6 results in 
attenuation of TIP60-dependent transcriptional regulation and apoptotic pathway. Mol 
Cell, 2010. 38(5): p. 700-11. 
129. Meissner, J.D., Nucleotide sequences and further characterization of human 
papillomavirus DNA present in the CaSki, SiHa and HeLa cervical carcinoma cell 
lines. J Gen Virol, 1999. 80 ( Pt 7): p. 1725-33. 
130. Kooistra, S.M. and K. Helin, Molecular mechanisms and potential functions of histone 
demethylases. Nat Rev Mol Cell Biol, 2012. 13(5): p. 297-311. 
131. Shweiki, D., et al., Vascular endothelial growth factor induced by hypoxia may 
mediate hypoxia-initiated angiogenesis. Nature, 1992. 359(6398): p. 843-5. 
132. Chen, C., et al., Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction 
between H-ras and hypoxia. J Biol Chem, 2001. 276(12): p. 9519-25. 
Indexes     
118 
133. Christman, J.K., 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA 
methylation: mechanistic studies and their implications for cancer therapy. Oncogene, 
2002. 21(35): p. 5483-95. 
134. Ghoshal, K., et al., 5-Aza-deoxycytidine induces selective degradation of DNA 
methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-
adjacent homology domain, and nuclear localization signal. Mol Cell Biol, 2005. 
25(11): p. 4727-41. 
135. Park, I.S., et al., Characterization of the methylation patterns in human papillomavirus 
type 16 viral DNA in head and neck cancers. Cancer Prev Res (Phila), 2011. 4(2): p. 
207-17. 
136. Semenza, G.L., Oxygen sensing, hypoxia-inducible factors, and disease 
pathophysiology. Annu Rev Pathol, 2014. 9: p. 47-71. 
137. Havula, E. and V. Hietakangas, Sugar sensing by ChREBP/Mondo-Mlx-new insight 
into downstream regulatory networks and integration of nutrient-derived signals. Curr 
Opin Cell Biol, 2017. 51: p. 89-96. 
138. Chai, T.F., et al., Hypoxia-inducible factor independent down-regulation of 
thioredoxin-interacting protein in hypoxia. FEBS Lett, 2011. 585(3): p. 492-8. 
139. Stoltzman, C.A., et al., Glucose sensing by MondoA:Mlx complexes: a role for 
hexokinases and direct regulation of thioredoxin-interacting protein expression. Proc 
Natl Acad Sci U S A, 2008. 105(19): p. 6912-7. 
140. Stine, Z.E., et al., MYC, Metabolism, and Cancer. Cancer Discov, 2015. 5(10): p. 
1024-39. 
141. Wong, W.J., et al., MYC degradation under low O2 tension promotes survival by 
evading hypoxia-induced cell death. Mol Cell Biol, 2013. 33(17): p. 3494-504. 
142. Okuyama, H., et al., Downregulation of c-MYC protein levels contributes to cancer 
cell survival under dual deficiency of oxygen and glucose. Cancer Res, 2010. 70(24): 
p. 10213-23. 
143. Calleja, V., et al., Role of a novel PH-kinase domain interface in PKB/Akt regulation: 
structural mechanism for allosteric inhibition. PLoS Biol, 2009. 7(1): p. e17. 
144. Vlahos, C.J., et al., A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-
morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem, 1994. 
269(7): p. 5241-8. 
145. Hirai, H., et al., MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by 
standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. 
Mol Cancer Ther, 2010. 9(7): p. 1956-67. 
146. Ihle, N.T., et al., Molecular pharmacology and antitumor activity of PX-866, a novel 
inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther, 2004. 3(7): p. 763-
72. 
147. Brunn, G.J., et al., Direct inhibition of the signaling functions of the mammalian target 
of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. 
Embo j, 1996. 15(19): p. 5256-67. 
148. Gharbi, S.I., et al., Exploring the specificity of the PI3K family inhibitor LY294002. 
Biochem J, 2007. 404(1): p. 15-21. 
149. Dittmann, A., et al., The commonly used PI3-kinase probe LY294002 is an inhibitor of 
BET bromodomains. ACS Chem Biol, 2014. 9(2): p. 495-502. 
150. Zask, A., et al., Synthesis and structure-activity relationships of ring-opened 17-
hydroxywortmannins: potent phosphoinositide 3-kinase inhibitors with improved 
properties and anticancer efficacy. J Med Chem, 2008. 51(5): p. 1319-23. 
151. Sarbassov, D.D., et al., Phosphorylation and regulation of Akt/PKB by the rictor-
mTOR complex. Science, 2005. 307(5712): p. 1098-101. 
152. Garcia-Martinez, J.M., et al., Ku-0063794 is a specific inhibitor of the mammalian 
target of rapamycin (mTOR). Biochem J, 2009. 421(1): p. 29-42. 
153. Sarbassov, D.D., et al., Rictor, a novel binding partner of mTOR, defines a 
rapamycin-insensitive and raptor-independent pathway that regulates the 
cytoskeleton. Curr Biol, 2004. 14(14): p. 1296-302. 
   Indexes 
119 
154. Choo, A.Y., et al., Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-
type-specific repression of mRNA translation. Proc Natl Acad Sci U S A, 2008. 
105(45): p. 17414-9. 
155. Glancy, B. and R.S. Balaban, Role of mitochondrial Ca2+ in the regulation of cellular 
energetics. Biochemistry, 2012. 51(14): p. 2959-73. 
156. Chae, Y.C., et al., Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming. 
Cancer Cell, 2016. 30(2): p. 257-272. 
157. Osawa, M., et al., Solution structure of calmodulin-W-7 complex: the basis of diversity 
in molecular recognition. J Mol Biol, 1998. 276(1): p. 165-76. 
158. Collatz, M.B., R. Rudel, and H. Brinkmeier, Intracellular calcium chelator BAPTA 
protects cells against toxic calcium overload but also alters physiological calcium 
responses. Cell Calcium, 1997. 21(6): p. 453-9. 
159. Reed, P.W. and H.A. Lardy, A23187: a divalent cation ionophore. J Biol Chem, 1972. 
247(21): p. 6970-7. 
160. Teeter, M.E., M.L. Baginsky, and Y. Hatefi, Ectopic inhibition of the complexes of the 
electron transport system by rotenone, piericidin A, demerol and antimycin A. Biochim 
Biophys Acta, 1969. 172(2): p. 331-3. 
161. Wheaton, W.W., et al., Metformin inhibits mitochondrial complex I of cancer cells to 
reduce tumorigenesis. Elife, 2014. 3: p. e02242. 
162. Gonzalez, E. and T.E. McGraw, The Akt kinases: isoform specificity in metabolism 
and cancer. Cell Cycle, 2009. 8(16): p. 2502-8. 
163. Kohn, A.D., F. Takeuchi, and R.A. Roth, Akt, a pleckstrin homology domain 
containing kinase, is activated primarily by phosphorylation. J Biol Chem, 1996. 
271(36): p. 21920-6. 
164. Rauniyar, N. and J.R. Yates, 3rd, Isobaric labeling-based relative quantification in 
shotgun proteomics. J Proteome Res, 2014. 13(12): p. 5293-309. 
165. Stich, M., et al., 5-aza-2'-deoxycytidine (DAC) treatment downregulates the HPV E6 
and E7 oncogene expression and blocks neoplastic growth of HPV-associated cancer 
cells. Oncotarget, 2017. 8(32): p. 52104-52117. 
166. Skowronski, K., et al., Ischemia dysregulates DNA methyltransferases and p16INK4a 
methylation in human colorectal cancer cells. Epigenetics, 2010. 5(6): p. 547-56. 
167. Zhou, X., et al., Hypoxia induces trimethylated H3 lysine 4 by inhibition of JARID1A 
demethylase. Cancer Res, 2010. 70(10): p. 4214-21. 
168. Harikumar, A. and E. Meshorer, Chromatin remodeling and bivalent histone 
modifications in embryonic stem cells. EMBO Rep, 2015. 16(12): p. 1609-19. 
169. May, M., et al., The E6/E7 promoter of extrachromosomal HPV16 DNA in cervical 
cancers escapes from cellular repression by mutation of target sequences for YY1. 
Embo j, 1994. 13(6): p. 1460-6. 
170. Filippakopoulos, P., et al., Selective inhibition of BET bromodomains. Nature, 2010. 
468(7327): p. 1067-73. 
171. Chaidos, A., V. Caputo, and A. Karadimitris, Inhibition of bromodomain and extra-
terminal proteins (BET) as a potential therapeutic approach in haematological 
malignancies: emerging preclinical and clinical evidence. Ther Adv Hematol, 2015. 
6(3): p. 128-41. 
172. Helfer, C.M., J. Yan, and J. You, The cellular bromodomain protein Brd4 has multiple 
functions in E2-mediated papillomavirus transcription activation. Viruses, 2014. 6(8): 
p. 3228-49. 
173. Schwarz, E., et al., Structure and transcription of human papillomavirus sequences in 
cervical carcinoma cells. Nature, 1985. 314(6006): p. 111-4. 
174. Dooley, K.E., A. Warburton, and A.A. McBride, Tandemly Integrated HPV16 Can 
Form a Brd4-Dependent Super-Enhancer-Like Element That Drives Transcription of 
Viral Oncogenes. MBio, 2016. 7(5). 
175. Warburton, A., et al., HPV integration hijacks and multimerizes a cellular enhancer to 
generate a viral-cellular super-enhancer that drives high viral oncogene expression. 
PLoS Genet, 2018. 14(1): p. e1007179. 
Indexes     
120 
176. Wouters, B.G. and M. Koritzinsky, Hypoxia signalling through mTOR and the 
unfolded protein response in cancer. Nat Rev Cancer, 2008. 8(11): p. 851-64. 
177. Brugarolas, J., et al., Regulation of mTOR function in response to hypoxia by REDD1 
and the TSC1/TSC2 tumor suppressor complex. Genes Dev, 2004. 18(23): p. 2893-
904. 
178. Sarbassov, D.D., et al., Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly 
and Akt/PKB. Molecular Cell, 2006. 22(2): p. 159-168. 
179. Maehama, T., et al., Selective down-regulation of human papillomavirus transcription 
by 2-deoxyglucose. Int J Cancer, 1998. 76(5): p. 639-46. 
180. Bost, F., et al., Energy disruptors: rising stars in anticancer therapy? Oncogenesis, 
2016. 5: p. e188. 
181. Ko, Y.H., et al., Advanced cancers: eradication in all cases using 3-bromopyruvate 
therapy to deplete ATP. Biochem Biophys Res Commun, 2004. 324(1): p. 269-75. 
182. Divolis, G., et al., Differential effects of calcium on PI3K-Akt and HIF-1alpha survival 
pathways. Cell Biol Toxicol, 2016. 32(5): p. 437-49. 
183. Zhou, S., et al., BAPTA-AM, an intracellular calcium chelator, inhibits RANKL-induced 
bone marrow macrophages differentiation through MEK/ERK, p38 MAPK and Akt, but 
not JNK pathways. Cytokine, 2010. 52(3): p. 210-4. 
184. Monick, M.M., et al., Phosphatidylinositol 3-kinase activity negatively regulates 
stability of cyclooxygenase 2 mRNA. J Biol Chem, 2002. 277(36): p. 32992-3000. 
185. Marderosian, M., et al., Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability 
in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling. 
Oncogene, 2006. 25(47): p. 6277-90. 
186. Ma, Y.Y., et al., PIK3CA as an oncogene in cervical cancer. Oncogene, 2000. 19(23): 
p. 2739-44. 
187. Janku, F., et al., Assessing PIK3CA and PTEN in early-phase trials with 
PI3K/AKT/mTOR inhibitors. Cell Rep, 2014. 6(2): p. 377-87. 
188. Narayan, R.S., et al., The allosteric AKT inhibitor MK2206 shows a synergistic 
interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures. 
BMC Cancer, 2017. 17(1): p. 204. 
189. Clevers, H. and R. Nusse, Wnt/β-Catenin Signaling and Disease. Cell, 2012. 149(6): 
p. 1192-1205. 
190. Buechling, T. and M. Boutros, Chapter two - Wnt Signaling: Signaling at and Above 
the Receptor Level, in Current Topics in Developmental Biology, C. Birchmeier, 
Editor. 2011, Academic Press. p. 21-53. 
191. Roarty, K., et al., Loss of TGF-beta or Wnt5a results in an increase in Wnt/beta-
catenin activity and redirects mammary tumour phenotype. Breast Cancer Res, 2009. 
11(2): p. R19. 
192. Ying, J., et al., WNT5A exhibits tumor-suppressive activity through antagonizing the 
Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer. Clin 
Cancer Res, 2008. 14(1): p. 55-61. 
193. Niehrs, C., Function and biological roles of the Dickkopf family of Wnt modulators. 
Oncogene, 2006. 25: p. 7469. 
194. Lau, M.T., C. Klausen, and P.C. Leung, E-cadherin inhibits tumor cell growth by 
suppressing PI3K/Akt signaling via beta-catenin-Egr1-mediated PTEN expression. 
Oncogene, 2011. 30(24): p. 2753-66. 
195. Ormanns, S., et al., WNT signaling and distant metastasis in colon cancer through 
transcriptional activity of nuclear beta-Catenin depend on active PI3K signaling. 
Oncotarget, 2014. 5(10): p. 2999-3011. 
196. Miles, A.T., et al., Induction, regulation, degradation, and biological significance of 
mammalian metallothioneins. Crit Rev Biochem Mol Biol, 2000. 35(1): p. 35-70. 
197. Datta, J., et al., Metallothionein expression is suppressed in primary human 
hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer 
binding protein alpha by phosphatidylinositol 3-kinase signaling cascade. Cancer 
Res, 2007. 67(6): p. 2736-46. 
   Indexes 
121 
198. Xu, W., et al., Hypoxia activates Wnt/β-catenin signaling by regulating the expression 
of BCL9 in human hepatocellular carcinoma. Scientific Reports, 2017. 7: p. 40446. 
199. Chen, C. and H. Okayama, High-efficiency transformation of mammalian cells by 
plasmid DNA. Mol Cell Biol, 1987. 7(8): p. 2745-52. 
200. Butz, K., et al., Functional p53 protein in human papillomavirus-positive cancer cells. 
Oncogene, 1995. 10(5): p. 927-36. 
201. Lu, S., et al., Identification of an additional hypoxia responsive element in the 
glyceraldehyde-3-phosphate dehydrogenase gene promoter. Biochim Biophys Acta, 
2002. 1574(2): p. 152-6. 
202. Dimri, G.P., et al., A biomarker that identifies senescent human cells in culture and in 
aging skin in vivo. Proc Natl Acad Sci U S A, 1995. 92(20): p. 9363-7. 
203. Weber, M., et al., Chromosome-wide and promoter-specific analyses identify sites of 
differential DNA methylation in normal and transformed human cells. Nat Genet, 
2005. 37(8): p. 853-62. 
204. Gunther, T., et al., Investigation of Viral and Host Chromatin by ChIP-PCR or ChIP-
Seq Analysis. Curr Protoc Microbiol, 2016. 40: p. 1e.10.1-21. 
205. Hanahan, D., Studies on transformation of Escherichia coli with plasmids. J Mol Biol, 
1983. 166(4): p. 557-80. 
206. Sambrook, J. and D.W. Russell, Molecular Cloning: A Laboratory Manual 2001, New 
York, NY, USA: Cold Spring Harbor Laboratory. 
207. Brummelkamp, T.R., R. Bernards, and R. Agami, A System for Stable Expression of 
Short Interfering RNAs in Mammalian Cells. Science, 2002. 296(5567): p. 550-553. 
208. Pursiheimo, J.P., et al., Hypoxia-activated autophagy accelerates degradation of 
SQSTM1/p62. Oncogene, 2009. 28(3): p. 334-44. 
209. Chen, K.F., et al., Transcriptional repression of human cad gene by hypoxia inducible 
factor-1alpha. Nucleic Acids Res, 2005. 33(16): p. 5190-8. 
210. Jensen, K.S., et al., FoxO3A promotes metabolic adaptation to hypoxia by 
antagonizing Myc function. Embo j, 2011. 30(22): p. 4554-70. 
211. Yu, F.X., et al., Adenosine-containing molecules amplify glucose signaling and 
enhance txnip expression. Mol Endocrinol, 2009. 23(6): p. 932-42. 
212. Xu, M., et al., An unbiased in vivo screen reveals multiple transcription factors that 
control HPV E6-regulated hTERT in keratinocytes. Virology, 2013. 446(1-2): p. 17-24. 
213. Wu, S., et al., Transcription factor YY1 contributes to tumor growth by stabilizing 
hypoxia factor HIF-1alpha in a p53-independent manner. Cancer Res, 2013. 73(6): p. 
1787-99. 
214. Horvath, P. and R. Barrangou, CRISPR/Cas, the immune system of bacteria and 
archaea. Science, 2010. 327(5962): p. 167-70. 
215. Jinek, M., et al., A programmable dual-RNA-guided DNA endonuclease in adaptive 
bacterial immunity. Science, 2012. 337(6096): p. 816-21. 
216. Doench, J.G., et al., Optimized sgRNA design to maximize activity and minimize off-
target effects of CRISPR-Cas9. Nat Biotechnol, 2016. 34(2): p. 184-191. 
217. Sanjana, N.E., O. Shalem, and F. Zhang, Improved vectors and genome-wide 
libraries for CRISPR screening. Nat Methods, 2014. 11(8): p. 783-784. 
218. Tuttle, R.L., et al., Regulation of pancreatic beta-cell growth and survival by the 
serine/threonine protein kinase Akt1/PKBalpha. Nat Med, 2001. 7(10): p. 1133-7. 
219. Ramaswamy, S., et al., Regulation of G1 progression by the PTEN tumor suppressor 
protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc 
Natl Acad Sci U S A, 1999. 96(5): p. 2110-5. 
220. Livak, K.J. and T.D. Schmittgen, Analysis of relative gene expression data using real-
time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001. 25(4): p. 
402-8. 
 
